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FOREWORD
Governments around the world obsess about how they can ensure that basic 
research is turned into human benefit.  And governments do what governments 
can do, which is to provide catalysis through funding, tax breaks and a policy 
environment that facilitates rather than hinders innovation. But if you really 
want to discover how to innovate, read this volume, published in the 21st 
anniversary year of the first Witness Seminar on monoclonal antibodies. 
This is a master class on how to innovate in medicine. It is people who innovate 
and it is the people who scintillate in this extraordinary anthology. Their values and 
personalities come to the fore: humane, free-thinking, always wanting to try new 
things, to innovate. Their personality traits are also apparent, a cast of individualists 
and eccentrics, stubborn and cussedly single-minded, accompanied by a strong 
common denominator of caring and humane compassion. The vignette on cystic 
fibrosis reminded me of six months as John Batten’s SHO in the adult cystic fibrosis 
unit at the Brompton – an extraordinary clinician leading an equally extraordinary 
team.  The Witness Seminar on cystic fibrosis reminds us that the substantially 
increased survival of people with cystic fibrosis is due to the dedication of John Batten 
and his counterparts around the world.  The innate curiosity of clinical scientists 
shines through the vignettes; being both clinician scientist and naturalist is a common 
association, for example Cyril Clarke, Estlin Waters and Christopher Andrewes.
This volume also acts as a reminder of what it means to be professional – to be 
scholarly and rigorous in rooting out and applying evidence, to apply judgement 
in clinical decision making, to be prepared to innovate, and to be responsible and 
accountable for decisions.  I was transported in an instant to the Royal Postgraduate 
Medical School of my youth – and to many of the characters who passed through its 
doors.  It also reminds us how values, ethics and innovation are intertwined. There 
are examples from intensive care and leukaemia and from the deliberations of the 
London Medical Group and from innovators in public health and population studies.
I have always enjoyed the Witness Seminars – the witnesses are alive and their 
recollections vivid. They are always entertaining, not least because the participants 
sometimes disagree or have different recollections of the same events! Like all the 
best anthologies, this is full of gripping vignettes and stories. It should be read by 
all inquisitive doctors, which should give it a large circulation, since all doctors 
should be inquisitive.
Sir Mark Walport, Government Chief Scientific Adviser, UK
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Dr Georges Köhler, 
Sir Christopher 
Booth, Dr César 
Milstein (left to 
right) at the first 
Witness Seminar on 
Monoclonal Antibodies, 
1993 
INTRODUCTION*
In September 1993 the Wellcome Trust’s History of 20th Twentieth Century 
Medicine Group held its first Witness Seminar on the topic of monoclonal 
antibodies, for which the main witnesses, César Milstein and Georges Köhler, 
had shared the 1984 Nobel Prize in Physiology or Medicine. Our intention was 
to use the occasion to examine the events behind the headlines and accolades; to 
explore what did or didn’t happen; identify who were the influential players (not 
always synonymous with the best-known names); and to hear the voices and 
perspectives of a wide group of people who were ‘there at the time’ in different 
capacities. The success of that meeting, as assessed by the frankness of the 
participants on the day and their ready and enthusiastic engagement with the 
subsequent editorial and archival processes, compounded by several requests for 
copies of the edited transcript, encouraged us to develop a modest programme of 
four further meetings to record and reflect on recent biomedical history. 
Fast forward 21 years and we have now organized in excess of 60 Witness 
Seminars attended by more than 1400 people, and have advised several other 
groups and individuals on developing similar programmes. We have edited 
and published 58 transcripts of those meetings, most, but not all, in the freely 
* Page numbers refer to this volume; volume titles refer to the published Witness Seminars (see 
pages xvii–xx, 218–21 for full lists) 
xavailable series now entitled ‘Wellcome Witnesses to Contemporary Medicine’. 
The 49th volume in that series, Migraine: Diagnosis, treatment and understanding 
c.1960–2010, appeared recently. 
Some volume titles may seem obscure, even off-putting, to the non-specialist 
reader. For example, The Discovery, Use and Impact of Platinum Salts as 
Chemotherapy Agents for Cancer and Population-based Research in South Wales: 
The MRC Pneumoconiosis Research Unit and the MRC Epidemiology Unit do not 
immediately suggest the range and depth of human interest stories they actually 
contain. Thus, as we approached our 50th volume we decided to collect together 
edited ‘highlights’ taken from all the volumes, to illustrate the diversity and richness 
of many individual experiences of, and contributions to, recent biomedicine. The 
main objective of the Witness Seminar programme has always been to hear and 
record the authentic voices of our contributors; for this anniversary volume we 
want to introduce some of those less well-known voices to fresh audiences.
Selection and editing
Several people listed in the acknowledgements were involved in selecting suitable 
extracts. Some selectors read only one or two volumes; others read rather more; 
and between us the two editors have read, or re-read, all the volumes. There were 
no restrictive criteria – all were invited to select extracts that intrigued or amused 
them; that seemed representative of a theme, specialty, or period; or conversely, 
something that was unique. Consequently, these stories and snippets vary widely 
– some quirky, some moving, some amusing, some thought-provoking. We have 
not imposed a word length – some are short and pithy, one or two are rather 
more expansive.
Our first selection of extracts was over 500 pages long, and we have gradually 
refined, reduced, and edited our choices to produce a more manageable volume. 
For each extract, repetitions and discursive material have been removed, and 
sometimes sentences have been run together from adjacent paragraphs or pages 
to provide a continuous narrative. Dates or other explanatory material have been 
added where appropriate. Strictly speaking therefore, few of these extracts are 
verbatim quotes, and in the interests of readability we have intentionally avoided 
the large-scale use of ellipses, parentheses, and footnotes to identify our editorial 
work. For those who do want to read the unexpurgated text, each extract is 
carefully referenced to the original publication. Where absolutely necessary, 
editorial introductions have been added to a few extracts. 
We hope that enough introductory or editorial material has been provided 
to make each extract understandable, even if some of the precise technical 
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details may not be clear. For example, the reader does not need to know the 
detailed pharmacology of 5-HT to be able to grasp the significance of research 
programmes into anti-vomiting drugs or migraine therapies, or to appreciate the 
powerful stories told by the drug discoverers, the clinicians, and the patients.
We have organized the extracts under key words rather than themes, although 
occasionally some extracts read better if grouped together (e.g. ‘cystic fibrosis’, 
‘dialysis’). However, such a grouping is not exclusive. A reader particularly 
interested in, say, asthma may wish to read not only the entries identified under 
that heading but also entries on drug treatments, such as Intal and Salbutamol. 
The comprehensive index will guide the selective reader. For those with a more 
magpie approach, we believe that this is a book to dip into, hopefully with 
surprise and pleasure. 
Voices and people
For each Witness Seminar we try to recruit a range of appropriate participants. 
Given the primary focus of our programme on contemporary biomedical 
sciences, it is not surprising that clinicians and biomedical scientists frequently 
predominate. However, these are not homogeneous groups. We have had 
clinicians of practically every medical and surgical specialty, and research scientists 
representing an equally diverse range of disciplines, attend our meetings. We 
have also tracked down nurses, technicians, physiotherapists, and patients, and 
when apposite have sought out, inter alia, engineers, industrialists, journalists, 
and representatives from funding and government bodies. Consequently, many 
different voices are represented in the current volume, as in the series as a whole.
The personal stories and influences are often unexpected and frequently moving, 
such as the profound and lasting impact of a maternal death or an untreatable 
patient (p. 106, p. 3). Emotional responses often influenced specific career 
choices, such as fury at contemporary palliative care failures; astonishment at 
the power of new cancer drugs; or joy at new life (‘career influences’). Sometimes 
a career decision was influenced by something more mundane, such as a time-
consuming hobby. Sometimes hobbies not only influenced career choices, but 
also the direction of those careers, and in this volume bird-watching and butterfly 
collecting are just two that come to the fore as seminal influences. 
Some towering figures in late twentieth-century medicine who are no longer with 
us, such as Sir Christopher Booth, Sir Richard Doll, and Sir David Jack, have 
contributed to several of our meetings (e.g. Clinical Research; Population-based 
Research; Asthma, to name but a few), as have several Nobel Laureates (e.g. NMR & 
MRI; Clinical Pharmacology 1; Monoclonal Antibodies). But in keeping with our aim 
xii
to hear ‘other voices’, the testimonies in this book reflect the array of indispensable 
skills, expertise and experience contributing to contemporary biomedicine.
Patients have rarely been at the explicit heart of our meetings, but they and their 
needs are never far away, as emphasized, for example, by the robust remarks 
reported by Sir Michael Rawlins from the Committee for Safety of Medicines (p. 
29). And the direct contributions of dialysis patients, haemophiliacs, MS sufferers 
and many, many others, have all extended and enhanced the perspectives offered 
here and throughout our volumes. Whilst some such views have been appreciative 
or complimentary, those attitudes have not been universal. Occasionally, the 
unexpected consequences of therapeutic advances can create appalling problems. 
A whole patient group was devastated when the blood products used for the 
successful treatment of haemophilia became contaminated with hepatitis and 
HIV (pp. 31–2); and patients, doctors, and nurses have recalled the ‘nightmare’ 
of early dialysis (pp. 38–41). Tracey Humberstone describes with dignity, but 
also some despair, the problems of long-term survival as a ‘cystic’, in the face of 
constant nihilism from medical personnel who expect CF patients to die in their 
youth (p. 35). A few witnesses also broach a rarely mentioned consequence of 
some treatments: patient suicide (pp. 162–3).
The stories behind other therapeutic strategies, including hip replacement 
surgery, dialysis, and heart transplant might speak of heroic doctors battling 
against technical problems or unsympathetic administrators, but they also speak 
of heroic patients. The first heart transplant donor; the desperate MS patients 
pushing for cannabis-based medication to relieve their pain; the early dialysis 
patients; and constantly vomiting cancer patients are all included here, although 
their stories are more fully recorded in the respective volumes. 
Places
Almost inevitably, particular research units, hospitals, hospices, or companies 
achieve a number of mentions, reflecting the specific institutional or thematic 
emphasis of many of our meetings. But, as with our attention to the hidden 
voices of individuals, so too are we made aware of the importance of some of 
the less prominent institutions. Take, for example, the prime role of district 
general hospitals, rather than major teaching hospitals, in the development of 
replacement hip surgery, and in fostering intensive care (p. 163, p. 86). Some 
lesser known, to the wider public at least, MRC research units are also highlighted. 
Especially noteworthy are the contributions from the MRC Epidemiology Unit 
in south Wales and some of its pioneering and influential long-term studies on 
disease in miners, environmental lead, iron absorption, and aspirin.
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While predominantly reflecting British experience, this volume is not restricted 
to the UK. African medical education, research, and politics (pp. 95, 109); 
chemotherapy trials in India (p. 43); Sub-Saharan nomads (pp. 126–7), and 
international visitors and exchanges, including the highly desirable BTA (‘Been 
to America’) (pp. 12, 117) are all represented. Even Swiss transport systems 
appear unexpectedly (p. 68).
Technology
Technology, technical advances, equipment, materials, and design all figure 
in many of our witnesses’ memories. Several of our contributors to meetings, 
including those on Haemophilia, Maternal Care, and Intensive Care spoke of 
the impact that disposable plastics had made in their lives, and we could have 
produced a small volume on that one topic alone. Plastics for syringes, bloodlines, 
and indwelling catheters revolutionized clinical practice, in both diagnosis and 
therapeutics (p. 140) – as did disposable needles that did away with the need 
for the often insufficient re-sharpening of re-usable ‘sharps’. Plastics made no 
lesser an impact in the research lab – Ethel Bidwell’s account of wobbling along 
an Oxford road on her Vespa scooter with a glass Winchester of blood strapped 
to its pillion seat provides a lasting image (‘Haemophilia’ ). The development 
and impact of large-scale equipment, including imaging machines, ultrasound 
scanners, and dialysis machines have all been the subjects of dedicated meetings 
(NMR and MRI; Ultrasound, and Dialysis). Several unexpected stories have 
emerged, including the intriguing relationship of the obstetric ultrasound 
scanner to industrial metal flaw detectors used in shipyards (pp. 128–9); the 
question of who paid for the National Heart Hospital’s first NMR scanners 
(pp. 63–4); and the critical role of technicians in installing and maintaining 
medical equipment (pp. 167–8).
Recurring themes 
Some comments and themes recur frequently, but are here represented by few 
extracts, such as the aforementioned ‘plastics’. Support groups and research 
charities established by patients were also mentioned at several meetings, 
but in this volume are characterized by a small selection. These include the 
Foundation for Sudden Infant Death set up by a bereaved parent, and the 
National Asthma Campaign (pp. 161, 119). Both, like many such organizations, 
combined welfare support with education for patients, carers, and relatives, 
and then also started funding focused research projects, often well before 
these areas attracted financial support from any of the major medical research 
funding bodies. 
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Similarly important are the professional societies, often started by early pioneers 
anxious to find others with whom to exchange knowledge and expertise. 
Specialists in intensive care, haemophilia, palliative medicine, and atherosclerosis 
all initiated small discussion meetings that became larger academic societies; 
nurses too, in intensive care and genetic counselling here recall the importance 
of finding like-minded people. The clinical and academic exchanges and 
challenges, and the social importance of these networks, including two very 
different organizations – the International Narcotics Research Club and the 
Balint Society, are also emphasized (pp. 89, 41).
Other recurrent themes include drug development difficulties that are mentioned 
by several participants – stories of sumatriptan, Intal, and ondanestron all 
highlight the tensions that can occur between management and research; one 
participant recalled Sir James Black’s stricture that management wanting to stop 
a project was a sure sign of good drug development (p. 85). 
A frequent phrase we heard was ‘it couldn’t happen now’ – sometimes uttered 
with regretful nostalgia, sometimes with genuine relief. The antibiotic methicillin 
took only 18 months to market in the late 1950s, an enviable but impossibly 
fast time today (‘time to market’ ); although recollections of rudimentary 
clinical trials and the somewhat casual, even cavalier, care of volunteers at the 
time (‘antibiotics’; ‘Salbutamol’ ) and the regular habit of self-experimentation 
(‘volunteers’, ‘clinical trials’ ) give much food for thought. The figure of Roger 
Altounyan in developing asthma therapies stands out in particular (‘Intal’ ) but 
worthy too of recognition are, amongst others, the prisoners involved in rhesus 
factor experiments, and the volunteers in the Common Cold Unit, the Applied 
Psychology Unit, and the Epidemiology Unit (e.g. ‘prisoners’; ‘Common Cold 
Unit’; ‘alcohol’; ‘X-ray’ ).
Whilst ‘it couldn’t happen now’ has been a regular refrain, there has also been an 
occasional sense of ‘how could we have let that happen?’ Contemporary readers 
might be astonished to learn of the view in the early 1980s that not much more 
needed to be done to counter air pollution (‘air pollution’ ); and that by 1995 
MRSA was ‘no longer a problem’ according to some health authorities, and 
hospital isolation procedures were relaxed (‘isolation wards’, pp. 93–4). 
Inevitably, we have been unable to include many favourite, illuminating or 
challenging stories in this volume. The story of the MRC’s bag of shiny half 
crowns on a night train to Wales; the Sunday Times’ journalist who scooped Mrs 
Thatcher halting the ‘sex survey’ in 1989, and the role of the Wellcome Trust in 
rescuing that survey, are just some of the casualties (although they can be read 
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in full in Population-based Research and NATSAL). Absent, too, are the young 
women doctors, ‘Derrick’s dolls’, who collected the evidence that connected 
contraceptive pill use with thrombotic deaths (Committee on Safety of Drugs); 
the tragic leukaemia patients who died of iatrogenic heart failure (Leukaemia); 
and the astonishing story of how corticosteroids, used to treat mothers at risk 
of delivering a preterm infant with respiratory distress, were developed almost 
accidentally in New Zealand (Corticosteroids).
Indeed, there are so many more voices and stories to hear that we can only urge 
those who are intrigued, interested, or irritated by our selections for this volume, 
to read the original volumes, and to choose your own highlights. They are all 
freely available at www.histmodbiomed.org.
E M Tansey
Queen Mary, University of London
Dr Tilli Tansey at the Witness Seminar on the 
MRC’s Common Cold Unit, 1997
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Dr Jeffrey Aronson: 
Migraine
Age discrimination
When I was a medical registrar in the 1980s the local cardiac centre would not 
take a patient for coronary artery bypass surgery if they were aged 60 years and 
one day, I remember doctoring the notes to make the patient younger. 
Professor Mervyn Singer: Intensive Care, p. 81 
We always had totally inadequate physical facilities for the number of patients 
who were referred to us for dialysis and we had to have some form of selection. 
We tried to be totally unemotional about it. There were some people – not a 
good thing to say – who were obviously unsuitable. But we made it age-related, 
and anybody over 40 didn’t have a chance. 
Dr Margaret Platts: Dialysis, p. 71 
Air pollution
In about 1956 the MRC established the Air Pollution Research Unit, under 
Professor Pat Lawther’s direction, at St Bartholomew’s Hospital, and it stayed 
there doing seminal work until about 1980. By then levels of air pollution had 
fallen to such an extent that it was beginning to be believed that not much more 
needed to be done. 
Professor Robert Maynard: Environmental Toxicology, p. 46 
A – Monoclonal Antibodies to Migraine: Witnesses to Modern Biomedicine, an A–Z
2
Alcohol
In the 1970s we were looking at the effects of small amounts of alcohol on 
driving performance – this was before the breathalyser came in – and I set up an 
experiment around the streets of Cambridge. I was using the dual-task method 
for measuring peoples’ performance, 
giving them a subsidiary task to do as 
they drove around, and I set this up 
with a local car club. All car clubs met 
at a pub somewhere in Cambridge 
and we would go along and the people 
who volunteered would be there and I 
would say, ‘While I am telling you what 
I would like you to do, because we are 
developing this method of measuring 
drivers’ performance, would you like a 
glass of sherry?’ One of my colleagues, 
by the way, paid for the sherry, not 
the Medical Research Council, and I 
was able to do a proper experiment by 
treating the subjects, some of them to 
one glass of sherry, and some to two 
glasses of sherry. Naturally I had to 
join them, so it didn’t look phoney, 
and then we went out and ran the experiment. They would show that even after 
one glass of sherry there are ways of measuring small changes in drivers’ ‘reserve 
capacity’, as we called it at the time, but it was a bit naughty. 
Dr Ivan Brown: Applied Psychology, pp. 67–8 
Alliance for Cannabis Therapeutics
I started smoking cannabis in 1992, after I’d had MS for ten years. I found this 
helpful in all sorts of ways: relieving pain, stopping spasticity, helping me to 
sleep, helping me to eat. I wanted to find out if it did the same for other people 
as well. I brought this about via doctors, newspapers and TV, to find out if 
there was anyone else with this experience, and there was. Then I wanted some 
scientific evaluation of what happened, because before then it was just anecdotal 
evidence: people said it helped them with this or that, but I wanted some kind of 
scientific evaluation and some trials, to find out if this was recognized by anyone. 
Dr Ivan Brown 
testing a subject in 
research on the use 
of subsidiary tasks to 
measure the effects 
of small amounts of 
alcohol on drivers’ 
spare mental capacity: 
Applied Psychology
Monoclonal Antibodies to Migraine: Witnesses to Modern Biomedicine, an A–Z – A
3
I asked all these people to tell their doctor what had happened to them and to 
tell their local politician, to put it about to people that cannabis helped them. I 
started the Alliance for Cannabis Therapeutics with a couple of other patients 
who found that cannabis was helpful. 
Dr Clare Hodges: Cannabis, pp. 61–2 
Aminopterin
In 1948 a well-known poet, who was also an amateur mountaineer and a school 
teacher, had been on holiday in Switzerland mountaineering and to his horror 
found that he was getting breathless when he got beyond a certain height. He 
was worried about this and on his return his wife persuaded him to seek medical 
advice. He was diagnosed as having acute leukaemia. He had a horrible form of 
leukaemia that would now be called M5 – acute monocytic 
leukaemia. A colleague had just received a supply of a new 
drug (aminopterin) which had come from America and that 
was doing unexpectedly good things in the treatment of 
childhood leukaemia; and I took over his aminopterin to 
give to this patient. This would be impossible today – you 
would have to fill in all kinds of forms and it just couldn’t be 
done – but I took this stuff over. He went into a complete remission, something 
amazing. He had three months of good life and then he relapsed with multiple 
skin nodules, had more a, but it did no good and he died. The medical team were 
deeply apologetic for having inflicted what proved to be a useless treatment on 
her husband; but his wife said, ‘On the contrary, these three months were almost 
the best three months of our lives. Every day of good health was appreciated and 
it was wonderful, thank you very much.’ 
Professor David Galton: Leukaemia, p. 22 
Anonymity
Midwives would bring me samples of urine, and I would put a number on them 
and take them back to ALSPAC. I wasn’t quite sure what was happening to 
them but I gather they were analysed for, among other things, illicit drugs, and 
I think that cannabis came out quite high, higher than expected. The next thing 
I knew, as a very junior member of staff, was a consultant obstetrician ringing 
me up and saying he wanted the names of all these mothers. I said, “Well, they 
were collected anonymously so I’m afraid I can’t give them. ‘Don’t give me that! 
I shall go to Jean Golding, the ALSPAC Director, and find them.’ A lot of 
He went into a  
complete remission, 
something amazing.
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pressure was put on me. They were anonymous, thank goodness, but he was 
quite threatening in order to get it, because he was responsible for these people’s 
care; they were his patients and he needed to know who they were. 
Miss Karen Birmingham: ALSPAC, p. 47 
Antenatal corticosteroids
I first heard about antenatal corticosteroids for mothers in an undergraduate 
lecture in 1974. The possibility of preventing RDS (respiratory distress 
syndrome) made an immense impact on me because the first baby I delivered as 
an undergraduate died in the neonatal period from RDS, despite weighing seven 
pounds and being born at 36 weeks. So the scene was set for a lifelong interest in 
this topic. Later, in 1977, as a senior house officer in neonatal 
paediatrics, I attended a lecture on fetal lung maturation 
given by Professor Mel Avery, at the Irish Perinatal Society. 
At a time when young female medical graduates had few 
role models, an innovative paper delivered by an attractive 
woman made an enormous impression, especially as I was 
continuing to see premature babies die on a regular basis 
from RDS. At that time I was working in the National Maternity Hospital, 
Dublin, which fostered a culture of nihilism towards most medical interventions, 
with the exception of those ordained by institutional policy. I encountered a 
woman whose previous baby had died from RDS, and, together with a paediatric 
colleague, I approached the Master (Clinical Director) of the hospital to obtain 
permission to prescribe antenatal corticosteroids for this patient. That was the 
first and only time in a two-year spell in obstetrics and paediatrics between 1976 
and 1978 that I was allowed to prescribe antenatal steroids. 
Dr Patricia Crowley: Corticosteroids, p. 23 
Antibiotics
In reply to a plea for accelerated testing of antibiotics, I have great sympathy, 
but the early penicillins were in the pre-thalidomide period and toxicity was 
not really appreciated. I must say, when I look back at Brockham Park, the 
Beechams research facility, in the early 1960s, we were testing something like 
two new penicillins a week in human volunteers. Members of staff were paid 
three guineas [£3.15], plus a hearty breakfast, to give five or six samples of blood 
– no follow-up, no group medical attention afterwards. 
Dr Robert Sutherland: MRSA, pp. 56–7 
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Aspirin
I think the most rewarding thing of all that we have ever done is the aspirin 
studies. I know it took 20 years to convince consultants that this cheap little 
tablet could be beneficial, but it really was worth it. The 
first aspirin studies were hard, hard work, trying to recruit 
people by cold calling – I think because we didn’t have a 
reputation as yet. We were visiting hospital wards and 
taking names of men who had been discharged after an MI 
(myocardial infarction). In those days if you had had a heart 
attack you were considered a real invalid by your family and 
it was hard to convince people that a simple little aspirin 
tablet could be of benefit to them. Whereas now I think 
people have been brainwashed and they know of the benefits. Lots of papers 
have been written, but those were real pioneering days then in the early 1970s. 
Mrs Janie Hughes: Population-based Research, p. 75 
There’s also the problem now, in both primary and secondary prevention, that 
aspirin can be purchased over the counter, and I suspect that there are a lot of 
people taking aspirin who don’t realise that, particularly in primary prevention, 
the balance between the benefit and the risk is not as obvious as most people 
assume it is. In other words, there’s a fairly low benefit to be set against a not 
insubstantial risk. 
Professor Tom Meade: Platelets, p. 65 
The two interventions that we had come up with for colorectal cancer from 
the epidemiologists were resistant starch and aspirin, and so we set up to study 
1,000 people worldwide. In 2011 we reported that there was a 63 per cent 
reduction in colon cancer among the Lynch syndrome patients given aspirin. 
It did demonstrate that you could do these long-term intervention studies on 
people who were genetically motivated because of their own risk and the risk 
for their families. It changed the game quite a lot because we now have a real 
intervention to offer people. 
Professor Sir John Burn: Clinical Cancer Genetics, p. 81 
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Association of Radical Midwives
The Association of Radical Midwives, started in 1976, had 
a huge impact on midwifery and the visibility of midwifery. 
We all took a vow, I can’t remember what year it was, that 
we would tell somebody every day about being a midwife. 
And I still do that, every time I go to the supermarket, and 
I say, ‘Oh yes. I like lots of tea bags, because I am a midwife 
you see’. My children used to die of embarrassment, I have 
to say. But our strategic plan was to speak all the time about 
midwifery and being a midwife, to write as much as you 
can, to challenge every article that came up or every letter 
that came up, to join the Royal College of Midwives, and 
ginger it up and be part of it, and get it taken forward. 
Mrs Caroline Flint: Maternal Care, p. 63 
Asthma
Asthma care nurses
I am a nurse by background, and in 1983 I was just finishing a role with the 
Medical Research Council, when our GP, Dr Robert Pearson, turned to me and 
said, ‘You have looked at diabetes, you have looked at hypertension, I think we 
have got a major problem with asthma in the practice. We know it’s increasing and 
patients are not getting a good deal; why don’t you spend some time researching, 
looking at the role of the nurse in asthma?’ So I did this for a year and we found 
that by utilizing nursing skills, we were able to reduce the acute nebulizer use, 
but inevitably what we did was to increase the inhaled corticosteroid use. We 
went round various hospitals and I was a real nuisance, because I wanted to 
know what was going on, and the one thing that struck me at that time was we 
were giving messages that were too complicated for the patients to understand. 
Patients needed to have simple messages. The major requirement was that we 
needed to make people understand that prevention was possible, and that our 
goal should be having patients without symptoms. 
Mrs Greta Barnes: Asthma, p. 53 
Mrs Caroline Flint: 
Maternal Care
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Asthma patients, 1937
I thought I would describe what I was seeing 63 years ago and I would like 
briefly to describe three patients. They were all connected to the extent that 
there’s something that goes wrong with the definition of asthma. And I must 
remind you, of course, this is the pre-antibiotic era.
I was called from my room before 4 o’clock in the morning. My room, incidentally, 
was the room where penicillin had been discovered in 1928. I went down to see 
a patient and this infant was 12 months old, and the mother 
said that her boy had been wheezy and coughing nearly all 
his life; every cold caused severe wheezing. He had developed 
a cold two days previously and she was going to bring him 
along to the hospital, but with her eight other children she 
was so busy she didn’t have time. That particular morning 
the child had changed a lot, the coughing and wheezing had 
stopped and he had changed colour, and she was worried. 
And here was I at 6 o’clock in the morning seeing my first 
case of what I thought was acute asthma. This story was all 
lies, the child was quite cold; he had obviously been dead for some considerable 
time. I remembered my teacher, Dr Wilson – later Lord Moran, Churchill’s doctor 
– had said that the history was so important, but no one had ever suggested that 
the history you take might be a packet of lies.
The next case I saw two months later. I was on duty at 2 o’clock in the afternoon, 
and the nurse said would I please urgently see a boy who was having difficulty in 
breathing. She thought that I might have to admit this child to the ward, because 
he had acute asthma. In fact, this boy, aged 12, didn’t have acute asthma. He had 
had a sore throat the previous day and that morning speech was difficult, eating 
was difficult and now breathing was difficult. I gave one look at the throat and saw 
a diphtheritic throat, and the reason I remember this particular case is that I had 
never used force on any patient before or since, or ordered so much force to be used. 
As soon as I said to the mother, ‘He will have to go to the Western Fever Hospital, 
because he has got diphtheria and I have to take a swab before he goes,’ the boy 
shut his lips very tightly and would not allow this to be taken. So I got three hefty 
medical students, two of them in St Mary’s rugger team, two nurses and myself, 
and while I held his nose, we got a very good view of that throat. I took a swab and 
said, ‘Let go’, as I was causing acute obstruction with the tongue depressor and he 
went almost blue. The first cough that he took, very near my face, went all over 
me. Now that is another story, the bilateral membranous conjunctivitis that I had 
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three days later, that’s something different. I apologized to the mother that we had 
to use force, but I said that it was essential that I got a good view of that throat. The 
reason he was so difficult was that his school friend had been sent to the same fever 
hospital three days earlier with diphtheria. This was a bit of the history that I hadn’t 
got. And she added, ‘Two days before, he had difficulty in breathing and was given 
an operation on his throat, and he died on the table. That’s why my son didn’t want 
to go to this fever hospital.’
My third and final case. I was asked to see a boy in the ward. This boy, aged five, had 
his eighth admission in about ten weeks to the children’s ward with acute asthma and 
I had never seen so many notes as on this one boy, all from the social workers. His 
mother was a prostitute; she wasn’t even a Paddington one, she had a place just off 
the square in Mayfair – upmarket – and she was actually very pleasant. The father, on 
the other hand, was an alcoholic, but generally in prison. The story was that the boy 
had this intense fear of his father, he really was terrified of his father. I don’t know if 
anyone here has ever seen a one-cause asthma due to emotional causes, but everyone 
agreed that this was the cause. The reason I was asked to see this boy was that a new 
houseman had noticed that during his first admission and the last two admissions, 
the father was in prison so he couldn’t be the cause. I took a different history and the 
boy had a cat and he knew he was cat-sensitive, it had caused trouble to his eyes, to 
his nose, and if the cat scratched him, to his skin, and also caused him asthma. So 
I said, ‘Why didn’t you tell anyone, you have been in here eight different times and 
you know the cause of your asthma and you have never told anyone?’ He said, ‘No 
one has asked me whether I have a cat at all, you are the first person.’ I said, ‘Why 
didn’t you tell them that you knew the cause?’ He started crying and said, ‘Well, 
my cat produced kittens on my bed two days before I came into hospital, I know 
that you will advise me to get rid of the cat,’ and he cried and cried and cried. I 
think somehow that he had one-cause asthma due to allergy. Those are three patients 
where the history was not quite what one thought it might be. 
Dr Bill Frankland: Asthma, pp. 6–9
Asthma treatment, 1950s–1960s
My impression when I was a student and a houseman is that 
asthma in childhood then was very much what you might call 
an ‘orphan disease’. Nobody was that interested in it. There 
was no adequate treatment and children didn’t ordinarily die 
from it, so the principal physicians really tended to pay it little 
attention. What treatment there was, as I can remember just 
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after the war, was ephedrine and things of that sort. Potassium and stramonium 
were very popular for asthma and for whooping cough. Antihistamines were tried 
extensively with, I think, no success, although we thought there was some. But 
there was no really effective safe treatment until, I would have thought, the 1950s 
or 1960s. 
Dr Archie Norman: Asthma, p. 9 
Avon Longitudinal Study of Parents and Children (ALSPAC)
Most of the paediatricians knew that ALSPAC was being run on a wing and a 
prayer, and there was a bit of disquiet, but I think Jean Golding, the Director, 
had an aura about her that people believed that she would come through. I 
think Jean’s greatest characteristic is her dogged optimism that things will come 
right. That inspired people like me to follow, but some of her senior colleagues 
were less sanguine about it. A note came down from higher up in the university 
that ALSPAC was in the red, and shortly after 
that came an open threat from finance that they 
were going to freeze all the senior academics’ 
discretionary funds to pay for the ALSPAC debt. 
I’ll never forget the reaction of my seniors – it was 
quite an eye-opener for me as a young academic 
about the way that the seniors behaved, because 
people just came out of the woodwork, livid that 
the pot of discretionary money that they’d been 
building up over the years could just go to pay 
for Jean Golding’s irresponsible debt. This was a 
major ruction that actually took some time to heal 
between the different academic paediatricians, 
and I’ll never forget it. We were saved because of 
Sir John Kingman, the Vice-chancellor of the University of Bristol at the time, 
who is a statistician and really understood the value of longitudinal studies. 
Professor Alan Emond: ALSPAC, p. 17 
The ALSPAC ethics committee was innovative in a variety of ways, one of which 
was that we had study mothers as full members of the committee. That was 
extremely helpful. We also had a teacher. Ultimately, as the years progressed, 
we had fathers and young people, the progeny of ALSPAC, the ‘Children of the 
90s’ themselves, now represented as full members. That was so, so important. 
Among the rules that were set down, we had to get the balance right of being 
Professor Jean 
Golding, Professor 
Alan Emond: ALSPAC
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sufficiently prescriptive and proscriptive to protect the participants, without 
producing such inflexible rules and regulations that further development was 
prevented. Obviously, we had to have very high levels of confidentiality and 
anonymity, and there was a ‘golden rule’ that those who collected data should in 
no way be involved in analysing it. There were, of course, occasions when some 
of the biological samples, for example, showed some results that were way out 
of the normal range, and we felt we had to have an avenue of going back to the 
individual. In general, the information people got was about how things were 
going in general in the study, not about their individual results. But there were 
occasions on which we felt we had to go back to the 
individual and we had to lay down the best rules we 
could, before this had been thought of by any other 
organization. We came up with the working rule that 
one had to have a strong indication of a condition 
that had a serious risk of harm for which there was a 
known remedy. We were also sure at that time, and 
still are, that we were not going to divulge genetic 
information. We got quite a lot of stick for that. The 
trump card they tried to play was autonomy, you know: ‘It’s our information, it’s 
our right to get it’, but we were able to balance that, put autonomy in its proper 
place, with justice and with doing good and not doing harm. 
Professor Gordon Stirrat: ALSPAC, p. 35 
It wasn’t just an ethics committee for ALSPAC incidentally, it was an ethics 
and legal committee, and that too was important. Indeed, it reached further. It 
served as an ethics and legal and scientific appraisal committee, and was actually 
concerned to ensure that what was done was good science, but it also recognized 
that there was a tension between what might be the best science, in other words, 
what might be the fullest information that could be obtained, and the possible 
shortcomings and disadvantages of actually seeking that information. Some 
information might be potentially upsetting to parents; for example, where it 
touched on sexual health, sexual experience, questions of paternity, evidence 
of possible abuse and so on. There was a great deal of debate about the ways 
in which the study could be safeguarded and the willingness and keenness of 
participants maintained, not just at the outset, that was fairly easily done – 
you’ve seen the enthusiasm of parents from the beginning – but ongoing, year 
after year. Maintaining the reputation of ALSPAC was high among the concerns 
of the Ethics Committee. It had to preserve the reputation of the study. 
Dr Ian Lister Cheese: ALSPAC, p. 34
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Investigating  
cardiac output 
– Professor Ron 
Bradley and 
Dr Margaret 
Branthwaite:  
Intensive Care
Beechams
Mr Lazell, who later became the Chairman of the Beecham Group, decided that 
it was about time Beechams had a research group, so he bought an old house in 
the midst of Surrey, Brockham Park, and set up a central research group there. 
Initially that was a general purpose research group that did all sorts of things – 
studied the effect of light on the colour of Lucozade, studied the use of cysteine 
in Silvikrin hair tonic and various things of that sort. It was officially opened 
by Sir Alexander Fleming in 1947. Now this might have been a coincidence, 
but there was no doubt that his shadow fell over Brockham Park for some years 
afterwards. I joined the company in 1952 when the labs had been going for 
about five years and by which time they had moved more in the direction of 
what we used to call ‘ethical pharmaceuticals’, but we now call prescription 
medicines. Mr Lazell felt that the introduction of the NHS in 1948 was going 
to destroy the over-the-counter pharmaceutical business and, as you probably 
realise, Beecham had a big commercial interest in Beecham’s Powders, Beecham’s 
Pills, Veno’s Cough Cure etc. You name it, they were all on the shelves in Boots. 
Dr Peter Doyle: Post Penicillin, pp. 25–6 
In 1984 at Beecham, the actual driver of the 5-HT
 
anti-emetics research 
programme was Gareth Sanger. He was working hard on the whole thing at the 
time and knew the pharmacology, that is the classic pharmacology, of 5-HT. But 
we ran into some very stiff opposition from management. On one occasion we 
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had a project meeting where our second in command of 
research sat there and told us that Beecham would never 
go into anti-emetics again, because they had been burnt 
in that area before. Gareth and I sat there and we had all 
this data produced at the time. We knew exactly what 
was happening, we had the data right down the line. The 
compounds, 5-HT
3
 antagonists, were so effective against 
anti-cancer therapy-induced emesis, that we both just got 
up there and, even though the Chairman was telling us ‘No 
we’re not going to do it’, we kept on at it. After we came out 
of the meeting, one of our colleagues turned to us and said: ‘I thought you were 
both going to get fired on the spot’, because we just would not give up on it; we 
knew we had something. It was because of Gareth’s drive that Beecham research 
really was very focused; and that was where a lot of the drive came from on the 
Beecham side of it. However, for a long time Gareth did not get much support, 
but ultimately things moved forward. 
Mr Wesley Miner: 5-HT, p. 60 
Been to America (BTA)
We were very privileged to travel round to other units in the UK, and to go abroad 
to gain further experience in the 1960s to 1970s. I was very fortunate in 1970/1 
to go to Massachusetts General Hospital, Boston, to work as a research fellow 
in the respiratory care unit run by Henning Pontoppidan for 18 months. Such 
leave was allowed at senior registrar level and, apart from broadening the mind 
and obtaining insight into the culture of another country, the ‘Been to America’ 
(BTA) label was thought to be a brownie point on your CV for a consultant post 
in the UK. At the senior registrar level, the BTA was almost obligatory. 
Dr Doreen Browne: Intensive Care, pp. 41–2, 59 
Biochemistry and biochemists
In 1959, as a student, I remember going to see the Royal Free Hospital’s twin-
coil kidney. I was not interested in the machine as my eye was taken by a lady 
who was weighing salts using laboratory scales. She was measuring the chemicals 
to make up the dialysate fluid. Nobody has mentioned that you could not do 
dialysis without a biochemist 
Dr Rosemarie Baillod: Dialysis, p. 22 
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In the laboratory it was the chemists who were helping with diagnosis; they were 
performing laborious and painstaking analyses of metabolites in the urine and in 
post-mortem material from spleen, liver, brain, and so on. It was these metabolites 
extracted from the liver and urine that we subsequently came to use as natural 
substrates for the enzyme analysis. You couldn’t ring up Sigma (a major chemical 
supply company) as we do these days and get the substrates sent by post overnight. 
Mrs Elizabeth Young: Genetic Testing, p. 39 
Birdwatching
In my case, there was an overlap between counting birds and epidemiology. I 
had been interested in birds from a very young age but I was also interested in 
the scientific side of birdwatching, especially bird migration and bird numbers. 
When I was on St Kilda I wrote about a dozen papers and short notes for 
ornithological journals and for the Proceedings of the Zoological Society of London 
on various aspects of birds and on the grey seal. I was interested as a naturalist. At 
that time I didn’t have any real knowledge of statistics. It was my birdwatching 
that kept me scientific during my medical student days. I used to read some of 
the bird journals; the medical journals were too heavy to read as a student. I 
don’t know how some of our medical students now manage, but they can and 
do. I felt the teaching we had at London was not very scientific, it was more of an 
apprenticeship: I do this, so you do this. The birdwatching kept me critical of the 
scientific side of things. When I joined the MRC it was very much the other way 
round. It was the epidemiology that was the scientific side, and I think I have 
been able to apply a bit of it to my birdwatching. The two have run together, one 
perhaps ahead of the other, but the two are related. I think that someone who 
wants to count wrens on St Kilda has got something in common with someone 
who measures the haemoglobin level in a population. My experience of working 
alone on St Kilda and writing papers on natural history probably helped me 
when starting in medical research. 
Professor Estlin Waters: Population-based Research, pp. 67–8 
Bone cement
Simplex C, the original bone cement, was manufactured in a back street in 
Stamford Hill, London, and the owner of the firm was an American who happened 
to be a patient of mine, which is how I know the story. There were inhibitors 
in the compounds that had to be mixed together, and this company, North Hill 
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Plastics it was called, had the patent on these inhibitors, and the US FDA would 
not grant permission for the cement to be used. So, the Americans fell quite 
behind, and patients were coming over to this country for hip replacements. 
This irritated the Americans no end, and I think the first person actually to do 
a total hip replacement in the US was Harlan Amstutz, who had worked for a 
year at the Royal National Orthopaedic Hospital, Stanmore, and went back to 
special surgery in New York with a McKee prosthesis in his pocket along with 
some cement, and the FDA gave him permission to do a one-off operation in 
1962/3. In the end, of course, the Americans bought out this company. 
Mr Alan Lettin: Hip Replacement, pp. 57–8
Breastfeeding
In the 1950s mothers were advised to ‘time’ suckling and they all displayed 
their watches or clocks nearby; on the first day, one minute on both breasts 
was allowed at four-hourly intervals, this was increased to two minutes on day 
two, three minutes on day three and so on until ten minutes was allowed. This 
prescribed time had been arrived at because a bottle-fed infant would consume 
formula milk from a bottle in 20 minutes.
As a student midwife in Glasgow in the 1950s, and 
later in Dundee as a staff midwife, one had to be 
on one’s guard about mentioning breastfeeding, 
as bottle-feeding mothers would feel guilty. 
Supplementary and complementary bottle-feeds 
of formula milk were given to the breastfed 
infants secretly by midwives and nursing staff. 
When my first baby was born in 1954 I insisted 
that he remain in the room with me at all times. I 
was not popular and was considered somewhat of 
a rebel, but I simply could not trust the staff that 
he would not receive formula milk. I breastfed 
the baby when he needed to be fed and had no 
problems. 
Ms Ellena Salariya: Breastfeeding, pp. 22–3, 58 
Ms Ellena Salariya: 
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British Atherosclerosis Society
I was working in considerable isolation and was concerned – maybe because 
we were in Scotland – that nobody else seemed to be the least bit interested in 
atherosclerosis. So I took myself off to meet the vascular pathologist John French 
in Oxford. This was 1958. The Great Western Railway was late by 20 minutes, 
and John met me at the station in a terrible flap, as he had bicycled down from the 
Dunn School of Pathology. He said, ‘Could you afford a taxi? Prof has got a lecture 
at five past 1 o’clock and he’s waiting for you.’ Now, I hadn’t done my homework, 
I didn’t know who ‘Prof ’ was. When I went up the stairs, at the double, there 
was this steely grey-haired man whom I later recognized as Howard Florey, Nobel 
Prize-winner in Physiology or Medicine in 1945. He said, ‘If 
you want to try to form an atherosclerosis group go ahead, 
but it won’t work, because there aren’t more than nine people 
in the country who are the least bit interested in the subject, 
and you have got three of them here, you, French and me.’ 
He then produced a bottle of white wine out of his desk with 
three glasses, one for himself before the lecture, and one for 
each of us, and poured half the bottle into the glasses. He 
told me to go away and find 20 people, and he told French 
to find £250 a year, and to come back in three months, which we duly did. This 
time French and I met, and prepared our brief before meeting the Nobel Prize-
winner. We thought we had better get it right. I found 18 people, and French had 
got £250 for three years from ICI (Imperial Chemical Industries) – a lot of money 
in those days. We went through the list and off we set with the Atherosclerosis 
Discussion Group, now the British Atherosclerosis Society. To initiate it, Florey 
again produced a half bottle of white wine and three glasses. To this day I do not 
know whether that was the same bottle of white wine or not. 
Professor Michael Oliver: Platelets, pp. 25–6 
Brompton cocktail
What was this Brompton cocktail? Generally speaking, it was a mixture of 
morphine and cocaine in honey or syrup plus alcohol. It was probably used as 
a post-thoracotomy analgesic at the Brompton Chest Hospital, London, and 
as a cough and respiratory sedative in terminal tuberculosis. So probably the 
Royal Marsden and the Brompton Chest Hospitals were using the cocktail, even 
though they weren’t disseminating its use. When was this formula published? It 
was some time in the 1950s in a supplement to the hospital formulary, either at 
To initiate it, Florey 
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the Royal Marsden or the Brompton Chest Hospital. In 1958 it first appeared in 
Martindale’s Extra Pharmacopoeia, and then the British National Formulary and 
then eventually in the 1970s it was being published in four formulations. 
Dr Robert Twycross: Pain, p. 27 
Butterfly collecting
One of the things I remember most fondly about the days at Harvard Hospital 
were visits from the parent institute in London of Christopher Andrewes, Forrest 
Fulton, and other scientists, and there would be the most long and intensive 
discussions on the virology of the problem. Andrewes had a wonderful trick of 
suddenly coming into one’s lab in the afternoon and saying, ‘I say, would you 
like to go for a walk in the New Forest?’ He had a car and, of course, in those 
days very few people did, and we would be driven into the New Forest and he 
would be carrying his butterfly net, because his sideline was entomology, and 
there, while walking along the path, one would talk about what experiment 
should be done next on the common cold. 
Professor James Lovelock: Common Cold Unit, p. 221 
Butterfly genetics
I think that the genetics group as a whole, and Cyril Clarke in particular, were 
outstandingly talented. They were able to stand back from the immediate and 
specific aspects of the field, whether this be serology, or paediatrics, or obstetrics, and 
look at it as a kind of research problem from first principles. Cyril, in particular, was 
very much a person of first principles. Because of his basic experience in genetics, 
he was able, I think, to move from one situation to another in a way that perhaps 
people more immediately involved in the applications were not. People are often a 
bit disparaging about his butterfly work, but in fact it is strikingly modern. Workers 
in genetics use model organisms all the time, and now in human genetics one shifts, 
as indeed Cyril did then, between one species and another without much trouble. 
We know the genomes are all very similar. I think Cyril may have chosen butterflies 
as a rather unorthodox model organism, and I am quite sure one of the reasons he 
chose them was because they were more enjoyable than something like Drosophila 
to work with. There was extraordinary ability in the research design and original 
thought, and Cyril imparted that to all the people who were working with him. 
Professor Peter Harper: Rhesus Factor, p. 38
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C
Professor Sue Povey: 
Clinical Genetics
Cancer care
Cisplatin, the platinum-based chemotherapeutic drug, had an unintended but 
major contribution to make to medical oncology. The reason is that cisplatin 
led to great benefits because it caused emesis, and all the interest that there 
was in emesis and the control of emesis now cuts across to almost every other 
anti-cancer drug where the control is as good or better. Cisplatin ultimately 
caused a revolution in cancer care, in that having the ability to control emesis 
meant that patients generally could be treated on an outpatient or ambulatory 
basis, rather than having to stay in the hospital because of the dehydration and 
electrolyte imbalance that often occurred. This benefit of looking at the emesis 
was definitely stirred by cisplatin. 
Professor Richard Gralla: Platinum Salts, p. 46 
Cancer genetics
In the late 1960s quite a lot was known about chromosome abnormalities in 
cancer cells, but they were thought to be a consequence of the disease process 
rather than anything to do with the causation of the cancer. Nothing was 
known about genes that caused cancer, and the few rare inherited cancers, like 
retinoblastoma, were thought to be oddities of little importance. I already had 
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a clue that cancer genes were important from the work that we had done in 
Edinburgh on a specific chromosome abnormality that occurred in one type of 
leukaemia. I had shown, further, that male breast cancer was commoner in men 
with an abnormal XXY chromosome complement, suggesting that genetic make-
up was important in the causation of cancer. Further, from what I had read of 
earlier work by scientists such as Theodore Boveri, it seemed clear that genetics 
would be important in cancer causation. I also believed, since so many things 
about human beings were determined by an interaction between genetics and 
environment, that cancer, too, was likely to have a major genetic component. So 
off my grant application went to the British Empire Cancer Campaign Scientific 
Committee (BECC) in London. The reply which came back, many weeks later, 
was a bit of a bombshell. Effectively, it said that the BECC was surprised that I 
did not know that cancer was caused by environmental factors, such as smoking 
cigarettes, the use of tars, mineral oils, and other industrial chemicals. Genetics 
had little or nothing to do with it. However, since I was a new professor, the 
Committee would give me a small grant to get me going, on the understanding 
that I would come back with something more sensible in a couple of years. 
Professor David Harnden: Clinical Cancer Genetics, p. 99 
Cannabis
I had just come back to Israel from the US and I was interested in the chemistry 
and biological effects of natural products, and chose a few topics, one of which 
was cannabis. I asked the NIH in 1961/2 to support Dr Yehiel Gaoni and me. 
The Head of Pharmacology at the National Institute of Mental Health, Dr 
Daniel Efron, told me that they hadn’t awarded a single cannabis grant; they 
were not interested in cannabis; they thought that it was a drug used mostly in 
Mexico and South America: ‘It’s not an American problem; when you come up 
with something more significant and relevant, please call 
us.’ Nevertheless, my colleague, Dr Yehiel Gaoni and I went 
ahead. About a year later, I got a call from Dr Efron asking 
me whether I was still working on cannabis and when I said: 
‘Yes,’ he asked, ‘Can I come over?’ So, he came over and I 
inquired: ‘What’s the rush?’ He said: ‘Well, a senator called 
us and asked whether cannabis will ruin his son’s brain 
because he was caught smoking pot.’ The senator asked 
the NIH whether they had any medical or physiological 
information on cannabis. They had none because nobody 
was working on it; they hadn’t given a single cannabis grant 
‘…a senator called 
us and asked whether 
cannabis will ruin his 
son’s brain because he was 
caught smoking pot.’
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ever, I believe, maybe a decade previously, but anyway, at that time, they had 
no projects. By that time we had isolated the principal active component in 
cannabis, a molecule called tetrahydrocannabinol (THC) and elucidated its 
structure. Dr Efron took with him the world’s supply of THC, about ten grams. 
Quite a bit of the early pharmacological work in the US on THC was done with 
the material that Dr Efron got from us and NIH was happy. We got a grant and 
then later had to reapply many times; the grant continued for nearly 40 years, 
and this was my main source of support. 
Professor Raphael Mechoulam: Cannabis, pp. 7–8 
A large number of patients have reported, in the vernacular, that use of street 
cannabis in smoked, cooked or other forms, was giving them marked benefit. 
My temptation was to believe them. Why other people didn’t, I’m not sure. 
What was interesting when we started the programme was that as soon as we 
announced it, people started writing to us. We had a secret address and still do, 
but they wrote to the newspapers that covered the stories; they wrote to the 
BBC; they wrote to the Home Office. We used to receive a mailbag from the 
Home Office once a week. Over time, we had about 4500 patients who wrote to 
us and about 30 per cent of them had experience with cannabis. We then drew 
up, I think, a 70-point questionnaire and wrote back to them all. We wanted to 
know everything about what they did: where they found their cannabis; what 
type it was; whether they felt some was better than others; what caused them to 
Professor Raphael 
Mechoulam: Cannabis
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take more; what caused them to take less – supply was the problem that caused 
patients to take less, not side effects – and what other medicines they’d been on. 
We found a very clear picture of what the material could do and what we had to 
do then was to try to maintain that. Information from David Baker’s research, 
and a lot of research throughout the world, was beginning to add biological 
and scientific credibility to a quality of data, which, sadly in this day and age, 
physicians don’t heed very well. I think it is at their risk that they don’t heed and 
don’t seem to listen to the patients. I know that David’s study was absolutely 
heralded as ‘the actual proof ’, in that six mice got better; so that was fine. The 
fact that we had 4,500 patients, 1,000 of whom had got better, was irrelevant, 
because it was a different quality of data. 
Dr Geoffrey Guy: Cannabis, pp. 55–6 
Career influences
I was assigned to be oncologist Eve Wiltshaw’s houseman by 1974. One of the 
things that I had to do was to give this platinum stuff to a patient with ovarian 
cancer. I had been taught that you couldn’t treat people with advanced cancer 
and that the drugs didn’t work and that they always died. The patient got very 
sick and looked a bit peaky, but came back about two weeks later without any 
cancer. That was what converted me to spending the rest of my career as a 
medical oncologist. 
Professor Hilary Calvert: Platinum Salts, p. 27 
I suppose the reason I went into clinical pharmacology is 
possibly almost unique. I started at King’s College, London, 
aged 17, and I thought, ‘Well, I don’t want to complete 
preclinical studies too quickly and start clinical studies’. (I 
should also add in parentheses that my favourite pastime 
was spending the long vacation cycling across Europe to 
the Alps and back with a couple of friends.) So, I did a 
BSc in physiology, which meant two extra-long vacations, besides just one for 
the ordinary preclinical course. The part of the BSc that I enjoyed particularly 
was pharmacology. Having done the BSc and wanting another long vacation, I 
thought I would spend one more year and do a Master’s degree by examination 
in pharmacology. My entry into clinical pharmacology could be put down to a 
passion for transcontinental cycling. 
Professor Brian Prichard: Clinical Pharmacology 1, p.17 
…the reason I went into 
clinical pharmacology is 
possibly almost unique.
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My interest in palliative medicine was triggered by anger: the shock as a young 
doctor working in a general hospital where I was taught not to get too close to 
the patients or I’d begin to suffer with them. As a young psychiatrist, I did all 
the wrong things. I did get close to my patients. I got close to two patients who 
had both attempted suicide after the loss of a loved person. I got very interested 
in the developing field of psychology of stress and loss, and felt that this was 
somewhere I wanted to go. 
Dr Colin Murray Parkes: Palliative Medicine, p. 10 
In the late 1970s and early 1980s I worked with John 
Batten as a senior registrar at the Brompton, and one of the 
things that got me into CF was the evidence of the benefit 
of specialist aggressive units. You could see when patients 
came into hospital sometimes just how much you could 
improve them. They would come in malnourished, badly 
infected, really dying and, with intensive treatment, you 
could actually pull people right back, and that convinced 
me of the importance of both a positive approach and 
special clinics. It is worth remembering the impact of nihilism on the patients 
and their families before that time, many of whom had been told, ‘Your child 
will die at the age of five, oops, all right, by the age of ten. Still alive – well, wait 
until 15’, and we would then inherit them with this feeling of nihilism and 
negativity running all the way through that child’s life. 
Professor Duncan Geddes: Cystic Fibrosis, p. 22 
I was attracted into perinatal medicine by my experience in the slums of Dublin 
as a medical student. We were on our own without midwives or doctors. Another 
medical student and I attended 44 home deliveries in six weeks. It made a 
tremendous impression on me – the joy and excitement of the whole experience. 
Even though there were hairy moments, there was always a tremendous party 
after the birth in which all the neighbours joined in. This was a great bonding 
occasion for the community. It is sad that we have taken childbirth (and death 
for that matter) and shoved it away in hospital. In the home, though, there is 
the opportunity to share the joy at the arrival of the new baby, renew friendships 
and make up quarrels. 
Professor Peter Dunn: Maternal Care, p. 69 
It is worth remembering 
the impact of nihilism 
on the patients and their 
families…
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Cervical screening
In about 1964 the then Ministry of Health agreed that cervical smear tests should 
be offered, and available, to every woman. There were really no formal plans of 
how this should be done, but every pathologist became responsible for this. I think 
there were four or five training schools set up, and these were very important. 
I know there was Erica 
Wachtel (Hammersmith) 
and Chandra Grubb (Royal 
Free) in London, Betty 
Attwood in Birmingham 
and Blanche Butler in 
Manchester. One sort of 
offered oneself to these 
schools for training; there 
seemed to be no special 
funding for it, but that was 
the way to get your training, 
and that was the way that I 
got mine, with Erica Wachtel. It was fairly basic training, because you were 
shown slides, and told: ‘This is abnormal and this isn’t’. There was no one to 
explain to you what you were looking at or to explain that the aim of the exercise 
was to detect a precancerous condition. Many of the pathologists, who were 
responsible for offering or arranging screening in their own hospitals, really were 
not in a position to cope with the job because it is very time-consuming, and 
they were willing to take on anyone. I remember saying: ‘Well, I have been to a 
training school, I know how to do it.’ They said: ‘All right, we will take you on 
a trial basis.’ You were put in a little hole in the corner to get on with it on your 
own. I remember I actually sat in a fireplace, my feet were in the fireplace, and 
my microscope was on the mantelpiece and I had a suitably high stool to sit on. 
Until I proved my worth, I wasn’t given an office or a proper desk or anything. 
Professor Dulcie Coleman: Cervical Cancer, pp. 11–12 
To start with, we had people who were formally training to be laboratory 
technicians and then I think it was probably in the 1970s that we took on a 
group of women, mainly part-time, who became cytoscreeners. They were 
different to the people who were qualified with the Institute of Biomedical 
Science (IBMS); they didn’t have any formal qualifications, and they were often 
derided and called shopping-bag screeners, but they were absolutely fantastic at 
Three Aylesbury 
spatulas and one Ayre 
spatula, 2009: Cervical 
Cancer
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what they did. They were able to sit down quietly and concentrate and look at 
every cell that was being passed under the microscope, and I can say that that 
group of women now are nearly all retired, and it’s extremely difficult to replace 
them. The IBMS now think that we should have biomedical scientists with 
degrees and formal qualifications in cytology, but I can honestly say that on the 
whole they are not nearly as good at screening as those women from the 1960s 
and 1970s. 
Mrs Marilyn Symonds: Cervical Cancer, pp. 21–2 
Child protection
One of the most difficult things in my involvement with ALSPAC was trying to 
balance my responsibilities as a clinician participating in safeguarding children 
in the NHS with my responsibilities to the study. I felt that ALSPAC had to 
adopt the same thresholds of concern as were current in clinical practice. There 
were a couple of occasions where it did result in the family withdrawing from the 
study, and that caused a lot of heartache, but I think my conscience is clear that, 
at the end of the day, we did pertain to the same thresholds that were around at 
Mrs Marilyn Symonds, 
cytology laboratory, 
Stoke Mandeville 
Hospital, Aylesbury, 
1964: Cervical Cancer
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the time. There were one or two quite worrying cases of neglect and abuse, and 
of mental health issues, that we had to take account of. These are not written up 
anywhere, but that did go on behind the scenes. 
Professor Alan Emond: ALSPAC, p. 77 
Cholesterol
I saw a man in the Tower Hamlets heart attack register. Well, I didn’t see him, 
but I interviewed his widow. He had had an attack of chest pain in the night 
and the emergency doctor had come along and said that it was indigestion, and 
nothing to worry about, and he died before morning, his wife finding him dead, 
downstairs on the sofa at daylight. He had been admitted three years earlier to 
St Bartholomew’s Hospital and I noticed on his notes that his cholesterol had 
not been measured when he had his MI (myocardial infarction) or afterwards. 
The interesting thing was that he was only 28 years old when it first happened, 
but it was not considered necessary in 1968 to measure the cholesterol levels in 
a young man with a coronary in a London teaching hospital. 
Professor Hugh Tunstall-Pedoe: Cholesterol, p. 58 
Cisplatin
[In the 1970s cisplatin, a compound containing platinum salts, revolutionized the treatment 
of solid tumours such as those of the testes and ovaries for which there was no effective 
treatment. Unfortunately it caused massive emesis (vomiting) and some patients refused 
life-saving therapy because of these side effects. The development of powerful anti-emetic 
drugs to counter platinum-induced vomiting subsequently changed all cancer treatment.]
Wiltshaw:  In 1971 there was no other oncological unit in the country, and 
almost no other unit in the world, that was doing clinical studies in drugs, and, 
as you can imagine, we were not favoured doctors at the time. And, in fact, 
we were called the ‘death-watch beetles’, because we had to go to see people 
who were dying, and try to treat them with totally ineffective drugs. Nitrogen 
mustard was about the only drug that resulted in any kind of improvement. The 
situation in the 1970s was that we had this tiny medical unit that had no staff; 
there were two doctors, haemato-oncologist David Galton and myself, or David 
Galton and somebody else. There were no junior staff and we relied on David 
Galton’s international reputation to attract fellows from abroad to help us with 
the work, and these people were funded by themselves or by their countries; 
there was no such thing as funding for a clinical fellow for medical oncology. 
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Nevertheless, they did come and that was a great help to us. There was no senior 
house officer, there was no registrar, and there was certainly no nurse to help you. 
So we did all our IV therapy and work, blood products and so on, ourselves. It 
was impossible to do things in a big way at that time. To consider a collaborative 
trial was impossible. There was no unit to which you could hand out helpful 
hints and ask them to collaborate with us. Again, remember, there were no nurse 
data managers, so it was a slow business. The other side of the coin at the time 
was that there were few restrictions on trials: virtually no ethical permission was 
needed, and the hospital relied on the doctors not to do anything that might 
be considered detrimental to cancer patients. Again, all our patients knew the 
diagnosis in the 1970s. They might not have known it when they came to the 
hospital, but they were told when they arrived. We found that when they were 
asked if they would enter a study, often comparing drug A with drug B, very 
few refused. However, that kind of permission given by patients was well below 
what you would have to do now. Patients were not told about all the hazards that 
might occur. We are talking about ‘luck’ in terms of platinum compounds, and 
one of the things that we decided was to treat patients with ovarian cancer, not 
because we thought that this was the drug for ovarian cancer, but for another 
reason. One was that I had a small practice in ovarian cancer patients. The second 
was that we knew that this was about the only adenocarcinoma that responded, 
however badly, to alkylating agents. They did have a small response rate, and 
therefore we thought that this might be amenable to the new drug. That turned 
Dr Eve Wiltshaw: 
Platinum Salts
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out to be a very appropriate way to go. The first use of cisplatin was impressive to 
me, and I reported this to the cisplatin group at the Oxford conference in 1973. 
Twenty patients were treated and several showed dramatic regression of tumour 
masses and the disappearance of ascites – this was despite the fact that most were 
seriously ill before having this drug.
Calman:  What a remarkable testimony that was, and it shows, I think, two 
things: one, the courage of the oncologists but, just as importantly, the courage 
of the patients to be part of that process. You also mentioned the death-watch 
beetle bit. Sixty per cent of the patients referred to me in Glasgow in the first 
six months of my appointment there died within the month without treatment. 
That was the referral practice, which many of us saw in the early 1970s, and 
things changed at just about that time. 
Dr Eve Wiltshaw, Sir Kenneth Calman: Platinum Salts, pp. 25–6 
Clinical pharmacology
I had a row at the interview for the Professorship of Clinical Pharmacology 
because I insisted that I wanted to continue to do clinical medicine and this was 
contrary to some opinions in Oxford at the time. I very much liked doing clinical 
medicine, and I don’t think that a clinical pharmacologist 
could hold his head up unless he knows about the prescribing 
of drugs to people who are ill. Also, the clinical students will 
soon find you out if you are just a theoretician. You have 
got to know what you are talking about on a ward round 
or whenever you are teaching clinical students; you really 
must know the practical implications. I think it is extremely 
important to maintain this contact with ordinary, grubby, 
day-to-day medicine. Our problem is – and it hasn’t been 
said yet – that we are not organ-based. That’s why the subject finds its position 
difficult. Those who fund the NHS would rather pay the pharmacists – cheaper 
– to look after the drugs, not the clinical pharmacologists. So there is still a 
serious problem, I think, in the identity of the subject of clinical pharmacology. 
Professor David Grahame-Smith: Clinical Pharmacology 1, p. 34 
You have got to know 
what you are talking 
about on a ward 
round…
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Clinical research
It saddens me as I reflect upon what’s happened over the last few years (1990s), 
because I have seen how difficult it has become to pursue clinical research in the 
atmosphere of medical schools. The pressure of the NHS on beds, on positions, 
anything where you have to apply the lessons you learned from research to the 
care of patients and their prospering, is blocked by the way in which the NHS 
has regressed. Last year it was my privilege again to go round as an observer 
for the Wellcome Trust with the working party that looked at the possibility of 
providing clinical research facilities in various of our university medical centres. 
For me the wheel had turned full circle; from being able easily to run a medical 
unit, previously, in the heart of a medical school in London, we were now having 
to go and look at the facilities that were desperately needed in practically all our 
major teaching hospitals. They just were not there. And the Wellcome Trust was 
able to provide facilities, buildings and equipment, to five centres. As far as I was 
concerned, you could have made a strong case, and a strong case was made, for 
another dozen. Now that is where clinical research has arrived at over the last 20 
years, which seems to me a great shame. There is no shortage of people as one 
looks at the quality of those coming through both the MRC and the Wellcome 
Trust and all the other research bodies, but we are at risk of not being able to 
provide them with the right places in which they can pursue that clinical research. 
Professor Sir Stanley Peart: Clinical Research, pp. 41–4 
Clinical research methods
Between the time the Clinical Research Centre (CRC), Northwick Park, in 
London, was planned and its opening in 1970, a distinct change had taken place 
in the nature of research. For instance, there were observation wards throughout 
the research wing, the purpose of which was to allow patients to be observed 
and studied. And there were metabolic wards for long-term collection of excreta, 
etc. Neither of these facilities was much used because, by the time the CRC 
opened, new methods of clinical research had been introduced that depended 
less on direct patient study and more on sophisticated laboratory investigation. 
I believe there was a fundamental change in the way research was carried out as 
measurement technology developed. 
Sir Raymond Hoffenberg: Clinical Research, p. 33 
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Clinical trials
You must remember it was quite a different kind of clinical 
trial in the 1950s and 1960s from the kind done today 
because there were no lawyers looking over our shoulders 
with regulations, and it didn’t cost you £100 million in 
order to get a drug passed by the US FDA. So when we’d 
got something that worked reasonably well on laboratory 
infections, we took a few doses ourselves to determine the 
basic pharmacodynamics and then persuaded somebody to 
let us try it in the field. I don’t really think we did very much 
damage, and I think we did a bit of good. 
Dr Len Goodwin: Africa, p. 78 
Clinicians and drug discovery
A little warning: management takes a lot of notice of clinicians. The more 
eminent they are the more notice they take. Syntex/Roche was developing 
prokinetic drugs based on 5-HT
4
 agonists and they’d gone down the road quite 
a long way, although I was not in charge of this programme. But the company 
moved that programme forward and then they brought in some very eminent 
gastroenterologists after an awful lot of pre-clinical work and one of them asked 
in front of management: ‘Does this compound prevent pain? Gastrointestinal 
pain,’ and the answer was: ‘No, it doesn’t.’ The clinicians said: ‘Well, that’s it, 
it’s useless. We must have a drug that is analgesic for these IBS (Irritable Bowel 
Syndrome) patients.’ The company called him in and no matter what we said 
to management it was of no avail – the programme was stopped. It can be very 
damning how very quickly a whole programme can come to an end. 
Professor David Clarke: 5-HT, p. 109 
Committee on Safety of Drugs (CSD)
At our first Adverse Reactions Subcommittee meeting, in July 1963, we asked 
the secretariat to prepare a letter to be sent to all doctors in the United Kingdom. 
This was a warning about serious adverse reactions, which had been reported from 
patients who had been given monoamine oxidase inhibitors, used in the treatment 
of depressive illness. It was sent to all doctors in February 1964 and the circular 
went out on the now characteristic bright yellow paper, in bright yellow envelopes. 
These have been used for warnings about adverse reactions to drugs ever since.
…when we’d got 
something that worked 
reasonably well on 
laboratory infections, 
we took a few doses 
ourselves…
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This was the first official warning about adverse drug reactions ever issued by any 
drug regulatory body. There was an unexpected reaction to that warning from Dr 
William Sargant, a very distinguished psychiatrist at St Thomas’s Hospital, London. 
He believed so greatly in the value of monoamine oxidase inhibitor drugs that he 
would not accept that they caused any serious adverse reactions and he castigated 
the CSD in no uncertain terms. We were to find that this was not an uncommon 
response to reports that we issued about adverse reactions to drugs. There were 
always doctors who thought our warnings meant that the drugs were banned from 
use (which was not true), and that patients for whom the drug was of special value 
would be denied the treatment they needed (which was not true either).
It became clear to me later from colleagues that there were three reasons why hospital 
staff did not send in reports, even when an adverse drug reaction was the cause of a 
patient’s admission to hospital. The day-to-day care of patients and drug prescribing 
was usually the responsibility of junior doctors who did not necessarily realise that it 
was their duty to look for, and report, adverse reactions to drugs. Secondly, although 
they had been asked to report ‘suspected adverse reactions’, many physicians felt 
they should only report a reaction they were certain had been caused by a drug. And 
certainty is hard to achieve, when a patient may be receiving several drugs at the 
same time. Thirdly, some doctors were worried that drugs they valued greatly could 
be taken off the market if they reported adverse reactions to them. 
Professor Owen Wade: Safety of Drugs, pp. 123–4, 125–6 
Committee for Safety of Medicines (CSM)
The one other thing I’d like to say is about patients. All the way 
through my period on the CSM we did think about patients. 
We thought about them all the time. We may have looked 
at the risk–balance ratio in a sort of patronizing way, and I’d 
accept that. We may not have had meetings in public – in that 
period no scientific committee had meetings in public – but 
to say we didn’t think about patients is completely wrong. And 
the one person, above all, actually – surprisingly – who was 
always talking about patients, was the late Sue Wood (Principal 
Assessor, CSD). And although she was a very difficult woman 
in many ways, and she and I had huge arguments, which 
apparently reverberated around the building, nevertheless she 
was always, always talking about the ‘poor ******* patients’, as 
she put it. ‘What are you going to do about them?’ 
Professor Sir Michael Rawlins: Clinical Pharmacology 2, pp. 61–4 
Professor Sir Michael 
Rawlins: Clinical 
Pharmacology 2 
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Common Cold Unit
I remember my friend and I going to the Common Cold Unit as young medical 
students, and the very first thing we did was to look at the list of the other 
volunteers. We could speak to any of them over the phone. So we looked down 
the list quickly where there was a Miss Somebody and a 
Miss Somebody in a particular hut and sure enough they 
usually turned out to be students of some kind or other, 
especially as we were going there in the university vacation 
time. And so one picked up the phone and made contact 
with those two and what could one do? Play chess over the 
phone, which we did a great deal. We weren’t allowed to go 
within I don’t know how many yards it was of each other, 
so sometimes we’d do a walk and wave at each other and all 
one could look forward to was the social on the final evening, which hardly gave 
time for any relationship to develop. Anyway, they were enjoyable days and I am 
only too pleased to have made perhaps a very tiny contribution. 
Mr Michael Cox: Common Cold Unit, pp. 262–3 
Condoms
One of the jobs that the duty anaesthetist had to do was to buy a dozen condoms 
at the local chemist’s shop, because, at that time, tracheostomy tubes tended to 
be very crude, and we found the best ones were silver tubes with a home-made 
cuff made from a condom on the outside. These things did tend to burst from 
time to time, but we always had half a dozen ready for changing over. It was a 
very good way of keeping the tracheostomy tube clean, because, of course, the 
inner tube was silver, it was taken out, and it worked as an airtight fit as well. 
Dr Joseph Stoddart: Intensive Care, p. 44 
Although SIGMA (Socio-sexual Investigations of Gay Men and AIDS) actually 
began in 1982 to research homosexual behaviour in a multi-site context, the 
project wasn’t fully funded until 1986. It’s worthwhile, I think, to say that at one 
point, the ESRC (Economic and Social Research Council) was asked why it had 
not funded research in sexual behaviour and AIDS in that crucial period, and 
they said they had received no grant applications. In fact we had submitted an 
application, and I was subsequently able to get them to withdraw that statement. 
But they were certainly worried about the intentions of Mrs Thatcher, who had 
quite publicly threatened to get rid of sociology from the ESRC on the grounds 
We weren’t allowed to  
go within I don’t know 
how many yards it was  
of each other…
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that it was not scientific. Therefore, for the ESRC to be seen to be paying for 
a project that was so strongly controversial simply wasn’t on. In the end we got 
the funding from the Department of Health primarily for looking at condom 
adoption, and only secondly from the MRC. We were able to demonstrate that 
the adoption of condoms by gay men took place in the early part of the period 
and that, by 1986, when we got funding to look at this, the process of condom 
adoption was virtually finished. It was only because of the medicalization of the 
research problem that we got the funding to mount the project. With the social 
sciences we wouldn’t have, in fact, got any funding. 
Professor Tony Coxon: NATSAL, pp. 12–13 
Conferences
I learnt more in unofficial discussion around the swimming pool, than I did 
from any of the formal presentations, because I met people, I talked to them 
informally, and I got many ideas and contacts from that very nice relaxing two 
hours. There is a lot to be said for not overburdening your conferences with too 
many papers. 
Dr David Wheatley: Psychiatric Drugs, p. 193 
I have an uneasy feeling that the pharmaceutical industry may be unduly 
influencing the dissemination of information about psychopharmacology 
through their heavy involvement in the organization and funding of international 
conferences. I remember that when I attended the First and Second British 
Lithium Conferences in 1977 and 1987 respectively, these meetings were not 
sponsored by the pharmaceutical industry to any great extent and were held in 
Lancaster and Wolverhampton, not particularly glamorous settings I think. 
Dr Philip Harrison-Read: Psychiatric Drugs, p. 195 
Contamination problems
In 1985 tests for HIV were introduced to the Blood Transfusion Service and, in 
fact, tests for HIV became generally available. We were all asked by the parents 
of the haemophiliac children we were looking after, ‘Please test our children’ and 
that’s what we did. But we read the message wrongly. What they were asking us, 
without saying so, was, ‘Please find my boy is negative’. In those days when the 
first test came out, the concept of counselling was really not very well understood, 
and certainly we didn’t understand it. We told the parents the results and then 
an enormous flood of anxieties and queries came in and people came and talked 
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to us. When the test was first introduced, a large number of 
our boys were quite small, but as time went by, little boys 
of 12 became big boys of 16 or 17 and it became time for 
them to know. In a children’s hospital, it is very difficult 
to inquire into the sexual habits of your patients. It is just 
not in the ethos of a children’s hospital, and we thought 
that all these boys should know their HIV status. Whether 
or not they would actually modify their behaviour we very 
much doubted, although we did have condoms available 
in the Haemophilia Centre. It proved very difficult to get them to talk and it 
proved impossible to persuade their parents to tell them. Eventually we came 
to an agreement that if the boys asked, we would tell them. Various ways and 
means were found to raise the topic so the boys actually asked us, so they could 
be told. One father came to my office at 8 o’clock in the morning and he said, 
‘I hear what you are planning to do. On no account should my son be told, it 
will destroy him’. Eventually the boy found out and said he was grateful to be 
told because it was all hushed up so much at home that he thought something 
much more serious must be afoot. You will all remember how dreadful it was at 
the time with the television advertisements showing rolling waves and talking 
about HIV and safe sex, and so forth. When this happened in a haemophilia 
household the television was turned off. 
Dr David Evans: Haemophilia, pp. 27–9 
Controlled trial
Archie Cochrane was very quick to confess that he had never done a randomized 
controlled trial but he stimulated everyone in the MRC Pneumoconiosis Unit to 
think in those terms; it was almost a religion at the unit, and many, many others 
did randomized controlled trials. But Archie did publish a delightful paper that 
I am sure most people are aware of. ‘My first, worst, and most successful clinical 
trial’ described his experience in the prisoner of war camp with famine oedema. 
His output measurement was the buckets of urine that were carried out from the 
different wards. I would just like to tell a little fact about that. Archie talked about 
it occasionally to us in the unit, but I asked him if he would address a meeting. 
I had arranged a conference on some topic, and I invited all the speakers and 
a few key people to a dinner the evening before, and when I did this I usually 
asked somebody to give a talk on something to entertain the guests after their 
dinner. I asked Archie on one occasion would he tell us about his experiences in 
the prisoner of war camp and about this controlled trial, and he agreed with very 
In a children’s hospital, it 
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great reluctance. As he told the story and spoke about the horrific conditions in 
the prisoner of war camp he almost broke down emotionally. He had very great 
difficulty in finishing the story, but afterwards he came and thanked me. He 
said, ‘You have helped me to get over that difficulty and I am glad you did it.’ 
Very shortly after that he wrote it up and it was published in the British Medical 
Journal but that was the only controlled trial that he did. 
Dr Peter Elwood: Population-based Research, p. 23 
Coronary heart disease (CHD)
We set up incidence studies of CHD among men in a wide range of occupations 
to give us information to go alongside the national mortality statistics. The studies 
included a huge range of occupations: medical practitioners, schoolteachers, 
factory workers, and, very importantly, a range of 
occupations in London Transport and the civil service. In 
1949 I had a hunch that acute myocardial infarction could 
be related to occupation. It was more common in men 
than women, in middle age than in youth; there were some 
hints in the national mortality data. Within a year there 
was an intriguing suggestion of some protection against 
CHD, in particular against the most serious acute coronary 
syndrome – sudden death as first clinical manifestation – in 
the conductors of London’s double-decker buses compared 
with the drivers, and in postmen versus three sedentary grades of office workers 
in government. We were soon struggling with the far more difficult issues of 
research into exercise in leisure time by a population rapidly becoming sedentary 
by the early 1970s. 
Professor Jerry Morris: Cholesterol, pp. 41–2 
We are actually on the verge (2005) of a pandemic of CHD far greater than we 
have ever seen before. We think we are beating it here, and we are, but CHD is 
not due to deficiency of statins. It is also not, by and large, a deficiency of genes; 
it is nutritional. I think that was why people had a lot of trouble accepting the 
cholesterol hypothesis in Britain. When all we could do to lower cholesterol 
was to criticize the food and agricultural industries, and to talk about diets, 
there were great forces ranged against people who wanted to lower cholesterol. 
These industries killed a lot of the enthusiasm for nutritional change by their 
promotion of negative views. I don’t want to talk about individuals, but it was 
very obvious that if you had certain speakers at a medical meeting their lectures 
…I had a hunch 
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would be organized and arranged by the food industry. In the early days of 
gene work as well, the suggestion that CHD was genetic was publicized because 
it was a distraction from nutrition. When statins came along then we had a 
big industrial force raised behind cholesterol-lowering with drugs. Statins have 
undoubtedly been a great boon. They have been a great success and we haven’t yet 
seen their full benefits, but we shouldn’t lose sight of the fact that one casualty of 
statins has actually been the nutritional hypothesis. For most parts of the world 
where CHD is going to be important in the future, it is a nutritional problem. 
It can only be tackled nutritionally: drugs are too expensive there. I think that 
point has been lost sight of and it worries me greatly. 
Professor Paul Durrington: Cholesterol, pp. 53–4 
Cypriot community in London
In the 1970s, I was specializing in the clinical management of thalassaemia 
and what happened within a month, a few months of my having set up this 
clinic, was that a rather rapidly growing number of patients 
attended our own hospital or were referred to us from 
adjacent hospitals. The struggle for independence in Cyprus 
from 1957 to 1960 caused 10 per cent of the entire Cypriot 
population to migrate to the UK because of civil strife 
and economic depression. Most came to North London 
in the intake area of my hospital (University College), and 
adjacent hospitals, and so we started seeing thalassaemia 
major. I worked out that at least 14 per cent of these people 
carried beta thalassaemia, which was a lot. It turned out to be 17 per cent in the 
end. We had a population at very high risk, and patients started cropping up in 
all the hospitals round about, so I became a sort of referral centre. I very quickly 
found out that if a woman who had had a child with thalassaemia major became 
pregnant, they rang me up in a panic and asked me to arrange a termination 
because they were so afraid of having another child with this hopeless prognosis 
and a very punishing treatment of monthly blood transfusions. 
Professor Bernadette Modell: Clinical Molecular Genetics, pp. 23–4 
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Cystic fibrosis
Cystic fibrosis – adult patients
Cystics are, and are going to be, living longer and we have got to take away 
the age barrier, which would change the view of people treating cystics. I get 
very annoyed. Nihilism is a constant problem. Somebody asked me at lunch 
two months ago (and it’s the first time it hit me), when they asked a younger 
colleague (who is not CF), ‘What’s your ambition?’ The colleague turned round 
and said ‘My ambition is…’ She then asked me what my ambition was, and 
I thought to myself that I really had no ambition because I was supposed to 
have died when I was 16, and then it was 18, and so it has gone on – even now 
at the age of 38. If a cystic isn’t strong enough to say, ‘Well, there’s a first time 
for everything,’ it is extremely difficult to live through. There is a first time for 
everything, good and bad, and I get very annoyed when people fail to think that 
how they treat the patient now can affect the patient in the future. 
Miss Tracy Humberstone: Cystic Fibrosis, p. 72 
Cystic fibrosis – dietary management
During the late 1970s and early 1980s there was an enormous difference in 
dietary management as we went from low-fat diets, from dietary restriction in 
people who were undernourished, to Pancrease and high-fat diets, and suddenly 
people’s weight took off, and instead of inheriting very malnourished sort of 
sexually immature 18 year olds from the paediatricians you began to get these 
rugby first-row forwards coming through. 
Professor Duncan Geddes: Cystic Fibrosis, p. 22 
Cystic fibrosis – infection
 A young man with cystic fibrosis in 1990, or 1991, had acquired Burkholderia 
cepacia infection, possibly from contact with someone who had been to a 
Canadian cystic fibrosis camp, and he met and fell in love with and was shortly 
to marry a girl who also had cystic fibrosis, and she grew Staphylococcus aureus 
only in her sputum. Within two months of the start of that relationship, this girl 
had also acquired B. cepacia. The young man died within six or eight months 
of their meeting, following a lung transplant operation and three months later 
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the young woman died. This terrible event alerted us to the facts of this dreadful 
infection by which so many clinics in the UK have been so scarred over the years. 
This is a problem that we are only now getting to grips with through segregation 
and other infection-control measures. 
Dr David Stableforth: Cystic Fibrosis, pp. 31–2 
Cystic fibrosis – treatment in 1945
It’s difficult nowadays to envisage what it was like in 1945, but for those of us 
who had come back from the war to this country, it was an extremely exciting 
period. So many new advances in medicine: paediatrics itself had become 
accepted as a real branch of medicine, and not a junior partner; there was the 
discovery of the antibiotics that totally changed our attitude 
to infectious disease, which was of particular importance, 
of course, regarding CF; last, but not least, was the advent 
of the NHS in 1948. We could prescribe drugs without 
worrying whether the family could afford them, a matter 
of immense importance in a persistent long-term disease 
such as cystic fibrosis. Treatment – again primitive. The 
symptomatic steatorrhoea was controlled to some extent by 
pancreatic tablets or powder, and by a strict low-fat diet, 
which may not have been the best thing, but at least reduced the number of 
offensive stools, and certainly reduced the amount of offensive flatus, which 
for schoolchildren was very upsetting and unpleasant. The low-fat diet was 
supposed to be supplemented by a high-protein diet, but as much as one insisted 
on children having a high-protein diet, it was virtually impossible. These were 
still the days of rationing; proteins of any sort, and particularly meat, were in 
short supply and very expensive, and certainly there weren’t many children who 
received even a normal protein diet by today’s standards. Chest infection, usually 
considered to be staphylococcal, was treated with courses of penicillin and then 
aureomycin, or terramycin, or whatever was coming along. Physiotherapy was 
really pioneered in this country, rather than in the US, with postural drainage 
and chest tapping. Surprisingly these very primitive measures did decrease 
early mortality and at least temporarily improved the outlook for the older and 
therefore less severely affected child. 
Dr Archie Norman: Cystic Fibrosis, pp. 4–6
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Mrs Diana Garratt 
neé Northover: 
Dialysis
Department of Health
The most dangerous organism we have is the Department of Health. This has 
become very clear to me. From about the early 1990s, we were being forced into 
accepting excessive surgical admissions to reduce waiting lists, or to have our 
finances cut. I once tried to close a ward at the John Radcliffe Hospital, Oxford. 
The Chief Executive said: ‘Certainly we will do that, but you realise that it will 
cost us £500,000 if we don’t meet our expected patient put-through rate: think 
of the hospital, please’. And I foolishly conceded. 
Dr Joe Selkon: MRSA, p. 37 
Dialysis
Home dialysis
Dialysis, especially home dialysis, changed the face of British medicine. It 
introduced the nurse specialist, teamwork, particularly in the home. It introduced 
informality between staff, nurses, and doctors, and it gave patients the chance to 
have their say. This really was a huge change in the manner in which health care 
was delivered in this country. 
Dr William Cattell: Dialysis, p. 76 
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Home dialysis: a home dialysis administrator’s perspective
I was frequently the last person any patient with renal failure wanted to meet, 
because when they met me it was confirmation that their renal function was 
not going to return and starting home haemodialysis was further confirmation 
that their kidneys weren’t going to work unless they had a successful transplant. 
In the early days, I had to liaise with the local authority who weren’t always 
very happy about meeting the costs of the adaptations. 
The home dialysis treatment room requires a mains 
water supply and drainage to facilitate effluent from the 
water softener and dialysis machine, waterproof flooring 
and shelving, and a separate metered electricity supply. 
However independent we made the patients, what went on in their homes 
was a different issue. Frequently the spouse or partner provided considerable 
support. Few homes have spare space, and in the 1970s the dialysis equipment 
was considerably larger than that used today. Lack of adequate space to house 
the dialysis equipment and disposable dialysis supplies might necessitate the 
building of an extension to the home or a cabin in the garden, usually with 
covering from the house to the cabin. Only adults used the cabins. No patient 
was ever allowed to dialyze at home without a functioning telephone in the 
treatment room. Many of them had never had a telephone in their house and, as 
far as they were concerned, a phone in the house was the harbinger of bad news. 
Patients were overwhelmed at having to cope; learning to dialyze independently 
at the same time as having adaptations done and equipment installed by renal 
technicians caused considerable strain. 
Miss Mary Selsby: Dialysis, pp. 60–3 
Home dialysis: a patient’s perspective
I am a renal patient, started in 1969. It was January 1970 when Rosemarie 
Baillod came round to set me up at home on haemodialysis with my first shunt 
and I remember the room very well. We had a de-aerator, it looked like a toilet 
cistern, high on the wall above the bed. Actually, I think I was dialyzing on 
the table at that time, we hadn’t organized the bed. The rest of the family went 
on around us; we had a small TV, my younger brother and sister and the cat, 
who went very soon after because it was sitting there watching the pulsating 
blood lines and that was very nerve-wracking, very, very nerve-wracking. We 
got through it, but it was an enormous effort. Every day you were either on 
the kidney machine, or you were hoping that the machine, which was not at 
Patients were overwhelmed 
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all reliable compared with the modern machines, would work, that the kidney 
would not burst, that you wouldn’t have a blood leak. 
Mrs Diana Garratt: Dialysis, pp. 56–7 
Home dialysis: her mother’s perspective
Diana had two siblings and really dialysis had to be a normal part of the family 
pattern; it couldn’t take priority. The other two children needed attention. The 
last thing I would like to say is that the funny thing about home dialysis is that 
when we had got past the ten-year mark – we went on for about sixteen years 
before Diana got a transplant in 1985 – what we found was that you worked so 
hard and you had so little rest, that when finally you’d finished with the dialysis, 
the Kiil (part of the dialysis equipment) was put on the local dump and the 
transplant was working, you couldn’t really remember what you had been doing 
a lot of the time. So this was extreme, emotional, psychological, and mental 
fatigue. I don’t know what the two sides of the brain were playing at! But I kept 
a friendship going with another dialysis mother, and she said, ‘I need you as my 
Diana Northover, 
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witness, because I have got to talk to somebody, I have got to know that we really 
went through it.’ She suffered from the same thing. So when people say, ‘Oh, go 
and learn French by total immersion’, I have to say that what we learnt on home 
dialysis was certainly ‘home dialysis by total immersion’. 
Dr Jean Northover: Dialysis, pp. 58–60 
Dialysis: patient selection
In the early days, the early 1960s, when we had to be highly selective, our only 
criterion for acceptance was: ‘Can we get this patient back to work?’ 
Dr John Goldsmith: Dialysis, p. 70 
Difficult doctors
My generation – becoming a general practitioner as I did in 1975 – was greatly 
influenced by the publications and the work of psychoanalyst and GP educator 
Michael Balint and the Balint Society. There was a realization that when there 
were difficulties in the relationship between a doctor and a patient, it wasn’t 
just that these were ‘difficult patients’, but Balint turned the searchlight on the 
‘difficult doctor’ and asked why was that doctor having a particular problem in 
this way. And that gave a way in which young and old within the groups could 
discuss what was the real issue that one was trying to deal with; was it something 
within one’s own experience, or was it one’s own set of attitudes that was creating 
the difficulty? Now I personally think that we are in great danger of having lost 
that from medical education. 
Professor Roger Higgs: Medical Ethics, pp. 55–6 
Disabilities
A 1972 conference, funded by Action Research, dealt with the causes of the 
main disabilities, cerebral palsy, mental retardation, blindness, and deafness, 
and was interdisciplinary; it had neonatologists, paediatricians, obstetricians, 
and geneticists, and the idea was to channel Action Research money to support 
paediatric research, particularly in the neonatal area, and possibly some obstetric 
research. What came out from the papers of that conference was that by far 
the largest proportion of those disabling conditions were essentially nothing to 
do with what happened during labour or delivery or in the newborn period, 
and a great deal more to do with genetics and environmental factors, and 
Action Research then decided not to publish the papers. Obstetricians and 
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neonatologists have had a lot of money in the past because they believed they 
were going to avoid these terrible conditions, but they are not responsible for a 
major fraction of them. 
Professor Sir David Hull: Neonatal Intensive Care, p. 58 
Doctor–patient relationship
When I first went into general practice, I asked one of my patients what she had 
been told at the hospital – this was 1976 – and she said: ‘Well, they don’t tell me 
nuffin’, doctor, ’cos they got that oaf ’. And while I was trying to work out who 
the oaf was that she was talking about, I realised that she meant the Hippocratic 
Oath. From her point of view, having been born at the end of the Victorian age 
in working-class London, she was very clear that doctors took an oath not to tell 
the patient anything, and that was her view. 
Professor Roger Higgs: Medical Ethics, pp. 62–3 
The idea that a doctor and a patient with a chronic condition take out a contract 
with each other, which is now standard in medicine, was pioneered in the 1960s 
in nephrology, almost by default. We were going to ask patients to do so many 
things with their lives and in their lives, and we were going to invade their homes 
especially and so they would have to take more responsibility as well. 
Professor Stewart Cameron: Dialysis, p. 43 
Doctors’ ignorance
The other day I was at Guy’s, where the ‘doctors of the 
future’ were present. It was a training evening where they 
have to diagnose what disease the patient has. One student 
doctor examined me, and was asked what her diagnosis was. 
In passing she said, ‘Well, I ruled out cystic fibrosis because 
she’s too old.’ I sat there and thought, ‘This is the young 
doctor of today, and she’s going out on to the wards and she 
is going to encounter CF in adults.’ Somebody asked me 
once, ‘Well, can’t you tell the doctors?’ If you are in hospital 
and that doctor is looking after you for two weeks or more. 
I try to say, ‘I want to help you. I have CF and I have lived 
with CF for 38 years, so please listen to me’. 
Miss Tracy Humberstone: Cystic Fibrosis, p. 72 
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Domiciliary care
The 1959 study in Madras of home versus sanatorium treatment for TB showed 
that domiciliary chemotherapy was as effective as in the sanatorium and caused 
no more disease among household contacts. It had a profound effect on our 
practice here, so that by the end of the 1960s most of the tuberculosis sanatoria 
and hospitals were either closed or were closing down. 
Dr Kenneth Citron: TB Chemotherapy, pp. 31–2 
Drug abuse
One of the focuses now in the [United] States, is on cocaine, with the emphasis 
on possibly manipulating the transporter pharmacologically as a way of dealing 
with dependence, and all that is to the good. It adds to medical knowledge, 
medical practice, and treatment. Whether it has achieved its aim, I’m not sure. 
Drug abuse is such a difficult and complex socio-economic problem, I’m not sure 
scientists will ever be able to come fully to grips with that. All that we can do is 
try to give a range of possible alternatives so that governments and the responsible 
agencies can try and make of it what they will. Science is not going to solve drug 
addiction. All it can do is provide tools that could aid social policies. 
Professor John Hughes: Endogenous Opiates, p. 90) 
Drug discovery
I was a lecturer at St Mary’s Medical School in the physiology department and 
I didn’t really want to just teach medical students and end up with a line in a 
textbook, so, I thought, I want to discover a drug, and I was very fortunate 
and was employed by the pharmaceutical company Allen & 
Hanbury, later Glaxo, to find an anti-migraine drug. When 
I got there I found an empty lab and a girl sitting on a stool 
saying: ‘What are we going to do?’ I said: ‘Well, I don’t 
know; we’ll have to think about this’ because there were 
no preconceived ideas about how we should proceed. That 
would never happen today, to be given that freedom. I don’t 
think I would have discovered anything if I’d gone to Glaxo 20 years later. So 
the empty room is the first thing you need if you want innovation and what did 
I do? I went and spent three months talking to clinicians while I was waiting for 
equipment to arrive, finding out about migraine.
…the empty room is the 
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But I just can’t imagine how such a drug as sumatriptan would be discovered 
today. First of all if someone said: ‘Well, there are 14 different 5-HT receptor 
types and we know that 5-HT aborts a migraine attack, you go and find the right 
one.’ With just the molecular biology and paucity of whole tissue and in vivo 
pharmacology, it just wouldn’t work. Then if you have the Clipboard Charlies 
going around telling you how to run your project and how you should be doing 
it, that would kill it as well. So I think I was very, very fortunate in being at the 
right time in the right place with the right organization. 
Dr Patrick Humphrey: 5-HT, pp. 99, 101 
Drug testing in sports
My first involvement with the Institute of Sports Medicine was in 1965 when 
I found myself responsible for introducing drug testing into world sport in 
an event called the Tour of Britain cycle race, also known 
as the Milk Race. I was doing my PhD on stress on the 
heart, and I wanted to look at people involved in a long 
endurance event. I had tried to get on the Tour de France. 
The British Cycling Federation said: ‘Why don’t you go on 
the Tour of Britain?’ I didn’t even know what that was. So 
I got an invitation to it and the week before I went, it was 
announced in the press that I was going to do drug testing, 
but I knew nothing about it. My own university refused to 
help me, but a man called Arnold Beckett from King’s College London did. We 
started drug testing under the auspices of the Institute of Sports Medicine. That 
was in 1965. As a result of positive tests we banned the Spanish team, and I still 
don’t go to Spain. 
Professor Harry Thomason: Sports Medicine, pp. 19–20 
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Dr Stephen Lock: 
Medical Ethics
Educating children with chronic conditions
Concerning steroids in the 1960s and the 1970s, I saw a number of children 
with extremely severe asthma – stunted, ill, never at school. When treated with 
prednisone, say 5–10 mg daily, they could return to what appeared to be a 
normal life and normal schooling and this was a great result because they were 
no longer thought to be dim and unfit for school. They were normal children for 
that time. But after a year or so, it was becoming manifestly unsafe to continue 
with an asthma-controllable dose of prednisone or steroids and one had to stop. 
Dr Archie Norman: Asthma, p. 9
Selsby:  I liaised with schools so that the children on dialysis got back to their studies 
as quickly as possible. We were very fortunate at the Royal Free Hospital to have a 
superb teacher in the paediatric department who also liaised with the schools. We 
did have trouble with school outings as teachers wouldn’t want to take a dialysis 
patient. I would ask: ‘Have you got any asthmatics?’ ‘Oh, well, yes, but they are 
different.’ ‘No. They are more difficult to look after than a dialysis patient.’ We 
also had patients who would argue with teachers to be allowed to participate in 
sports and their teachers, being very protective, didn’t want them to do this.
Garratt:  I was always very popular on school trips because I didn’t need to go to 
the loo. So, I would actually be the one looking after all the bags. 
Miss Mary Selsby, Mrs Diana Garratt: Dialysis, pp. 62–4 
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Electron capture device
I invented, in 1956 at the National Institute for Medical Research at Mill Hill, a 
device called the electron capture detector. It was exquisitely but selectively sensitive 
to unpleasant substances, including halogenated compounds, and it could detect 
them directly in biological materials with minimal prior sample preparation. By 
1960 it was available from scientific instrument manufacturers in Europe and the 
USA, and was widely used. It was not long before the electron capture detector 
became the standard method for pesticide and herbicide analysis. Its disadvantage 
was that it was much too sensitive. As little as a few hundred thousand molecules 
of a pesticide like dieldrin or DDT can be detected, or in other words a few 
femtograms. At this sensitivity pesticides can be found in natural vegetation, even 
from a remote area such as the islands off Antarctica. As soon as a quantity is 
attached to a measurement, sadly it seems to acquire a spurious significance. 
Professor James Lovelock: Environmental Toxicology, pp. 5–6 
Endoscope/gastroscope
I believe the surgeon Harold Edwards smuggled an endoscope into this country 
in 1934. The cost of the Schindler gastroscope was £80 plus a £40 excise duty 
from Germany. This was quite beyond him as a mere private consultant surgeon 
starting his career at that time. But Hitler was just coming to power and he 
did the one good thing he ever did, according to Harold Edwards, he doubled 
the amount of Deutschmarks you could get per £1, which halved the price of 
the gastroscope. So all Edwards had to do was to smuggle the endoscope into 
this country to avoid the excess duty. He did this by despoiling its brand new 
container box with the heel of his shoe to make it look old. But he had a tough 
time with the customs man at 5.00 a.m. in Harwich, I believe. He published a 
confession in the British Medical Journal 50 years later! 
Dr Peter Down: Peptic Ulcer, pp. 46–7 
Environmental awareness
There was very little concern about world ecology before Rachel Carson’s book 
Silent Spring. We were all in a humanist frame of mind and the good of mankind 
seemed to be a sufficient aim for us to work towards. Certainly in the Medical 
Research Council I don’t think anybody seemed to feel that what they were 
doing could even conceivably be thought of as harmful to the environment. 
Professor James Lovelock: Environmental Toxicology, p. 8 
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Environmental lead
The MRC Epidemiology Unit conducted studies on environmental lead from 
1976 to 1982 and chose three areas in Wales with different levels of traffic, from 
a rural area to a very heavily polluted area. The heavily polluted area was Port 
Talbot, where there’s a motorway, which is elevated above houses. Along this 
motorway we chose houses on the main road and houses with the motorway over 
above, and we did lead sampling in blood and lead air sampling, and confirmed 
that the lead levels were very, very high, and air lead levels were very high. We 
also took blood from women from Beaufort at the top of one of the valleys, where 
there’s quite high traffic, and from Porth where there’s a one-way system and very 
heavy traffic. But then we went to three islands. Tory Island off the north coast of 
Ireland is a rather isolated community, and we were told it had no petrol traffic at 
all, never had and there was never likely to be any petrol traffic. My colleague was 
appalled to see a petrol-driven van sitting some little distance from the harbour 
and made enquiries about it. Apparently about two years previously the local 
authority had given a petrol-driven van to the islanders because there were two 
communities on the island and, the school was at one end of the island and, on 
wet days, the van would collect the children from the other community. The 
islanders had been told that petrol was put in at the back of the vehicle, and water 
in at the front, but they had forgotten to tell them that you also put in oil from 
time to time to lubricate the engine. So the van ran very happily for some time 
and then it seized up, and they just left it where it had ceased and never bothered 
with it again. With that background we felt we could call it a traffic-less island. We 
took blood from every adult, swept every house to get lead in dust, and measured 
air lead. We then went to Arran Island off the west coast of Ireland, and again my 
colleague was appalled to see a petrol-driven car on the island and he found that 
the district nurse on the island had brought a car over, sometime previously, and 
every time she went to the mainland, at most once a month, but probably not 
even that often, she took her petrol can and collected two gallons of petrol, put it 
into the car, drove the car until the petrol ran out, and then just left it wherever it 
was, until she next went to the mainland. So again we felt that we could call it a 
traffic-less island. The third island was truly traffic-less, and that was Sark in the 
Channel Islands. No one is allowed any mechanically driven vehicle of any kind, 
lawnmower included. So we truly did have a traffic-less, vehicle-less island, and 
we got blood from them. We found that the levels were almost identical to the 
areas in Wales. There was very little difference between them. 
Dr Peter Elwood: Population-based Research, p. 125 
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…lead levels in the water 
were really quite high, 
higher than the WHO 
recommendation.
The Welsh Office asked the MRC Epidemiology Unit to look at water lead. Some 
of the areas in Wales have a very acid surface water and old lead pipes. One or two 
studies had shown that the lead levels in the water were really quite high, higher 
than the WHO recommendation. We went to north Wales and did a number of 
surveys of water lead and blood lead, and estimated that the contribution that 
water was making to blood lead levels was quite substantial. Whereas with air lead, 
no matter where we went we couldn’t get estimates of the contribution to blood 
lead from air higher than about 10 per cent. Now there were uncertainties in this. 
Food lead was obviously a very important source and food handling wasn’t nearly 
as careful as it is now. I suspect that a damaged conveyor belt might be repaired 
with lead solder, whereas now they wouldn’t dare have lead solder anywhere near 
food handling. I suspect that the fall in lead levels, which has been shown quite 
conclusively in many studies over the years, has been largely due to a reduction 
in water lead and in food lead. We certainly showed that the lowering of water 
lead was important and was effective. On two occasions we 
were alerted to the fact that the Welsh water authority was 
going to change the pipes to an estate or to a village, and 
so we went and got blood lead levels and then we followed 
the blood lead levels following the change, the removal of 
the lead pipes and the putting in of copper pipes, and we 
showed very nicely the fall in blood levels and we showed 
the sort of half-life of blood lead from those studies. 
Dr Peter Elwood: Population-based Research, p. 124 
Transport on traffic-
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Epidemiology
I realised that epidemiology is really a democratic subject, high response rates 
means one man one vote, everybody in a community is important. We need 
everybody’s blood pressure, we don’t just need the blood pressures of people who 
have come along to see you about their blood pressure or have coronaries, we 
need the whole distribution. 
Dr Julian Tudor Hart: Population-based Research, p. 66 
Epstein–Barr virus
It would be nice to point out that African experience and African staff have 
contributed something rather important to world medicine. I think of the time 
I went through to Makerere and met Denis Burkitt. He was, I believe, originally 
there in the Colonial Medical Service as a practising surgeon, but with an eye for the 
unusual. He had just shown that he could treat the so-called Burkitt’s lymphoma 
by chemotherapy and also that it had a very unusual distribution. Then the English 
virologist Tony Epstein observed herpes-like particles in the tumours, and discovered 
what is now called the Epstein–Barr virus. But I think it was truly remarkable that 
a very busy person doing what could have been called ‘just’ routine work was able, 
within the environment of that day and that place, to make completely original and 
lateral-thinking observations of something that has had an enormous effect since. 
Dr David Tyrrell: Africa, p. 41 
Ethics
If we look back at the beginning of intensive care 
in the 1950s, it is probably fair to say that none 
of us were taught anything about ethics then, 
and medicine was a paternalistic subject: doctor 
knows best. Since that time, medicine has become 
infinitely more complex and has the capacity to 
create harm as well as benefit. At the same time, 
patients have become more sophisticated and 
want to have their say in what is done. Intensive 
care, perhaps, has brought more focus on some 
of the ethical disciplines, for two reasons. First 
of all, it is often previously healthy adults who 
become acutely sick. Such patients were legally 
Dr Margaret 
Branthwaite:  
Intensive Care
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incompetent. But perhaps the most important of all is the proximity, in time, 
between the decision taken and the outcome. If chemotherapy is withdrawn 
from somebody with leukaemia, the outcome may not be entirely clear – how 
the death is going to occur nor when. If you discontinue mechanical ventilation 
in somebody who can’t breathe, the outcome is very immediate and there in 
front of you. So intensive care, to some extent, became a focal point for the 
emergence of ethics as a conflict in medicine. 
Dr Margaret Branthwaite: Intensive Care, pp. 73–4 
Ethnic minorities
There was increasing interest in the health of ethnic minority groups around 
in the late 1990s, so although it wasn’t in the original NATSAL application, at 
a later stage we decided to try to obtain funding to boost the samples of black 
African, black Caribbean, Pakistani, and Indian ethnic groups. Because they are 
all small minorities in the UK population, the numbers would be too small to 
analyse separately, without ‘boosting’ their numbers for the survey. So that was 
quite a unique feature with lots of challenges. 
Mr Bob Erens: NATSAL, p. 51
We also had posters up at libraries and various hospital 
waiting rooms, clinic waiting rooms, GP waiting rooms, 
and so on, which may have attracted some people who 
wrote in, as many did from the outset. Incidentally, we also 
made a big effort to attract ethnic minority families, at least 
those where the mother was not English-speaking. We had 
little cards to introduce the study to the mothers printed 
in seven different Asian languages. I don’t think we were 
hugely successful but I think it was very important that we did what we could. I 
made some visits to a local temple and a mosque and so on, trying to spread the 
word – we weren’t very successful, but we tried. 
Mrs Sue Sadler: ALSPAC, p. 31 
Exchange transfusion for Rhesus babies
My first contact with exchange transfusion was in 1949 as a student in Belfast, 
when I was hauled in to assist with an exchange transfusion and my job was to 
keep a count of the blood taken out and also to wipe the clots with a wipe or 
cotton wool so that the outflowing blood could be measured in a galley pot; the 
We had little cards to 
introduce the study to the 
mothers printed in seven 
different Asian languages.
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transfused blood was given through a vein exposed by a small incision at an ankle. 
That baby lived. Then in 1954 I got to Malta and within a few days was doing 
an exchange transfusion with glass cannulas and bits of metal linked together 
with rubber tubing, and with just a two-way syringe. The Henderson syringe 
with three-way flow (in, out, and for the blood) made a huge difference. Later 
on, the better plastic catheters also made a huge difference, and the procedure 
ceased to be a nightmare. 
Professor Charles Whitfield: Rhesus Factor, p. 18 
Expert committees
The difficulty that all expert committees face is that sometimes you may have to 
sum up and conclude dead against what the public or at least the vociferous part 
of the public hope you will conclude. That’s really difficult to do, and to protect 
advisers from abuse is terribly important, otherwise governments will not be 
able to attract advisers of sufficient quality. What we will attract are people of 
enormous courage, of course, but not necessarily enormous ability; the two don’t 
always go together. 
Professor Robert Maynard: Environmental Toxicology, p. 36
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Facial recognition
In terms of long-term memory the MRC Applied Psychology Unit has had quite 
a lot of involvement, some of the time with very practical issues. We were asked 
to help the military improve face recognition and it became clear after a while, 
as this was during the early Northern Ireland troubles, that the purpose was to 
improve the military’s chance of catching terrorists, and I can remember having 
a real crisis of conscience, ‘Could this be used to suppress civilization as we know 
it? And so forth.’ In fact it turned out that we discovered that it was rather hard 
to teach people to improve their memory for faces, and it was very easy to make 
it very hard to recognize people by using disguise. We had a number of people 
around the unit wearing false beards, and wigs, and moustaches, serving as targets 
for recognition experiments, and one of the things that emerged was that if the 
photograph was in three-quarter rather than full face, performance was rather 
easier. And so we thought ‘Aahhah!, this is something that we should definitely 
develop.’ I happened to notice in the National Portrait Gallery that nearly all 
portraits were in three-quarter view, and I thought, ‘Ah those portrait painters 
knew a thing or two.’ I tried to develop it; I thought maybe all passports should 
be three-quarter, so let’s just check it out. A number of us, with help from the 
Cambridge Evening News, set up a study whereby in each of a series of small towns 
around Cambridge, on a Friday evening, there would be a photograph of targets 
in different views, profile, frontal or three-quarter, and then our targets would 
zoom around Cambridgeshire, walking around a series of different towns, each 
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of them having seen a photo in a different view. The newspaper assured us that, 
‘All you need to do is tell people to ring in if they see the target, you will get huge 
numbers of responses.’ I sat by the telephone with my son to help me from 9.00 
in the morning until 5.30 that evening, when I got my first and only response; 
it wasn’t three-quarter. We also had another interesting task that was to evaluate 
a course that claimed to train people to be better at recognizing faces. It used a 
procedure, a very ancient procedure, developed initially by Leonardo da Vinci, of 
‘reading’ a face by breaking it into features. We discovered that after this three-
day course, people were somewhat worse at recognizing faces, so at least we saved 
somebody some money. 
Professor Alan Baddeley, Applied Psychology, pp. 58–9 
Familial cancers
A patient had his second colon cancer at 63 – his 
first colon cancer had been at 38. He also had 
prostate cancer and he died within a year, but 
he first gave me all the information that he had 
collected on his family and put me in touch with 
his daughter, whom I contacted subsequently, and 
his wife, so I had access to others in the family. I 
spent many hours on roads in Newfoundland 
going to different small communities and talking 
to people in their homes. Every time somebody 
said, ‘I’ll speak to my grandmother because 
she knows more of the history’, or ‘You need to 
know about that other part of the family’ and 
they would contact them. Even before the days of 
ethics concerns, people wanted us to get the full 
picture. They knew there were other people that 
could help with the family history. The gentleman, 
who was from Wesleyville, told me that one sister 
had two colon cancers and had died in her early 
50s; the other sister had had endometrial cancer. 
As I put the pedigrees together they were very, 
very interesting because there was very little about 
endometrial cancer in terms of Lynch syndrome at 
the time. This wasn’t polyposis – it fitted best with 
Lynch syndrome but the endometrial and ovarian 
Map illustrating 
geographic location 
of two branches of 
a Newfoundland 
HNPCC family: 
Clinical Cancer 
Genetics
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cancers were striking in these two families. Now it turned out they were the first 
two HNPCC (hereditary non-polyposis colorectal cancer) families I had seen. Two 
years later, I was visiting a woman in Moore’s Cove whose father had died at the 
age of 29 of colon cancer and he was part of the family of the first proband, and 
her husband finally came inside. The fishermen tended not to come in and talk to 
those like myself who were not originally from Newfoundland – and he said, ‘Now 
she must have a cup of tea before she drives home.’ Not knowing quite what to say 
to me he brought the Bible for me to look at. The Bible had nothing written inside 
the front cover; but it did have a sheet of paper inside the back cover, which was 
the marriage certificate of his wife’s greatgrandmother and it said, ‘Julia Ann T of 
Wesleyville, married to John W of Point Leamington.’ The gentleman seen before 
in hospital was a T of Wesleyville – I could then go to the archives and find the exact 
connection four generations back. So this was one very large family. At that point, 
the family, then called Family C, was large enough to do the mapping. So it was the 
clinical picture and the knowledge of the migration patterns within Newfoundland, 
the settlement and migration over the centuries that gave the clues. 
Professor Jane Green: Clinical Cancer Genetics, pp. 34–6 
Familigram
One of the things that I did was to invent a research tool, which I never actually 
published or used. I made something, which I called a ‘familigram’. It looked 
remarkably like music manuscript and I think that’s why I liked it so much 
because it didn’t have very much to do with technical medicine, with which 
I was rather disenchanted at the time. What I did was to plot on this ‘music 
manuscript’, the attendances of members of the same family, of which I had a 
very detailed family tree. You can only construct such a register in a small town 
where everybody knows everybody else. The bars of this music were months 
and you could then see incredibly interesting runs and patterns, if you chose 
the right families. What was interesting was that I was introduced to a woman 
called Ruth Peachie. She was an anthropologist from the [United] States who 
had invented exactly the same tool. I don’t know what she ever did with it after 
that, but she and I met and had a wonderful time talking about what those 
patterns might mean. It was the tension between the narrative and the numerate 
that seemed to me to be at the heart of the nature of general practice. 
Professor Marshall Marinker: General Practice, p. 125 
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Farley’s infant food – contamination
One further outbreak of infectious disease helped sustain the momentum for the 
revival of public health. This was the Farley infant food epidemic in 1985, in 
which a number of babies became ill and died throughout Britain. It turned out 
that the common factor was an infant food infected with Salmonella ealing, but 
this seemed unlikely as this had only been found in seagull droppings, so there 
was great scepticism. But then, in the end, the mystery was solved, because the 
bacterium was found in the water tank in the Farley infant food factory and the 
tank had been contaminated by seagull droppings. I was seen as someone who 
against the odds had got it right; a bit of luck. 
Sir Donald Acheson: Public Health, pp. 19–20 
Fathers
Emond:  One thing that I do regret about recruitment in ALSPAC is that we 
didn’t enrol fathers separately and in their own right. Because, over the years, 
with family reconstitution and so on, it’s become extremely difficult to track 
men and to actually look at, not just their genetics, but also their influence on 
the family. I know men are not very good at follow-up studies, but they need to 
be enrolled in their own right.
Davey Smith:  I would support that comment and we are currently (2011) 
attempting formal enrolment of the fathers and partners, but obviously it 
probably would have been simpler to do it earlier, and would have been more 
successful. But, of course, given the restrictions on funding, staffing, etc., it’s 
difficult to do these things if the situation isn’t pre-planned.
Mumford:  I was secretary of the Ethics Committee at that time. I remember that 
we certainly considered the issue; it came up before the Ethics Committee, and 
we decided against it. We decided this because of the question in a lot of people’s 
minds about the link with the issue of paternity and whether mothers might be 
upset at the thought that the samples would be used for paternity tracing. I think 
the figures we had at the time suggested that something between 5 and 30 per 
cent of children were going to be brought up by men who were not their natural 
fathers, but not all those men knew it. Would opening questions about biological 
samples in particular raise questions in people’s minds and put them off the study 
entirely? I think, because of this the Ethics Committee ruled against the idea. 
Professor Alan Emond, Professor George Davey Smith, 
Mrs Elizabeth Mumford: ALSPAC, pp. 32–3 
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Ferrets
Ferrets have been alluded to as little vomiting 
animals; without the ferret, none of the anti-
emetic research would have got anywhere. This 
is one area that would never have gone forward; 
you couldn’t have done it without the ferret and 
animal experimentation. Up until that time, the 
way I had conducted the experiments was that I 
dosed the animal with cisplatin and if you have 
a control animal dosed with cisplatin it takes 60 
minutes before the cisplatin will begin to cause 
the animal to vomit. So I would do that, but 
prior to that I would dose with a 5-HT
3
 antagonist, and essentially the animals 
just would not vomit. So you wouldn’t see any vomiting with the animals at 
all. Well, while I was running these experiments, I figured, ‘Well, I have to run 
a control experiment with this; I have to make sure the cisplatin is getting on 
board’. So I decided what I would do is with every four animals, I would dose 
all of them with cisplatin, but one wouldn’t get the 5-HT
3
 antagonist. And I 
would watch them all. I did this a couple of times and by about the third time I 
was getting complete inhibition with the 5-ht
3
 antagonist and the animals were 
just not vomiting at all, but this poor little control animal without the 5-HT
3
, 
right on 60 minutes, bingo, he began vomiting. This began to concern me, 
because I figured, ‘Well, okay, I do know the cisplatin is 
on board, but I am going to have to do something. I can’t 
just let this poor little guy go away and vomit the whole 
time’. You cannot dose a ferret easily. They just will not let 
you do it. So I had to surgically prepare the animal with 
a little intravenous cannula and it used to be exteriorized 
right at the back of the neck. I was working on my own 
with the ferrets at this time at Beecham Pharmaceuticals. 
They wouldn’t even let me in the experimental areas with 
the ferrets, because nobody liked them. So I was in a little back ‘kitchen’, in my 
cell, with my four ferrets, and I had to think of a way of putting the connector 
on the little valve at the back of the neck of the animal, so that I could actually 
get the 5-HT
3
 antagonist on board while the animal was vomiting. The only 
way I could think of doing this, once the other animals had been dosed with the 
5-HT
3
 antagonist, and this animal had actually started vomiting, is to wait until 
the animal is vomiting, he is not going to be paying attention to my fingers. I am 
…without the ferret, 
none of the anti-emetic 
research would have got 
anywhere.
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not going to lose fingers this way. So this is exactly what happened. I waited until 
the animal started vomiting. I knew the cisplatin was working at that point, and 
I just very nimbly and very quickly fastened this little connector and while the 
animal was actually right in the middle of the emetic response, I whacked in the 
5-HT
3
 antagonist, and within five seconds the animal was normal, completely 
normal. This was one of the most exciting things I have ever seen, and it really 
gave me confidence then that we had something big. Then, of course, I was stuck 
with the situation, how am I going to get this little connector off the animal, 
because it was now completely normal. So I decided what I would do. Ferrets 
absolutely love milk, and so I prepared a small bowl of milk and I put it in his 
pen, and the ferret ran over and I got the little connector off and that was it. 
Mr Wesley Miner: Platinum Salts, pp. 55–6 
Fetal monitoring
Electronic fetal monitoring is a wonderful example of over-used technology, 
ultrasound is another example; they are grossly overused and we don’t seem to 
be able to stop that. 
Ms Beverley Beech: Maternal Care, p. 46
The first opportunity that I took to do a systematic review using meta-analysis 
related to different ways of monitoring babies during labour (published 1979). 
Electronic fetal heart rate monitoring had been introduced in obstetrics not long 
previously, sometimes accompanied by fetal scalp blood sampling to assess fetal 
acid-base status, particularly if the heart rate had raised concerns. It was being 
suggested by some people that these more intensive methods of intrapartum fetal 
monitoring should replace intermittent auscultation using fetal stethoscopes. I 
set about analysing three published reports of RCTs (randomized controlled 
trials) comparing different methods of intrapartum fetal monitoring, and the 
findings from one unpublished RCT, which were kindly made available to me by 
the investigators. About 2,000 babies had been born to the women who had been 
entered into these four trials: 13 of their babies had had neonatal convulsions. 
With the help of a medical statistician – Klim McPherson – I analysed the 
distribution of these babies among the comparison groups in the RCTs. This 
revealed that the pattern was very unlikely to have occurred by chance: the 
analysis suggested that continuous electronic fetal heart rate monitoring with 
scalp sampling might reduce the risk of neonatal convulsions. 
Sir Iain Chalmers: Corticosteroids, pp. 53–4 
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Fieldwork
Fieldwork has changed enormously because people distrust you nowadays, 
whereas, perhaps even 20 years ago, working in the Rhondda, in particular, was 
easy because everybody left their keys in their door and you just turned the key 
and shouted, ‘Can I come in?’ and they would say ‘Yes’, without even knowing 
who you were. In the early days, I think I am right in saying this, we didn’t even 
write to the people and say we were coming, we just cold-called, which we are not 
in favour of doing at present [2000]. Years ago people knew 
their neighbours, they knew lots about them, they knew 
the people across the road, they knew the people down the 
road. Nowadays no one wants to tell you anything about 
anybody, because they are always afraid of being accused 
of revealing things to agencies like the DSS (Department 
of Social Security), and so it’s a closed shop. You can rarely 
get any information from neighbours these days. You cannot call at the corner 
shop, or the post office, which is what I used to do a lot, to learn about people’s 
movements, that’s out now. So now you have to rely on health authorities or 
ONS (Office for National Statistics), if you have flagged people, rather than by 
word of mouth with neighbours. Valleys people stay valleys people, but in the 
big towns like Cardiff and even Caerphilly, they do move and change. I am a 
valleys person, so I suppose I am a bit biased, but valleys people are communities 
and they care about what goes on around them and they are very friendly, they 
are very warm, on the whole, whereas town people are cold, distant. Cardiff 
particularly is very cosmopolitan with lots of flat dwellers and you are not even 
knocking on a door, you are buzzing on an intercom at the bottom of the block 
of flats, so you don’t get tremendous satisfaction from home visiting as we did 
years ago. 
Mrs Janie Hughes: Population-based Research, p. 117 
Fieldworkers
Fieldworkers are rather a speciality, and to have a love of going out and meeting 
people and accepting the challenge of getting a high-response rate demands 
a certain kind of person and we seemed to get those people. We also could 
give them a career and a career structure; the medical and the non-medical 
people, and the support staff, they all had career structures within the MRC and 
permanent posts most of them. This was very beneficial to the development of 
an area of research, rather than just a one-off project. There was continuity, and I 
Nowadays no one wants 
to tell you anything about 
anybody…
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knew that when we followed up Caerphilly, we wouldn’t have to start recruiting 
another set of staff for phase two and phase three. We would have the same 
people going back, who knew the area and were known by the men. That was a 
tremendous advantage. 
Dr Peter Elwood: Population-based Research, p. 110 
First heart transplant in the UK
The operation
On that day, the donor arrived at the hospital at 14.25 and went into ventricular 
fibrillation in the lift going up to the theatre and the heart was kept going by 
external cardiac massage. We had twin theatres at the Heart Hospital, and the 
recipient was in one theatre with Donald Ross getting him 
ready and I had the job of taking the donor heart out. The 
patient was on the table by 14.35 in the afternoon and a 
number of observations were made and blood cultures were 
taken. The ventilator was switched off at 16.09, and by 
16.30 all the traces on the various recordings were flat. The 
ventilator was restarted at 16.38, external cardiac massage 
was given, the chest was opened, heparin was given, and the 
heart was actually removed by 17.47; it took 11 minutes to 
get the heart out. Removing the heart was a novel experience 
and I saw parts of the intrapericardial anatomy in a novel 
way. I was relieved to get the donor heart out without damage, which, of course, 
would have been a sad thing to do at the beginning of this whole procedure. The 
time for the insertion of the donor heart, up to the time that the aortic clamp 
was released, was 48 minutes. The donor heart was not refrigerated in any way, 
other than being kept in a bowl of cold saline while it was transferred from one 
theatre to the other and I must say that we were all immensely relieved to see 
that it was able to beat when the aortic clamp was released. It was an intensely 
dramatic moment, I think for everybody there, as it became pink and began to 
beat when the aortic clamp was released. 
Sir Keith Ross: Heart Transplant, p. 10 
Removing the heart 
was a novel experience 
and I saw parts of the 
intrapericardial anatomy 
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Post operation
After the operation we had no resident anaesthetist at that 
time, so I slept on the trolley next to the patient in the 
operating theatre and unfortunately in the middle of the 
night the central venous line came out and we had to put 
another one in, and I was worried in case I was the first 
anaesthetist to kill a heart transplant patient. I wasn’t sure what anaesthesia for 
heart transplant patients who had had the operation was, but eventually we did 
insert the central venous line under local. 
Dr Alan Gilston: Heart Transplant, p. 12 
Clinical moratorium
I don’t like the term moratorium very much. It implies some higher authority, 
saying ‘stop’. Really I was part of that clinical moratorium, which was a self-
imposed moratorium as far as we were concerned. After our early euphoria we 
realised that we were abysmally ignorant and didn’t know how to assess rejection 
or how to treat it. Our second case was basically a failure. At that stage I made a 
decision that I would do one more and that would be it – either it would work or 
not. We did another one, which didn’t work for very long, and that triggered my 
self-imposed moratorium, which I think applied to most of the people working 
at that time when the great fall-off occurred. So it implies that the surgeons did 
have a sense of responsibility and then, of course, the Government moratoria 
came into play. However, I think doctors should be given some credit for a sense 
of responsibility in this respect. 
Mr Donald Ross: Heart Transplant, pp. 48–9. 
Heart transplant programme
The first response of the Department of Health was to say, ‘My God, this might 
work, it’s going to cost money, how much money?’ and they did a lightning 
survey of the costs of all kinds of medical procedures all over the UK, and what 
that revealed was that hospitals hadn’t the slightest idea how much things cost, 
that there was a 400 per cent difference in the cost of a valve replacement between 
hospitals A and B, and nobody really knew what anything cost and in particular 
nobody could estimate what a heart transplant would cost. So what they then 
did was say we need a heart transplant unit with 24-hour cover, with n-number 
of nurses, n-number of pathologists and this is going to cost that much; my 
…I slept on the trolley 
next to the patient in the 
operating theatre…
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goodness it’s too much, we can’t do it. The next stage was to set up committees, 
and one committee has 40 members, of which one had a passing knowledge of 
heart transplantation and none of the others, and many of the names I know to 
be implacably opposed to it. These committees never discussed the moral, ethical, 
legal considerations, only the cost and how the procedures could be stopped. 
Professor Donald Longmore: Heart Transplant, pp. 52–3 
Foot and mouth disease (FMD)
Why should a country like the UK, in which FMD is not constantly present, 
that’s not endemic, invest much money and time and effort in supporting a 
sophisticated high-security laboratory and also in research on vaccines and 
vaccination procedures?’ The answer, which I think is rather far-seeing, is that 
this is done to gain reflected benefit. Over 50 years ago it was thought that if the 
institute at Pirbright (Animal Virus Research Institute) could develop improved 
or new vaccines and control methods, and promote their use in the countries 
from which the UK obtains its supplies of meat and meat products, the reduced 
incidence of disease in those countries should result in a much lower likelihood 
of importing the virus and subsequently the occurrence of outbreaks in this 
country. In general I think this has proved to be the case. 
Dr Noel Mowat: Foot and Mouth, pp. 44–5 
Foot and mouth disease outbreak, 1967
From the point of view of the veterinary volunteers, they were away from home in 
fairly uncomfortable situations, and usually working long hours. One thing that 
we have got to remember is that there were no mobile phones in those days and 
if you wanted to talk to the wife or to a partner, you had to queue for a public 
call box, and if you took too long over a call, the people in the queue behind 
them got irritated. So that is a small thing, but it was from 
a social point of view, quite important. I would ask you also 
to look at the wives who were left behind to cope with life 
for weeks on end, because once anyone got into the infected 
area, well, that was it. It was almost as though he had gone 
to the North Pole. And the veterinarians were also doing a 
job that was not theirs by nature or by training really. Diagnosing disease and 
therefore death was a very depressing way of living. Can you picture what it was 
like living on a farm in an infected area, a ghost farm, because it had no animals? 
Miss Mary Brancker: Foot and Mouth pp. 34–5 
It was almost as  
though he had gone to  
the North Pole. 
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Foot and mouth disease vaccine trial, unexpected problems
I was in East Africa at the same time as Tony Garland, and we had some problems 
out there. In his vaccine trials in Embakasi, Kenya, he lost one vaccine trial 
because the control cattle were eaten by lions that had got underneath the fence 
from Nairobi National Park. 
Mr Gareth Davies: Foot and Mouth, p. 43 
Free drug samples for research
Andrews:  My perception was that it was much 
easier to get compounds in the 1980s and 1990s. 
The amount of bureaucracy to get a compound 
to try something in your model to see if it 
worked was a lot simpler. The speed with which 
compounds circulated was probably a lot faster 
then than it would be now if a similar situation 
arose.
Tyers:  Supplying compounds wasn’t only 
between industry and academia, it was also 
between industry and industry, because most of 
us had exciting compounds to work on that were 
in the public domain. 
Professor Paul Andrews, Dr Mike Tyers: 5-HT, p. 83
I’d like to say that when drug companies do this sort of altruistic thing it makes 
a huge difference to the field. The same thing happened with the prostaglandins: 
if it hadn’t been for Upjohn distributing free samples of standardized materials 
the field would never have got anywhere. 
Professor Rod Flower: 5-HT, p. 11 
Friends in high places
Higson:  Sometime very late in my career as Director of the Scientific and Technical 
Branch of the Department of Health, it must have been about 1986 or 1987, I 
got a call from the Secretary of State’s office to say that I was to go to the National 
Heart Hospital and see Professor Donald Longmore. This was on an instruction 
from Number 10 and I was to ensure that Professor Longmore got the NMR 
machine that he wanted! I’d got this call about midday. About 2 o’clock I was in 
Professor Rod 
Flower: Clinical 
Pharmacology 1
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the National Heart Hospital, and we talked and I went back realizing he was a 
very well-connected man. But I had no money and I spent the evening talking 
to people at the Department of Trade and Industry (DTI), lying through my 
teeth about a loan of some money to buy a machine, which in due course would 
be repaid from Donald’s charity or else by the Department of Health, neither of 
which either of us had the slightest intention of doing. I was leaning on the fact 
that Number 10 were keenly interested in this and you got an imager, Donald, 
and you never paid for it and neither did I on behalf of the Department of Health. 
The DTI made their sole contribution to MR imaging with your machine.
Longmore:  We got two more after that! 
Mr Gordon Higson, Professor Donald Longmore: NMR and MRI, pp. 65–6 
Funding research
By industry
Andrews:  From my perspective, with the 5-HT
3 
work that we did on emesis, there’s 
no doubt that it was funded mainly by industry. Quite a variety of companies 
supported it over the years; I think that was true for a number of us. Glaxo and, as 
it was originally, Beecham and then as it became SmithKline Beecham, probably 
were the two major funders, but then others came later. That made a very 
important contribution because, as far as I can recall looking back at the papers 
that were published in this area, there were almost never acknowledgements to 
the Wellcome Trust or the MRC for funding. I think I’m only aware of one grant, 
maybe two that they funded in that whole period that involved emesis in any of 
this pharmacological work. So it was really industry that drove it.
Sanger:  Is it worth commenting on the opinions that fellow academic colleagues 
had about the receipt of so much industry money?
Andrews:  Yes. I think the attitude clearly has changed and now it’s seen as quite 
favourable to have links with industry and be seen to be collaborative and having 
work that’s translational, but it was certainly not viewed quite so well in those 
days, in the 1980s and 1990s, let’s put it that way.
Hunter:  There was a lot of industry funding and also a lot of provision in kind, 
in terms of tools as well as for imaging. In terms of advancing our knowledge of 
5-HT pharmacology, industry funding played a big role. 
Professor Paul Andrews, Professor Gareth Sanger, Dr Jackie Hunter: 5-HT, pp. 80, 81 
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In developing obstetric ultrasound, it was a case of one 
step at a time. I was quite impotent on my own, so I had 
to seek resources from the company. The extent of the 
original undertaking on the part of Kelvin & Hughes, 
the marine navigation equipment manufacturers, was in 
a memo from Bill Slater who was the Deputy Managing 
Director and resident in Glasgow, which stated that Mr 
Brown had permission to spend half a day a week working 
with Professor Donald and had a budget of £500 with 
which to do the work. It was on that understanding that 
the first contact scanner actually came into being. It was 
a very elastic sum of money and it owed a great deal to 
the scrounging capabilities of the young Brown and the 
tolerance of other people, because everyone really was on 
the side of the angels. There was a general desire to help. 
Mr Tom Brown: Ultrasound, pp. 17–18 
In hospitals:
In the 1950s to 1960s there were some very rich hospitals. St Thomas’ Hospital 
medical unit, for instance, ran its research programme entirely at this stage on 
the interest from the endowment funds of the hospital, so 
they didn’t need to apply elsewhere. I can remember the 
first chap who did apply for an outside grant was looked on 
as a very strange sort of animal. I think the same situation 
probably applied at Bart’s and Guy’s, but these again were 
the rich hospitals. 
Dr Sheila Howarth: Clinical Research, p. 23 
In universities:
I recall clearly when I became involved in the early years of establishing a charity 
for the Muscular Dystrophy Group, founded in 1959, and we were at that time 
collecting money and were looking for people to do research in neuromuscular 
disease. Among those who were on our research advisory committee was a 
very distinguished provincial professor of medicine who was asked whether he 
was interested in embarking upon or in getting one of his members of staff to 
embark upon a programme of research. He wrote back to say that he had a 
member of staff who was writing up a family of patients with peroneal muscular 
Mr Tom Brown: 
Ultrasound
…the first chap who did 
apply for an outside grant 
was looked on as a very 
strange sort of animal.
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atrophy and if he had any difficulty in getting funds to buy his reprints he 
would come back to us. It took a long time even to educate some of the clinical 
professors who had been brought up in the kind of clinical background you are 
talking about. 
Lord Walton: Clinical Research, p. 27 
Guz:  I seem to remember the time in the 1960s when there were an awful lot 
of medical schools, certainly in London and some outside, that were really not 
interested, with some exceptions, in having some of their money coming to 
them from elsewhere. In my own medical school (Charing Cross) it’s widely 
known that my boss, Hugh de Wardener, actually spent time trying to get the 
Dean of the day, a very powerful figure, who refused to sign an application form 
for a grant that the NIH, Bethesda, Maryland wanted to give him. It was said 
that would remove the power from where it should be.
Walton:  I can only speak for the north-east, my own native city and the 
University of Newcastle upon Tyne, where they would grab any money that was 
coming from anywhere. We didn’t ever have that problem in the 1950s to 1970s, 
it only emerged as a difficulty in the 1980s. 
Professor Abe Guz, Lord Walton: Clinical Research, pp. 21–2 
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Professor Jane Green: 
Clinical Cancer 
Genetics
Genetic code
In 1951 Max Perutz produced his first X-ray pictures of haemoglobin with its pairs 
of alpha and beta chains. Francis Crick and Max suggested to a young post-doc, 
Vernon Ingram, because somebody had left some sickle cell blood in their laboratory 
by mistake, that it might be worth trying to determine its structure. Ingram tackled 
this problem using two-dimensional electrophoresis and chromatography, or 
protein fingerprinting as it was called, and found a single amino acid substitution 
difference between the two haemoglobins. This was a very under-estimated paper 
because it took the concept of one-gene-one-enzyme to one-gene-one-peptide 
chain and, incidentally, provided some of the first intimations of the nature of the 
genetic code. 
Professor Sir David Weatherall: Clinical Molecular Genetics, pp. 16–17 
Genetics network
I would like to emphasize how successful for genetics has been the development of 
a network of groups within the UK. That is rather special to the UK. It was made 
possible by each of us knowing one another, and deciding on sharing and having 
common interests and common meetings. It also occurred 
in the environment of the NHS, which is absolutely key, 
and something that is a tremendous advantage that the 
UK has, for example, as opposed to North America and 
That is rather special to 
the UK.
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Europe. Some of us were fighting political attempts to destroy this network 
in the Thatcher days and fortunately I am happy to say that in politics the 
pendulum has swung the other way again (2001). 
Professor Malcolm Ferguson-Smith: Genetic Testing, p. 68 
Genetic Nurses and Social Workers Association
One anecdote that reflects the naivety of the Genetic Nurses and Social Workers 
Association in the early days. We didn’t know what we were doing and it was 
decided that a constitution should be established for this new association. 
But noone had ever done that before and one of the members of the group 
was a member of a sailing club and she went and got the constitution for 
the sailing club and they crossed out ‘sailing’ and put ‘genetic nursing’. We 
lived with that constitution until the British Society for Human Genetics 
was formed. 
Professor Heather Skirton: Clinical Genetics, p. 71 
Geneva
We supplied this magnet to a clinic in Geneva. We had tested this magnet. 
Inevitably, you know, some magnets are better than others and some are worse. 
This was one of the best magnets we had ever made and we were very proud 
of it. We sent it to Geneva and no sooner was it put into use, we were told 
it wasn’t working properly. Time and again we went out there. Whenever we 
went out and operated it, it worked beautifully. Whenever we left Geneva we 
got complaints that it wasn’t working. A fair amount of bad blood developed, 
I have to say. The people out there said we hadn’t made a good instrument and 
we said that they didn’t know how to use it, and so it went on. The key to end 
the story was this was a magnet with a vertical field with coils in the horizontal 
plane. It turns out that all the trams in Geneva are fed off an enormous ring 
main and whenever a tram starts up the vertical magnetic field in the whole of 
Geneva changes by so much that one of these scanners is thrown completely 
out of focus. 
Professor Sir Martin Wood: NMR and MRI, pp. 69–70 
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Glasgow 1950s, obstetric ward
We were working in quite a Victorian environment. I was 
itching to get my hands on the equipment and determine 
what it could do, but there was absolutely no way in which 
a young male layman was going to lay a hand on a female 
abdomen in the obstetrics and gynaecology wards of the 
Western Infirmary in the 1950s. 
Mr Tom Brown: Ultrasound, p. 21 
GP maternity unit
In 1965 we started a movement in Oxford, for a GP maternity unit. We had 
a benefactor in the Chairman of the Hospital Board, who put up the £12,000 
that was necessary to build us a 12-bed, one delivery room, two first-stage rooms 
etc., nursery and the lot, and this was latched on to the end of the labour ward 
at the Churchill Hospital. The innovation then was that we were able to use 
domiciliary midwives, which we thought was a fairly major breakthrough. The 
midwives were a little bit hesitant for the first two or three years, but in the end 
they took to it. We could have a much more relaxed style of care. People could 
go home a couple of days or even a day after delivery, they didn’t have to wait ten 
days like they did in the specialist hospitals. 
Dr Michael Bull: Maternal Care, p. 24 
Grateful patients
Before ondansetron was approved in the [United] States by the FDA it was 
possible to use it off-label with the Surgeon General’s permission. There was a 
report through from our clinical trial researchers, who said that this woman was 
suffering from severe nausea and vomiting and could she take ondansetron as a 
means of overcoming it and the Surgeon General said, ‘Yes, she could’. Well, she 
took it and it worked very, very effectively. She said: ‘If I ever meet the guy who 
discovered this drug I want to give him a big kiss.’ 
Dr Mike Tyers: 5-HT, p. 106 
As a laboratory scientist I received letters from cancer patients thanking us for 
making their treatment more acceptable. This is surely almost unheard of? Their 
correspondence made for a good day and a very good year. We were all grateful 
…there was absolutely 
no way in which a young 
male layman was going 
to lay a hand on a female 
abdomen…
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for having the opportunity to make a difference. That is, all except my local 
health authority. The headlines in my local newspaper, the Bradford Telegraph 
and Argus, announced that the cost of the new antiemetic drugs had bankrupted 
the local health authority and that a Professor Naylor working at the local 
university was to blame. 
Professor Robert Naylor: Platinum Salts, p. 59 
This drug, sumatriptan, at the end of the day, didn’t need 
marketing because it worked. I’ve got a letter in my pocket 
which is one of many that I still receive from women saying, 
‘You’ve changed my life’, which is extraordinary; 20 years 
on you still get letters like that. 
Dr Patrick Humphrey: Migraine, p. 43 
Letter to Dr Patrick 
Humphrey thanking 
him for his part in 
the development of 
sumatriptan: Migraine
Sumatriptan
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Haemophilia
Haemophilia in the 1930s
I was born in 1925 and haemophilia was diagnosed when I was one year old by my 
falling out of my highchair and tearing the fraenum in my upper lip. Thereafter, 
very fortunately, I had a perfectly normal life, having only mild haemophilia, so 
I enjoyed my school days, but life at home was really severely shook up when 
I was five; my mother produced triplets who also had haemophilia and it was 
that which brought us into contact with Professor Macfarlane, Dr Macfarlane 
as he then was, at Bart’s Hospital. It was in 1934 when one of my brothers 
was admitted to Bart’s with a severe haemorrhage and, I think, two of them 
were treated there for long periods. We also used to go 
up and see Gwyn Macfarlane regularly every few months 
while he took blood tests. After he retired I remember 
getting a letter from him in which he said how he watched 
his delicate apparatus in his small room at Bart’s, most of 
which was constructed from Meccano, being crawled over 
by my three brothers like monkeys, wondering whether 
it was all going to get torn to pieces or not. But he was 
really a wonderful supporter to my mother, because at that 
time in the 1930s there really was no treatment other than 
…the real miracle was 
Macfarlane introducing 
the concept of blood 
transfusions from my 
mother to the boys…
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the Russell viper venom. But apart from that the real miracle was Macfarlane 
introducing the concept of blood transfusions from my mother to the boys, 
which, of course, in the late 1930s saved their lives on a number of occasions. 
Mr Clifford Welch: Haemophilia, pp. 40–1 
Haemophilia research, 1950
Bidwell:  I went to Oxford in 1950, to work with the pathologist Professor R G 
Macfarlane who said to me, ‘Well, we have got nothing to treat these haemophilic 
patients with, would you like to have a go at seeing if you can make something 
from animal blood?’ So that’s how I got started in 1952.
Lee:  Which animals did you choose first of all?
Preparation of animal 
antihaemophilic 
globin in 1955: animal 
blood is collected at 
the slaughterhouse 
and brought to the 
laboratory by Ethel 
Bidwell and her 
assistant Ross Dike: 
Haemophilia
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Bidwell:  Animals that were slaughtered in a slaughterhouse. I think the first thing 
was the bovine blood. When I got involved, it was done by the slaughterhouse 
men and they were very helpful, very kind. They wanted the very best for me. 
They wanted me to have the animals that had won all the rosettes at the shows, 
but ancient old cows were much better. I went down to the slaughterhouse on my 
Vespa motorbike and I came back with a large glass container. I got concerned 
lest I tipped off my motorbike and tipped blood on the floor.
Lee:  How much blood would you be collecting?
Bidwell:  About a gallon. People don’t realise that plastics were only just coming 
in. It cost me about the equivalent of a week’s wages to buy a plastic container to 
put the blood in so that it wouldn’t break on the road to Oxford.
Dr Ethel Bidwell, Professor Christine Lee: Haemophilia, p. 13 
Haemophilia treatment, 1960s
My first patient was in hospital 27 times before his 5th birthday and, worse 
than that, he saw 17 different doctors. Nobody was interested in haemophilia. 
Haemophilia was ‘a bloody nuisance’ and kids with haemophilia were ‘bloody 
nuisances’. Only one in 16,000 of the population has severe transfusion-dependent 
haemophilia, and so it’s easy to see where the resistance came from, particularly 
from the Blood Transfusion Service of this country and certain of its directors, to 
treating haemophilia at all, except as a hospital disease. There were letters in the 
medical press and the lay press, suggesting that people with haemophilia were not 
capable of treating themselves, that their parents should not take responsibility 
for them at home, that it was dangerous and unethical and immoral to put 
treatment into their hands. In two European countries, Italy 
and, I think, Spain at the time, it was illegal for patients to 
inject themselves with any medication, including factor VIII 
or factor IX. The other feature of medicine in those days 
that we tend to forget was its paternalistic nature; the doctor 
always knew best, nurses really didn’t come into it, and it 
was thought that it was not right to educate patients. But 
we are now (1998) talking about 30 years ago. It was for the 
doctor to say when patients needed treatment. That’s one of 
the reasons the children of that generation grew up crippled 
with haemophilic arthritis. 
Dr Peter Jones: Haemophilia, pp. 36–7 
In two European 
countries, Italy and, I 
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Handkerchiefs and the common cold
Booth:  The method you used in the early 1950s for measuring the severity of a 
cold was simply measuring the weight of a number of tissues was it?
Porterfield:  Not so much weight as quantities. There were several different 
markers. How many handkerchiefs they used, whether they were sneezing and 
coughing; these would be recorded for each volunteer and then at the end of the 
trial these would be totted up. 
Sir Christopher Booth, Dr James Porterfield: Common Cold Unit, p. 237 
Hearing aids
Could I go on to say something about acoustics? When John Lenihan started 
the Regional Physics Department in Glasgow, he was a great believer in seeing 
things that needed to be done and doing them. One of these things was to 
repair hearing aids and so he set up (this would be around 1954) a little 
workshop to do this. From that, he saw that the audiometers throughout the 
country were not calibrated at all: there was no systematic calibration and so 
they varied enormously in their accuracy. He set up a scheme in the department 
for calibrating audiometers throughout Scotland, which was later taken over by 
the Scottish branch of the Royal National Institute for the Deaf and a couple 
of years later was extended throughout the rest of the UK. Those of us who are 
hard-of-hearing owe a debt to that vision. 
Professor Joe McKie: Medical Physics, p. 78 
Dr James Porterfield, 
Dr Owen Lidwell, Sir 
Christopher Booth: 
Common Cold Unit
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Helicobacter pylori
[By the 1980s a common bacterium, Helicobacter pylori had been recognised as the principal 
cause of peptic ulcers, and it could often be eradicated by a simple course of treatment 
with bismuth. Prior to this, drugs for ulcers such as Zantac and Ranitidine had been major 
international ‘blockbusters’ and made many billions of dollars for drug companies.]
In the late 1980s there were serious problems here in implementing this new 
bismuth treatment for peptic ulcers, even once there was good scientific evidence 
that it was appropriate. And I think there were three factors that influenced 
this. One was clearly a professional prescribing inertia, people weren’t used to 
thinking of ulcers being due to infection, and the profession as a whole were 
not ready for it, and they didn’t like it. The second was that there was no 
pharmaceutical company promoting it. Most new treatments are promoted by 
pharmaceutical companies, but there was no new drug here to promote, there 
was no profit. Worse, there was every reason why the pharmaceutical companies 
in the gastrointestinal field should block this or should encourage it not to be 
developed, because it was going to undermine their main income. Money was 
being made at huge rates from cimetidine and Ranitidine, and these companies 
were the key companies promoting gastroenterology meetings and supporting 
gastroenterology research. Therefore one couldn’t expect them to come out 
and support this new treatment, which might undermine their revenue. And I 
certainly did feel the effects of this personally. 
Professor Kenneth McColl: Peptic Ulcer, p. 95 
High-dependency units (HDU)
The Brompton Hospital’s medical HDU opened in about 1972 or 1973. HDUs 
started as multicentre facilities, governed by the sort of ‘need’ that existed in 
that particular hospital. Ours at St Thomas’ was a need for severe acute asthma, 
because these patients almost always have their crises in the early hours of the 
morning when wards are least well-staffed; these patients are scattered all over 
the place, you had to run from here to there and if you usually get there too 
late, they were likely to be brain damaged, because they’re already anoxic when 
they arrest. We gathered all these patients together in an HDU. The crucial 
thing about high-dependency, to my mind, is that it does not require one-to-
one nursing care, and whether you put it a step down from the postoperative 
recovery room or a step down from an intensive care unit, the concept is still the 
same. In terms of follow-up, I would pay tribute here to the nurses, because, to 
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me, they were the people who first recognized that perhaps families and patients 
had lived through a quite punishing experience and maybe it didn’t all end when 
they left the doors of the intensive care unit, or even the doors of the hospital. 
Dr Margaret Branthwaite: Intensive Care, pp. 74–5 
Hip prostheses
Sometimes one had a note on the back of an envelope, or a cigarette box, saying: 
‘Can you make this?’ You had to go along with the surgeon up to a point, but 
usually some modification had to be made, with the surgeon’s approval. 
Mrs Phyllis Hampson: Hip Replacement, p. 42 
In 1994 a European Directive had come along, which 
directed that all hip replacements would have to have a CE 
mark. By 1998, all knee and hip replacements had to have 
the CE mark to conform with the European Directives. 
One thing that we immediately realised was that manufacturers could get a CE 
mark a year after the introduction of a new joint. Thus, provided the joints 
survived a year, they got their CE mark, and that, ladies and gentlemen, was how 
it was in 1998. There was no post-market surveillance and we were told that if 
we wanted to get into post-market surveillance we should have to turn over a 
European Directive from the European Commission, which sounded quite a 
formidable thing to do, even for orthopaedic surgeons. 
Mr Keith Tucker: Hip Replacement, p. 38 
Regarding metal standards, I can remember in the 1980s, in the British 
Standards Institute committee that Swiss materials were very much worse than 
the British materials, the Americans somewhere in between, and we couldn’t 
agree a standard. I think the Swiss were still using old railway lines. They had 
bought up the Burma railway and were manufacturing hip prostheses out of old 
railway lines. 
Mr Alan Lettin: Hip Replacement, p. 42 
HIV/AIDS patients
When the HIV problem arose in the 1980s there were two groups that went 
looking after these patients. One was the work that was started at the Mildmay 
Mission Hospital, led at that time by Veronica Moss, which came out of traditional 
Christian evangelicism. Then, on the other side of London, there was another 
There was no post-market 
surveillance…
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‘religious’ community and that was the gay community; I 
say religious because they had a particular world view in 
that they had certain things that they valued more than 
anything else. The London Lighthouse in west London was 
set up by the gay community for the gay community. It 
was really quite difficult getting my drug users, or refugees 
or people with haemophilia, into the Lighthouse. Equally, 
there were a very small number of hospices that were open 
to take people with HIV, of which Princess Alice was one. 
I often used to go trading around to see who I could match 
up to get in, if I simply couldn’t manage them at home. Underneath all this, for 
the patients there was an explicitly religious dimension to HIV, and that was 
that people wanted to go somewhere to die where, if you like, their ontology 
was recognized and their cultural needs were met. That was very, very important, 
because the HIV community – who were rejected initially by the traditional 
religious community – tended to correlate the religious community with the 
hospice community. 
Professor Rob George: Palliative Medicine, pp. 64–5 
Homebirth
I hate to think of this as ‘home versus hospital’. I think home birth has a place 
and hospital birth has a place. Some women don’t have homes, for some women 
home is not a safe place to give birth and we need a safe place where women can 
give birth in peace that isn’t their home. Unfortunately, hospital now appears 
to equal loss of control over the process, no continuity of carer, no one-to-one 
midwifery care and active management of labour. That is what hospital birth 
means in many, many places in Britain. 
Mrs Mary Cronk: Maternal Care, p. 76 
In the 1950s when I got my first obstetric consultant job, that was at Oldchurch 
Hospital in Romford, and we had about 2000 or more deliveries in the hospital 
and, listen to it, 2,000 deliveries at home. So home deliveries were then 
common. The reason was we had no beds; not enough beds and the reason why 
we didn’t have enough beds, is that we never thought of early discharge; we kept 
them in, I don’t know how long, a week, ten days, and therefore the rest were 
delivered at home. 
Mr Elliot Philipp: Maternal Care, p. 55 
...people wanted to go 
somewhere to die where, 
if you like, their ontology 
was recognized and their 
cultural needs were met. 
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Home freezers
Rizza:  Katharine Dormandy, the haematologist, was one of the few to start using 
cryoprecipitate for home therapy for haemophilia. I remember having a discussion 
with her about the problems of fridges without alarms on them, because if the 
patients were going to keep cryoprecipitate at home, deep frozen, then they had 
to know if the fridge had gone off, when they went away for the weekend. They 
had to have an alarm system fitted and those were very expensive at that time.
Tuddenham:  Katharine had a wonderful relationship with her patients. It was 
maternal in some ways, because she knew them all very well and their social 
circumstances, she put a very great deal of effort into ensuring that they would 
have the best possible circumstances for home treatment. She was a pioneer in 
that area and obtained, as you mentioned, money for them to have freezers in 
their own homes in which they kept cryoprecipitate. Katharine was a pioneer 
and it undoubtedly changed the lives of our patients at that time to have their 
own freezers filled with locally produced cryoprecipitate. 
Dr Charles Rizza, Professor Ted Tuddenham: Haemophilia, pp. 34, 35 
Hospices
People tend to think that a hospice is just a building, whereas a hospice works in 
the community and what has been shown is that treatment of pain in in-patients 
can actually be done at home and I think that’s enormously important. 
Dame Cicely Saunders: Pain, p. 29 
Mr Elliot Philipp: 
Maternal Care
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I was invited by Cicely Saunders to come and join the staff at St Christopher’s 
Hospice as a visitor once a week. I had the great privilege to chair an open meeting 
each week with all members of staff who wished to come. I can remember discussions 
about ‘should nurses wear uniforms or not?’ and ‘what should we do when a patient 
arrives at the hospital? Should the senior nurse remain on the ward and wait for 
the patient to come up, or maybe continue her ward round with Cicely, or should 
she immediately break off and go down to welcome the patient in the ambulance?’ 
We adopted the last of these alternatives. It was little things like this, which I think 
made a great difference to the holistic care that was growing up at that time. 
Dr Colin Murray Parkes: Palliative Medicine, p. 10 
I had a neighbour who went into St Christopher’s, and I visited him. I asked 
his wife on the way there: ‘What’s the difference? Why is he not in St Helier 
Hospital? Why is he in this place called St Christopher’s, which is so difficult 
to get to?’ And she said: ‘When he went into St Christopher’s, they cut off his 
number tag on the wrist and said, “You’re not a number; you’re a person”’. And 
I’ve never forgotten that remark. 
Mrs Jean Gaffin: Palliative Medicine, p. 15 
Hospices and AIDS patients
When the HIV/AIDS epidemic broke, in the mid- to late-1980s, I was frankly 
embarrassed by the hospice movement’s stricture that actually they would only take 
AIDS patients who happened to have a cancer. We never produced that regulation. 
At the Princess Alice Hospice we took about 60 or 70 AIDS patients over the next 
3 or 4 years, who were clearly dying and had made an informed decision that they 
didn’t want to die in their acute HIV unit or at home; they actually wanted to die 
in a hospice. The really interesting thing that did for the hospice was to make us 
think very clearly about what we were doing in terms of aspects of confidentiality: 
how did it impact on the local population’s ability to support 
us financially? Because there were lots of worries that if we 
stopped being a predominantly cancer hospice we wouldn’t get 
the funding. At that time, 90 per cent of the funding had to 
be found from charitable sources. Well, I can tell you that the 
pragmatic ladies of Surrey were far more understanding than 
colleagues in the hospice movement, so that the message was: 
‘Somebody’s got to look after these people; we’re glad you’re 
doing it.’ There was, if anything, an increase in voluntary 
funding rather than a decrease. 
Dr Andrew Hoy: Palliative Medicine, p. 62 
…the pragmatic ladies 
of Surrey were far more 
understanding than 
colleagues in the hospice 
movement…
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Hospice-at-home service
Cicely Saunders asked Barbara McNulty, who had been a district nurse, and 
myself, who’d been a general practitioner, to start the first hospice-at-home service. 
This was in 1969. And I’m so grateful for this; we spent quite a number of months 
going round local general practitioners and district nurses saying: ‘Do you want 
a service at home? And if so, what shape do you want it to be?’ The answer we 
got back was: ‘Yes we do want a service. We want advice on symptom control 
and support and counselling, but as general practitioners, we want to remain in 
charge of patients at home, and the district nurses to do the major part of the basic 
nursing that was needed.’ So that was how we set up the service and it opened in 
October 1969 and from the beginning it was a 24-hour service, 24 hours a day. 
Not indeed like the 9-to-5 that sadly Macmillan introduced 6 years later. The 
nurse always made the first visit, and that put the nurse at the key of our service, 
a very important service. I think that it made nurses into specialist nurses, before 
the term was widely invented, and gave so many competent nurses, quite rightly, 
a degree of responsibility and power. 
Dr Mary Baines: Palliative Medicine, pp. 60–1 
Hospital hygiene
The eminent pathologist Sir Robert Williams said that Staphylococcus aureus 
was his favourite organism, because it had designed hospitals. All the standard 
hygienic practices in hospitals that we are supposed to ensure is done – smooth 
floors, cleaning, damp mopping, hand washing, sterile uniforms, separate 
operating theatres, changing bedclothes, filtering the air – everything is directed 
primarily at the control of Staph. aureus. 
Professor Gary French: MRSA, p. 69
Hospital infection
The Department of Health was very much concerned whether the cost of 
introducing, building or putting clean air theatres into hospitals, and all the 
rest of it, was cost-effective. This was a very big thing, and I think there was a 
study by the MRC, of where the infection came from, and to my recollection 
a chap came to the British Orthopaedic Association and told us that it all 
emanated from the perineum of the surgeons and the nurses and the immediate 
consequences of that was that nurses no longer wore dresses in theatres, but 
wore trousers. It didn’t seem to me that that stopped the appropriately offending 
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bacteria from descending the trouser leg. And I thought I would carry this to its 
conclusion and I went to the theatre one day and tied string around my trousers 
just below the knee, which looked rather like those pictures you see of labourers 
in the fields in the nineteenth century and it caused considerable hilarity among 
the theatre staff, but the next day my anaesthetist went one better and came in 
wearing cycle clips on his trousers. 
Mr Harry Craven: Hip Replacement, pp. 76–7 
When I was in Bristol in the 1970s, William Gillespie was 
the Professor of Clinical Bacteriology there, who had a lot 
of experience of treating bacterial infections both in the 
war and after. He always used to rib me, because I was so 
interested in resistance due to penicillinase: ‘Oh well, if you want to get rid of 
staphylococcal infections, the way you do it is to arrange your patients in the 
wards.’ He saw then that the environment in which the patient was located was 
a very clear way for dealing with staphylococcal infections. Antibiotics could be 
useful, but the main thing was to give the patients space: isolate them and have 
sufficient space between the beds. 
Professor Sir Mark Richmond: MRSA, p. 18
‘…arrange your patients 
in the wards.’
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Sir David Jack: Asthma
Imaging the brain of a baby
How the baby studies got started – the reason was that those of us who worked 
in neonatal intensive care units were aware that there was a high-ish risk of brain 
damage in surviving infants and we wanted non-invasive methods for investigating 
the structure and the functions of the brain so that we could find out what were the 
causes, prevalence, timing and prognosis and so forth, of cerebral lesions. We had, 
in fact, introduced brain ultrasound imaging in babies in 1978, which gave us a lot 
of useful information, particularly about cerebral haemorrhage, which was one of 
the two main causes of damage to the brains of babies who needed intensive care. 
But that technique didn’t give much information about the early events in hypoxic-
ischaemic brain injury, which is actually the more important cause of long-term 
disability in survivors of intensive care. We were looking around for some new 
techniques which would non-invasively examine the brains of sick babies. Anyway, 
as far as the NMR spectroscopy was concerned, before getting involved with 
humans, we thought we ought to do some animal studies. We asked the question: 
if you reduce the oxygen supply to the brain of a rabbit do the predicted changes in 
the phosphorus metabolites and intracellular pH occur, and are they reproducible? 
And the answer to that was yes. The first baby’s brain was studied on 22 October 
1982 and we had been waiting actually to see if we could find a baby who we 
thought might have a unilateral lesion, and so would have a control hemisphere, 
and one day we found one that had something pretty suspicious looking on one 
IJK
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side on the ultrasound image, which we couldn’t understand. The baby was born 
six weeks prematurely and appeared clinically to be extremely well. I can remember 
the discussions with the father, who was a US lawyer whose wife had had this baby 
while travelling through London, and trying to explain how it would be jolly useful 
if we could put the baby in a magnet please. Anyway it worked out and we got the 
first human brain spectra. What we found was a good control spectrum on one 
side and evidence of seriously deranged energy metabolism on the other. The child 
is now (1996) 14 years old with a hemiparesis but a normal IQ and that’s just an 
instance of how NMR spectroscopy gives you a good idea of prognosis. 
Professor Osmund Reynolds: NMR and MRI, pp. 25–6 
Inbred strains of mice
The eminent immunologist John Humphrey once suggested to me (though I do 
not believe he put it forward) that the Jackson Laboratory in Maine should be given 
the Nobel Prize for developing inbred strains of mice. He pointed out, in my view, 
quite correctly that what really revolutionized animal immunology in the 1950s 
and 1960s was the development of inbred strains of mice. They enabled whole 
fields of immunology, which couldn’t be done in any other way, to be developed. 
Professor Sir Peter Lachmann: Autoimmunity, p. 61 
Infectious diseases
In September 1983 I was invited to become Chief Medical Officer and on 1 
October found myself sitting in the hot seat vacated by Sir Henry Yellowlees. Henry 
predicted that 80 per cent of my time would be involved with the NHS and the 
Minister’s relationships with the British Medical Association, 10 per cent would 
relate to the wider health issues, including smoking, alcohol, 
etc., and 10 per cent to represent the UK at WHO and other 
global organizations. Apart from the diseases of childhood 
and vaccination for them, infectious disease was not, as I 
remember, mentioned at all. In the eight years that followed, 
infectious diseases dominated my work and thereby led to a 
renaissance in public health in some ways. Of the infections that I dealt with in the 
period 1983 to 1991 the most important were HIV/AIDS and BSE. Public health 
that dealt with sexually transmitted infection was renewed by a substantial increase 
in public funds and an influx of high-quality recruits to this speciality. 
Professor Sir Donald Acheson: Public Health, p. 18 
…infectious disease 
was not, as I remember, 
mentioned at all.
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Informed consent
The first short-course chemotherapy study for TB that I had the privilege of 
coordinating was in 42 centres in East Africa and Zambia. Of course, there 
were no 20-page consent forms to be signed, and it would have been difficult 
to get African patients with tuberculosis to sign a 20-page form; they might 
have signed it, but they might not have understood it. I did it this way: when 
they came to the hospital, I would say, ‘Look, you have tuberculosis, if I give 
you treatment for 18 months, and you take it, you will be cured. But we have 
drugs that we want to test on you, and we think six months of treatment will 
be enough if we give you those drugs. But for that you will have to come into 
hospital and remain in hospital for six months. Can you do it? Or can’t you do 
it’? I think that was a pretty good way of getting informed consent from them, 
because those who couldn’t stay, didn’t stay. 
Dr Amina Jindani: TB Chemotherapy, pp. 20–1 
Smith:  Dr Dewar will have to forgive me. It’s really quite amusing in retrospect. 
I remember he got the consent from the patient, certainly for the first patient I 
know. I remember vividly his saying to the patient: ‘You are having a myocardial 
infarction, which is caused by a clot in your coronary artery, and we propose to 
unblock it.’
Dewar:  There were various ways of describing our intentions. I think I was 
rather economical with the whole truth. 
Dr Roger Smith, Dr Hewan Dewar: Platelets, p. 104 
Inland Revenue
There was an attempt at blackening my reputation as Chairman of the Committee 
of Safety of Medicines when one company persuaded a Member of Parliament 
to ask a question about how much money I’d been paid over the previous 
year, quite clearly hoping I hadn’t declared it in my income tax. As I couldn’t 
remember, I went back home and was relieved to see I had declared £2,600 but 
the Parliamentary Answer was that I’d only been paid £2,400 over the course 
of the year, so I breathed a huge sigh of relief that I’d paid 
£200 too much; it didn’t really matter. About a week later, 
I got a letter from the Inland Revenue questioning my tax 
return and my payments from the Department of Health. 
So I rang them up and said, ‘What’s going on here?’ And 
they said, ‘Well, we saw this parliamentary exchange and, 
…I breathed a huge sigh 
of relief that I’d paid 
£200 too much…
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you must understand, it was referred to us. We checked up your income tax and 
we realise you’ve overpaid, and we think it’s rather hard on you, and we think 
you ought to have an opportunity to claim the £200 back.’ 
Professor Sir Michael Rawlins: Clinical Pharmacology 2, p. 63 
Intal (Sodium cromoglycate)
The story of sodium cromoglycate is the story of Roger Altounyan. Roger was a 
physician at the Monsall Hospital in Manchester where he had an asthma clinic. 
He had a number of patients that he had characterized very thoroughly. At the 
time, circa 1963, he was employed by Benger Laboratories, at Holmes Chapel 
in Cheshire. The treatment of asthma then was by isoprenaline, administered 
by pressurized inhaler, the Riker Medihaler was the dominant dosage form I 
think. Asthma was a rather mysterious condition and I can 
remember Roger describing to me that schoolboys would 
be told by the headmaster to ‘brace up’, there was nothing 
really wrong with them. This seemed to be the picture 
of the disease at that time. Roger was looking for a long-
acting isoprenaline and he worked with chemists in the 
research division and ultimately they came across sodium 
cromoglycate. I think it is pretty well known that he used 
to screen these materials on himself. He’d take the research 
compound from a nebulizer and then administer his own 
antigen, and there are many stories of Roger being found 
slumped across his desk at work; whether they are apocryphal or not, I don’t 
know. One of the features in the development of Intal, which I think Sir James 
Black always reckons to be a good feature in the development of a drug, is that 
management stopped the project. Roger continued working at weekends with 
a chemist called Colin Fitzmaurice and they moved slowly on in this research 
‘outside company authorization’, if you like. On the base of his personal use 
Roger arrived at a dose of about 20mg for this compound, which exceeded the 
capability of the pressurized inhaler, and Roger was the first person really to 
realise the need for coordination – synchronization of dose administration with 
inhalation in portable inhalers – and he also is the inventor of the Spinhaler. 
He worked with a colleague in the workshop on the thesis of putting a capsule 
of drug on to a propeller, so when the propeller rotated the powder was thrown 
out. So Roger effectively developed both the drug itself, and certainly invented 
the delivery device. It isn’t really enough to discover these drugs, there really 
has got to be drive behind them from a management point of view to do it. A 
…schoolboys would be 
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young research director called Dr J S G Cox, an 
ex-Glaxo synthetic chemist, took over the project 
and it was really Jim Cox and Roger Altounyan 
who took this through to market. The product 
Intal was first marketed in the UK in 1967, 
which isn’t a bad record, 1963 to 1967 to market, 
but the period between 1963 and 1967 was 
manic inside the company. The drug had to be 
synthesized and all the industrial processes scaled 
up. The mechanism of the Spinhaler turned out 
to be complex, and it had to be understood, the 
design developed, and the powder technology 
comprehended. 
Mr John Bell: Asthma, pp. 26–7 
Intensive care
There is a distinction between teaching hospitals and regional hospitals. My 
colleagues had problems establishing intensive care in the former because of the 
competition from people who didn’t want their empires disturbed. On the other 
hand, those of my colleagues who set up intensive care in regional hospitals, the 
poorer the better – most of them were old workhouses – were welcomed. When 
I went to Sefton General Hospital in 1966 we had three regional units: a dialysis 
unit, a poisoning unit, and a medical cardiac unit. I treated patients on the ward 
for a while, and they weren’t doing too badly. But after four years, the physician 
superintendent came to me and said: ‘You’re causing disruption on the wards. 
The tropical people aren’t using a ward; would you like a ward for yourself?’ I 
couldn’t have had more cooperation. There was absolutely no antagonism, no 
empire building, no defence of boundaries. Nobody said: ‘You can’t treat my 
patients’. They said: ‘I think this patient’s going to die unless you do something 
about it’. And, for a while I walked six feet above the ground, because I thought: 
‘What a privilege to be able to treat the worst patients in the hospital’. Then I 
realised that was because the physicians and surgeons wanted to go home. 
Dr Tony Gilbertson: Intensive Care, pp. 65–6 
Sir James Black: 
Clinical Pharmacology 1
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Floorplan of 
Broadgreen Hospital 
Intensive Care Unit, 
Liverpool, 1964: 
Intensive care
Intensive care nurses
The question about intensive care letting nurses give dangerous drugs: this leads 
into something wider as well. The matron in Sefton General Hospital said: 
‘Well, the nurses can give dangerous drugs, but on two conditions: one is you 
have to have a morning course to teach them what to give and what not to give 
and so on, and you give each of them a certificate signed by you; and second, you 
must write a letter to me saying that you take responsibility for anything that 
goes wrong.’ Matron carried that letter for a long time. 
Dr Tony Gilbertson: Intensive Care, p. 65 
Intensive care units
I came back to St Thomas’ Hospital in 1960 and said that 
it needed an intensive care unit. I was told very firmly that 
Thomas’ could do anything anywhere and didn’t need 
an intensive care unit. I noticed that acute patients were 
being treated in general wards and getting into all sorts 
of difficulties. The mortality was very high from various 
tracheostomy complications and cross-contamination 
through the unsterilized ventilators, and including cross-
infections to adjacent patients in the medical ward. This 
reached a point where we were granted two bed spaces for 
I was told very firmly 
that Thomas’ could do 
anything anywhere and 
didn’t need an intensive 
care unit. 
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each of these patients, which cost the physicians beds. The cardiac surgeons 
wanted some special units for their postoperative work and the physicians agreed 
that an ITU (intensive therapy unit) was needed. There was a discussion in the 
medical committees and everybody said: ‘Wonderful idea, but not in my beds’. 
Fortunately, the hospital was building its first significant rebuild after the war 
and there was a 28-bedded ward planned to go on the same level as the four 
operating theatres. The Professor of Surgery had decided that that ward would 
be his. I was only a very humble senior registrar at the time, and the hospital 
administration decided that they could quietly appoint this senior registrar to 
turn this 28-bedded surgical ward into an intensive care unit. Because it was 
done under the counter, I had control and could do more or less what I liked, 
with the help of the planning nurse, a planner, an architect, and a couple of 
consulting engineers. And that’s how it happened. 
Dr Geoffrey Spencer: Intensive Care, pp. 38–9 
International markets
In 1972, I think it was, I was challenged by the pharmaceutical company Squibb. 
They had two drugs, Motival and Motipress for mixed anxiety/depression. These 
were compounds that had fluphenazine in them but this wasn’t clear from the 
names of the drugs, and fluphenazine was causing some adverse reactions. We 
recommended that the Minister should revoke the licence for these two drugs. 
And then Squibb appealed. We heard this appeal but didn’t agree with it, so we 
told the Minister to go on revoking. They could have gone to the Medicines 
Commission and had another shot at it, but no no, they sued the Committee on 
Review of Medicines, in particular me, as Chairman, for advising the Minister 
wrongly. And there was a long, drawn-out legal case. It was hell, I think, for the 
administrative officers of the outfit. I know I had to sign countless affidavits and 
the thing went on and on and on. Then eventually they gave up. But why did it 
go on so long? Because neither of these drugs was used very much in the UK, but 
they were in the US. And, of course, as soon as the decision was made that their 
licence was to be revoked, then WHO would tell every country in the world 
about this, and their market in the US would go down. 
Professor Owen Wade: Clinical Pharmacology 2, pp. 56–7 
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International Narcotics Research Club
Being part of the opioid research community, which was a relatively small 
community, was pleasant. Meetings of the International Narcotics Research 
Club never usually exceeded more than 250 or so people and I guess there was 
a core of 100 worldwide. That makes it a very tightly organized and related 
community and one of the nice things about doing science, I think for most of 
us who have stayed in science and been involved in various projects, the greatest 
pleasure is those relationships. There’s no doubt about that. The cut and thrust 
of scientific meetings, plus the social aspects of it. That is the scientist’s life. 
Professor John Hughes: Endogenous Opiates, p. 77 
Interviewers
On occasions ALSPAC’s interviewers came across situations that distressed 
them, and indeed really needed to be reported: potential child abuse, these sorts 
of things. One of the things that we did early on in the Committee was to 
set down the criteria and the mechanisms through which it was ethical, legal, 
and appropriate to bring those situations to the attention of the appropriate 
authorities. That was important not only for the whole conduct of the committee 
and of ALSPAC, but for those interviewers themselves because it gave them 
backup. They actually felt they were supported. 
Professor Gordon Stirrat: ALSPAC, p. 77 
For the interviewers, we had to go up and be what was 
called desensitized. We had to go in to the National 
Centre for Social Research office for two days and 
sit there while every term connected with sexual 
activities was told to us, because the project managers 
were concerned that when we all went out to do the 
interviews, we would come across all these sorts of things, and we were not 
supposed to respond. The interesting point was that at the end of that time, we 
were asked whether we wanted to continue to be put forward to do this survey at 
all, and loads of the men refused to take part. The male interviewers dropped out 
at that point, the women didn’t mind. 
Mrs Wendy Williams: NATSAL, p. 34 
…every term connected 
with sexual activities was 
told to us…
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Intractable Pain Society
In 1954 I had a year’s experience of this new phenomenon, pain clinics, in 
Pennsylvania. I found it quite fascinating and went back home to England and 
opened my own pain clinic as a regular session in 1959. There were quite a few 
clinics opened here and there in England, and by 1960 I wished that there was some 
way in which one could meet colleagues and discover what they were doing, what 
sort of complications they were getting, what sort of patients they were treating 
in their pain clinics, to get some joint information going. So in 1967 I invited 
everyone I knew in the pain field in England – there were 29 pain clinics in all – to 
the University of Manchester at Salford Hospital to a discussion meeting. Seventeen 
of the twenty-nine actually came and we had a splendid day’s discussion which 
everyone thoroughly enjoyed and, I think, benefited from. At the end of the day 
they unanimously voted that we should repeat this process the following year and, 
in fact, each year thereafter, and that was the start of the Intractable Pain Society 
of Great Britain. At first it was simply a sort of club, and then in 1974 we formally 
made it into the Intractable Pain Society, which was, in fact, the first national pain 
society in the world. I think we all learnt a great deal from it, and, of course, not so 
many years later the International Association for the Study of Pain (IASP) opened 
on an infinitely bigger scale and it has proved to be enormously beneficial to all 
those in pain relief. I think the multidisciplinary idea improved the whole system 
very much and the pain clinic movement has been extremely valuable. 
Dr Mark Swerdlow: Pain, pp. 10–11 
Iron supplements
The study of the effect of iron in bread on haemoglobin level in the Rhondda 
Valley surveyed, as I remember, about 8,000 women. We identified those who 
had haemoglobin levels below 11 grams, we gave them a month’s treatment to 
bring their haemoglobin level up, and then we put half of them on bread fortified 
with an iron salt, and half on ordinary bread, and we watched the haemoglobin 
level over the next two years. We estimated that the absorption of iron from the 
bread was only about 4 per cent. When I submitted the paper to journals they all 
refused it, and said, ‘This cannot be right, we all know that iron is absorbed from 
food at the rate of about 30 per cent in women with low haemoglobin levels, 
this cannot be right’. I had great difficulty publishing the paper. In the end we 
did publish it and over the next five, ten years, it gradually became apparent that 
iron absorption from food stuffs is about four per cent, so we were shown to be 
right in the end. The iron studies with South Asian women are perhaps the most 
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The iron studies with 
South Asian women 
are perhaps the most 
fascinating story of  
my life. 
fascinating story of my life. The studies of the absorption of 
iron from bread were radioactive studies, done immediately 
after I came to the MRC Epidemiology Unit in 1963. I set 
up these studies using radioactive iron, because such precise 
measurements of iron retention could be made. I got friends 
and colleagues to come to the medical school and have a 
special breakfast. We had baked some radioactive iron into 
bread and people received a slice of bread with this, and 
then a fortnight later, we asked them to go to Harwell, 
the UK Atomic Energy Research Establishment, and have 
whole-body measurements of the iron that had been absorbed from the bread. 
The absorption was almost nil. I got a bit of publicity because of this, both in 
this country and in the USA, and I was asked to join the WHO Committee on 
Iron Deficiency. The Committee wanted to know what fermentation did to the 
iron and would I repeat this study using chapattis? So I set up a study to look at 
radioactive iron absorption from chapattis. In order to mimic real life as closely as 
possible, I got an Indian woman to help make about 200 chapattis. We measured 
the amount of radioactive iron in each and stored them in a deep freeze. I went 
up to Coventry, where there was a fair-sized Asian population, with the help 
of the health authority and one selected GP. We did rough power calculations 
(on the back of an envelope in those days), and we estimated that the method 
was so precise that we could get very accurate measurements from a quite small 
number of women. So we selected 20 women, all over 50, not suffering from any 
important disease, but no one who might become pregnant. Each day a chapatti 
on dry ice was delivered to each of these women, who would defrost it and eat it as 
part of her meal. A fortnight later they were driven to Harwell and really I think 
I made 20 friends on that project, they were so friendly to us. We found that iron 
was no better absorbed or absorbed no differently from bread. This study was 
a seven-day wonder, and everyone forgot about it. Twenty, perhaps twenty-five 
years later, I was telephoned by a reporter making a television programme on the 
uses of radioactive iron in medical investigations. ‘Yes,’ I said, ‘I did look at the 
absorption of iron from bread, and I was also asked to look at it from chapattis.’ 
The television programme blew up this story of the radioactive chapattis in an 
incredible way. They interviewed one of the women and a relative of another, 
who made extraordinary claims that a research worker from the MRC (they 
didn’t name me) had given them chapattis and they had eaten a chapatti each 
day and were then driven in secret to a military establishment where they had a 
whole lot of measurements made. One woman said, ‘My hair fell out, I began to 
get pains and cramps, I became arthritic, I am now diabetic, and if only I hadn’t 
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touched those chapattis I am sure I would be fit and healthy ’ A relative of the 
subject who had died, said, ‘My mother’s health failed from that day on and she 
would be alive now were it not for those chapattis’. The health authority set up 
an enquiry at the request of the Asian community and I went up to Coventry. 
I had prepared over the weekend a very full account of what we had done and 
I had clipped to it an account of the original study published in the American 
Journal of Clinical Nutrition and I asked the chairman of the meeting if I could 
give an account of what I had done before there were any questions. Well, the 
meeting was exceedingly hostile. The health authority were 
obviously keeping neutral, but one or two there were not. 
Over the subsequent weeks I was accused of all kinds of 
things. For example, an Asian health visitor had been with 
me on this study and she could testify to the fact that I 
had explained all about the study to these women, but she 
refused, saying she had never met me, had never had any 
part in the study of chapattis, and knew nothing about it. Our administrator 
dug out a letter from the health visitor saying how much she had enjoyed the 
study, how well the people had been handled, and how delighted they were to 
take part, refuting many of the things that had been said. She also found a letter 
that I had written to the son of one of the women giving a complete description 
of the study. Another was from the physicist who had prepared the radioactive 
iron, which had been submitted independently to a number of experts, who 
said that it was an extraordinarily low dose. That was why we had used Harwell, 
which had the most sensitive counter in the whole country. Another accusation 
was that I had purposely chosen these women because they were illiterate. We 
found letters from three of them thanking me for the most interesting study, 
written in perfect English. So the thing took a long time to die. 
Dr Peter Elwood: Population-based Research, pp. 70–1 
Irritable bowel syndrome (IBS)
We already knew that 5-HT
3
 antagonist drugs are constipating and that’s probably 
through blocking cholinergic motor nerves, so we thought we should study IBS 
patients who had a predominant bowel habit of diarrhoea. These were people 
who were really in a terrible way; they couldn’t get to work. There were stories of 
people in the US buying a second house that was halfway to work so that they 
could stop off – it’s a very debilitating condition and very painful as well. With 
alosetron, which became Lotronex, we got good efficacy. Not only did it block 
the diarrhoea, but people said they’d never felt so well. This looked like a very 
Over the subsequent 
weeks I was accused of all 
kinds of things. 
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exciting, potentially important drug. Unfortunately, very soon into the drug’s 
life on the market, less than a year, I think, there were several patients who had 
ischaemic colitis, a very serious side effect, and the drug was stopped by the FDA, 
or GSK probably withdrew it before the FDA stopped it. Interestingly though, 
this drug is very effective and to this day we don’t know what causes the ischaemic 
colitis, but we do know that a lot of people said that this drug was so important 
that now it’s been brought back, but it’s under very, very tight specialist control. 
Dr Patrick Humphrey: 5-HT, p. 71 
Isolation wards
We were in favour of having isolation rooms in the hospital, but this was very 
unfashionable and thought to be retrograde. The days when you had to worry 
about infection were in the past and not something which the 1970s hospital 
needed to concern itself with! 
Dr David Tyrrell: Post Penicillin, pp. 37–8
I was amazed at the number of staphylococcal infections occurring in our surgical 
patients and the complete absence of adequate extract-ventilated rooms for the 
isolation of patients who had multi-drug resistant staphylococcal infections. I 
therefore spent three or four years building isolation rooms attached to the wards, 
with extract ventilation. However, by 1968 we were in serious trouble, for in that 
year we isolated staphylococci resistant to methicillin from 37 different patients. 
Despite everything we did in following the standard requirements the situation 
deteriorated further and MRSA were increasingly isolated from surgical wounds 
– from 37 in 1968 to 134 in 1973. Quite clearly, our hospital did not meet the 
requirements of a place that does no harm. The health authority understood 
our predicament and agreed to build a separate isolation unit of 12 beds. We 
started studying the epidemiology of methicillin-resistant staphylococcal strains 
throughout the hospital and found, surprisingly, that MRSA were circulating 
within the medical wards where no infections were occurring. However, when 
those patients were transferred into surgical wards, they 
went down with an MRSA infection after surgery and 
started an epidemic there. We therefore initially used our 
isolation ward to clear the presence of MRSA from our 
medical wards and screened new patients for surgery. 
Slowly, over two years, we succeeded in reducing the 
isolation of MRSA from all patients in this 1,000-bed 
hospital, and over the following five years to 14 (0.53 
…our hospital did not 
meet the requirements  
of a place that does  
no harm. 
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per cent) of the 26,586 admissions. In the ten subsequent years to 1994 there 
were seldom more than three patients with MRSA infections in any one year. 
Unfortunately, in 1995 the Newcastle upon Tyne health authority decided to 
use the isolation wards to treat AIDS patients only, since they believed MRSA 
were ‘no longer a problem’. Within a number of years the MRSA figures were 
back to those we started off with. 
Dr Joe Selkon: MRSA, pp. 16–17
Japanese prescribing
Let’s take Japan. It’s all to do with the reimbursement of doctors, who get a 
percentage of the cost of the product that they prescribe, and with the way that 
the Japanese Government works. They reduce prices regularly so that it’s the 
latest product that has the highest price and therefore the doctor prescribes the 
most recent products, which were developed by Japanese companies, and he gets 
the most money, so there’s a very simple situation in Japan. 
Dr Ralph Batchelor: Post Penicillin, p. 45 
Jumbo football
Tom Connors, the cancer researcher, was responsible for this strange athletic 
phenomenon which always happened after a scientific meeting and it was 
always in the bar when people were very drunk. It is called ‘Jumbo’, rugby 
football played on your hands and knees with a match box as a ball; one team 
defends one wall and the other team defends the opposite wall. It gets very 
bloody and expensive. 
Professor Kenneth Harrap: Platinum Salts, p. 24 
Juvenile chronic arthritis
In the late 1960s we were certainly very much in touch with the National 
Orthopaedic Hospital at Stanmore about children with juvenile chronic arthritis. 
I was persuaded by the late Barbara Ansell, who was a rheumatologist at the MRC 
Centre for Rheumatic Diseases, Taplow, Maidenhead, who thought we should be 
able to help these children with their hip problems. We are talking about children 
of 11 to 12 years of age and over, but they were all confined to wheelchairs with 
destroyed hips, and they could no longer manage the pain. We felt something 
should be done. So we were faced with this problem of largely custom-made 
prostheses for them, because they had small skeletons. Children with juvenile 
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‘…the evil eye of the 
child in the womb, upon 
the child already born’.
arthritis are not just small, but they are smaller than small; they are minute. 
They have all sorts of problems: bone problems, hypervascularity, anatomical 
deviations, a lot of anteversion, so we did have to call on help from the custom-
made prosthesis people. Of course, measuring at that time was very difficult, there 
was none of the technology of today, you merely had to take an X-ray with the 
artificial hip prosthesis held alongside the patient, judge that the magnification 
was roughly the same, and then send off the X-ray to Stanmore. Often we were 
held on tenterhooks, because there were a lot of telephone calls as to when it was 
going to be ready, and I can recall it was pretty well when the patient was on the 
table, a motorcyclist would arrive from Stanmore with the prosthesis in his pocket 
and you hoped that it would fit. Fortunately, mostly it did. 
Mr Malcolm Swann: Hip Replacement, pp. 32–3
Kwashiorkor
Cicely Saunders was working in West Africa and brought to public attention 
that lovely West African word ‘kwashiorkor’, which means ‘the evil eye of the 
child in the womb, upon the child already born’. What a prophetic statement. 
It wasn’t invented by her, it was an indigenous term 
throughout Nigeria and much of the rest of West Africa; 
it was saying that if you have too short a birth interval, the 
new pregnancy switches off the milk supply to the older 
child, who will die of malnutrition. I will never forget going 
for the first time to Port au Prince, in Haiti, to the antenatal 
ward and looking at a row of about 20 mothers with their 
children. All the mothers were pregnant, coming for an antenatal examination, 
and there wasn’t a single sound from any of their children. The obstetrician 
who was running the clinic said to me: ‘You see those children? They will all 
be dead within six months. They have all got kwashiorkor.’ I could see with my 
own eyes the evil eye of the child in the womb upon the child already born and 
how a short birth interval was having a disastrous effect. This was known in the 
developing world long before we discovered it. 
Professor Roger Short: Breastfeeding, pp. 47–8w
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James Lovelock: 
Environmental 
Toxicology
Laboratory of Molecular Biology, Cambridge
The functional role of institutes is critical. I came to the Laboratory of Molecular 
Biology to work with Fred Sanger, and chose a project out of three suggestions, 
and did an experiment suggested by Sanger that didn’t work. On the side I did 
experiments of my own, which Sanger didn’t discourage, and when these worked 
Sanger encouraged me to go on; he said ‘Do good experiments and don’t worry about 
anything else.’ I always felt that summarized it, one should do good experiments 
and not worry about anything else. Other factors were the general quality of the 
place and the non-restriction of the subjects: you were inventing subjects as you 
went along and noone stopped you crossing disciplinary boundaries. Once you 
were ‘trusted’ then you were free to develop ideas in the way you wanted. 
Dr César Milstein: Monoclonal Antibodies, pp. 24–5 
Laziness
Laziness is the mother of good science. Creation comes from moments when 
you don’t have anything to do. When you have no teaching, and basic admin, 
and extra commitments are seen to interfere with research, what if you have 
strong motivation, and don’t know what to do? If you are teaching, you can 
fill your gaps by teaching, but researchers have to fill the gaps with thoughts. 
Applications of science are important and socially attractive but they detract 
from the single mindedness of research. 
Dr César Milstein: Monoclonal Antibodies, pp. 25 
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Leukaemia
Leukaemia treatment, 1950s
In the early 1950s there were no platelet transfusions. I felt that we could stop our 
acute leukaemia patients from dying a miserable haemorrhagic death if we could 
get very fresh blood into them. Where were we going to get fresh blood? Very fresh. 
We had a system whereby we would invite two or three donors. Then one of us 
would bleed the first donor; the other one would put up a drip into the patient, and 
the idea was to get this blood in while it was still warm. Of course, we had the cross-
matching business, and it took a very long time to get three units of blood taken 
in such a way that they were really fresh and went in ‘hot’. We did find that the 
patients stopped bleeding for several days. We forget nowadays what a palaver these 
things were and the sheer time wasted in doing these things was quite extraordinary. 
Professor David Galton: Leukaemia, pp. 27–8 
Leukaemia treatment, 1960s
I was a student on Bodley Scott’s firm in 1962 and a 
houseman on the same unit for a year in 1965. There were 
up to 40 in-patients at a time with leukaemia and many others scattered in 
other wards throughout the hospital. Most had acute leukaemia and the median 
survival from diagnosis was about 12 weeks. Probably 1,000 went through Bart’s 
Hospital in this period and I don’t think there was a single long-term survivor. As 
a houseman, the dominant duty was putting up intravenous drips in the morning 
using Guest cannulae and taking them down again in the evenings. We might 
be putting up 30 or 40 drips per day and preserving the veins was all that was 
keeping these patients alive. Young patients when first admitted would start in 
a bed at the far end of the ward and would work their way up to the two single 
rooms that were at the entrance to each ward, 
where two or three of them would die every day 
– of course, some of the patients didn’t even know 
they had leukaemia in those days, which was the 
standard practice of those days. 
Professor Ray Powles: Leukaemia, p. 25 
…two or three of them 
would die every day…
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Leukaemia trials, 1980
While we were getting organized and getting children into centralized 
randomized clinical trials in the best traditions of the MRC, the results that 
we were getting weren’t quite matching up to those that were being obtained 
overseas by apparently similar protocols. This puzzled and worried us. So what 
we did in 1980 was to take a Children’s Cancer Group (CCG) protocol from 
the USA, word for word, comma for comma, and applied 
it in the UK simultaneously, with the cooperation of the 
CCG. The first thing that we noticed was that it was much, 
much more toxic than anything we had used before, despite 
the fact that on paper it looked very similar. The reason 
was that the protocol was much more prescriptive and did 
not allow the clinician the freedom to stop treatment when 
children got a little bit poorly. We pressed on and I have 
to say that we did lose some children, because we weren’t 
aware of the toxic side effects of this treatment, but once we got the hang of 
it, we produced the biggest single increase in overall event-free survival in this 
country. It was about a 20 per cent jump from the previous cohort studies to 
this one. We have never explained the reason for that jump, but we suspect it’s 
something to do with physician compliance with the protocol and sustained 
chemotherapy, both in the consolidation phases and the maintenance phases, 
but that’s still an open question. 
Professor Sir John Lilleyman: Leukaemia, p. 47 
Liberation of nephrology nurses and patients
Nephrology was one of the earliest specialties, perhaps along with intensive care, 
which, of course, was growing during the 1960s in parallel with the introduction 
of technologies in medicine, which liberated nurses in to a huge variety of 
roles and gave them greater responsibilities than they had had before; and how 
important that was, as it turns out, in the shape of medicine as we know it today. 
It was also one of the first specialties that liberated patients. I think that the role 
of increased nursing responsibility and the role of increased patient autonomy 
are two areas that nephrology significantly contributed to medicine in the past 
half-century. 
Professor Stewart Cameron: Dialysis, p. 42 
…we produced the 
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Listening to patients
The psychoanalyst Michael Balint taught a whole generation of doctors that 
it was very important to listen to what their patients were saying, and to listen 
without interpreting what they were saying, or telling them what they should be 
saying, or explaining to them better what to think. Simply to listen to what they 
were saying. That was enormously important. 
Professor Marshall Marinker: General Practice, p. 127 
Liverpool International Garden Festival
The International Garden Festival at Liverpool in 1984 provided the opportunity 
to develop the first large-scale public health promotion initiative, incorporating 
a static health fair with personal fitness training and personalized lifestyle advice 
to thousands of the 4.5 million visitors to the Garden Festival during a five-
month period. Health promotion was incorporated into and grounded in many 
aspects of the festival from nutrition advice in allotment gardens to agitprop 
drama on health themes located around the festival site, and in poetry, music, 
and health events. 
Professor John Ashton: Public Health, pp. 34–5 
London Hospital Pain Chart
In 1978, I undertook a descriptive study looking at intractable pain at the Royal 
London Hospital. As anticipated from what was happening on the wards, it 
was found that the majority of the patients referred had carcinoma, many of 
whom had secondary disease. They were nearly all found to be experiencing 
unrelenting, unrelieved pain. For each patient in the study I interviewed a 
doctor and a nurse significant in their care, and, if possible, a family member. 
We found that, despite staff awareness of palliative care and the success in the 
hospice movement, as it was called then, pain relief was not an aim: ‘Oh, yes, 
they can do it, but we don’t do it here’. It was salutary, and of great concern to 
find that hospital staff had very low expectations of what could be achieved in 
their own area of care at that time. It was an enormous worry and one that we 
tried to address with some urgency. We used the body outlines with observation 
and assessment of the patient, but it was totally patient-focused, so it brought 
both staff and patients together, looking at the pain, trying to break this dreadful 
cycle where people would give analgesics and go away and not go back to check 
that it did work. There was neither the knowledge nor the vigour to address 
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the problem, and, to be frank, I became quite haunted by 
what I heard. And as a result of the study we developed the 
London Hospital Pain Chart, which was accepted by the 
hospital and the medical college, and in various ways it was 
adopted and adapted in the wider health service. It may 
be still winging its way round various acute wards in some 
form, I hope. 
Mrs Jennifer Raiman: Pain, pp. 18–20 
London Medical Group
The London Medical Group (LMG), formed in the 1960s, was a really interesting 
bunch of people. We used to have meetings of general ne’er do goods and people 
who stirred up and asked questions that shouldn’t be asked of doctors and their 
responsibilities. It was really interesting and encouraging that, as a senior registrar 
at that time at UCH, when I started lunchtime meetings with students saying, 
‘Do you want to come and talk about some of the patients you’re looking after 
on the wards and the effect their illness is having on their lives?’, within about 
two months I had meetings of something upwards of 30 medical students sitting, 
wanting to talk about the broader questions of people’s suffering and illness. 
Professor Rob George: Palliative Medicine, p. 25 
I was involved with the LMG from 1971 onwards, and I 
found it incredibly interesting, because many of the subjects 
that were being discussed were simply not covered in the 
general medical syllabus. So, for somebody who was going to 
go on to do paediatrics, the first time I came across child abuse 
was in lectures by Dr Christine Cooper from Newcastle. In 
particular, one had an opportunity, through the LMG, to 
visit St Christopher’s Hospice and to learn about pain relief 
and palliative care. That stood me in very good stead when 
I was a houseman. The constant discussion on informed 
consent led to a bizarre situation when I was an SHO in psychiatry of having to sit 
my consultants down to give them a seminar on informed consent, because during 
my first turn on the electroconvulsive therapy rota, I discovered that not a single 
patient had given any form of consent at all. So the LMG was of a practical value 
to a junior doctor after qualifying. 
Dr Richard Nicholson: Medical Ethics, p. 12 
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Love between patients
Our patients fall in love with each other all the time. I am in charge of 
sexual morals on the ward and ask the advice from the sisters, because of the 
cohabiting that goes on. And that is absolutely serious. We have had patients 
leave their spouses to associate with others, and some of them actually do 
have very strong relationships and live with each other. Part of the problem 
obviously is with the inevitable sequelae if the patients don’t get a transplant; 
there are no offspring from two CF patients, because the men are sterile, so 
that’s quite fortunate. But the cohabitation of two CF patients can and does 
cause a lot of grief. 
Professor Kevin Webb: Cystic Fibrosis, p. 31 
LSD (lysergic acid diethylamide)
We gave volunteers LSD, and then gave the same 
volunteers LSD after they had previously been 
treated with 5-hydroxytryptophan. There was 
some significant attenuation of the effect of the 
LSD. I think this paper was quite a landmark. 
We could only do five patients, because the sixth 
was a disaster. The Maudsley registrar who was 
a volunteer, after getting a shot of LSD, really 
went round the twist and he was psychotic for 
six months and more. Those were the days, you 
know, when you didn’t really have to get ethical 
permission for anything. You are all shaking your 
respective heads in sorrow, I know. Well, we all 
did this sort of thing and it seemed all right at 
the time. 
Professor Merton Sandler: Psychiatric Drugs, p. 146 
Professor Merton 
Sandler: Psychiatric 
Drugs
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Lucy Baldwin machine
Nobody knew at that time, in the 1950s, what the percentage of gas and oxygen 
should be in obstetrics. We had been giving gas-and-air analgesia on the wards 
and on the district, but that is really a form of asphyxia, because you deprived 
the woman of oxygen, so it was very important we thought, to give oxygen; we 
didn’t know the quantities. We each had a machine called the Lucy Baldwin 
machine, because Lucy Baldwin had been one of the founders of the National 
Birthday Trust Fund. This was a modified dental machine. Independently, 
although we did consult one another occasionally, we were driven to the answer 
that it should be 50 per cent gas and 50 per cent oxygen. When I say we were 
driven, it was the midwives who told us, because the midwives were the people 
who were watching the women in labour and had seen what gave them most 
relief without asphyxiating them, or leaving them without control. 
Mr Elliot Philipp: Maternal Care, p. 57 
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Sir Peter Mansfield 
(in dark glasses), Sir 
Godfrey Hounsfield 
(holding microphone): 
NMR and MRI
Magnetic resonance imaging (MRI)
A very bright graduate student of mine, Steve Busby, suggested ‘why don’t we look 
at the metabolites in a living organ like a piece of muscle, then we can immediately 
tell what is happening.’ Everybody pooh-poohed the idea, but nevertheless they 
went away and did the experiment. That was the first in vivo tissue experiment, 
at the end of 1973, on a living piece of muscle. So I went to the British Heart 
Foundation (BHF) and said, ‘Look, I think I could have a beating heart inside a 
magnet and find out the biochemistry of the heart during a heart attack.’ And they 
sent the eminent cardiologist Sir John McMichael down: we had this 3-mm tube 
magnet with a little mouse heart beating in it and we put it in an old spectrometer 
and we watched it for about 20 minutes and saw the signal building up. Then we 
said to Sir John, ‘Now we’ll turn the oxygen off, that’s a heart attack, and you can 
see those signals go away’, and he got so excited that he went back to the BHF and 
said, ‘We must support this, it’s going to be tremendous’. 
Professor Sir George Radda: NMR and MRI, pp. 22–3 
The ‘Malawi clause’
Malawi is one of the countries in the world that is heavily dependent on tobacco-
growing. During the late 1980s and the 1990s, the minister of health for Malawi 
would frequently stand up when these tobacco resolutions were being debated in 
the WHA (World Health Authority) and ask for something to be inserted at the 
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behest of both his country and the people who bought its products – the tobacco 
industry. If you look through those resolutions, you will always find something 
that I came to fondly call the ‘Malawi clause’ and usually it had to do with the need 
to acknowledge tobacco farmers, which everybody agreed was a good thing to do. 
There was a constant pressure through the voice of this official representative to 
the WHA for a weakening of these resolutions. To the credit of everybody else, I 
think the potential damage was always limited, but I think it is important to signal 
that, indeed, there was pressure that the WHA had to deal with. 
Mr Neil Collishaw: Tobacco Control, pp. 10–11 
Masks for drug delivery
Steroids were used mostly in treating asthmatic adults and with children there 
was the difficulty of getting the drug into them. The development of the large-
volume spacers really made a considerable impact on the management of 
younger children with asthma and enabled us to deliver 
both bronchodilators and prophylactic medication such as 
steroids to these children. I suppose as a result of my interest 
in anaesthetics, I was very keen to get the drugs into the 
small babies and initially used an anaesthetic mask. I then 
attached this to a spacer and saw that if I could deliver a drug 
into babies in this way, we might be able to treat smaller 
children. Over the course of three years, I worked, cutting 
and pasting, and using sellotape, to develop some kind of a 
mask and thought that this was kind of relatively innovative, until I saw that ten 
years earlier a doctor in Canada, a Dr Freigang, had done it all before and had 
developed his own large-volume spacer and his own mask. But it did mean that 
we could now deliver medicines to children of all ages. 
Dr Paul McCarthy: Asthma, pp. 56–7 
Materials for hip prostheses
I was working in the aircraft industry before returning to the academic world in 
1954. I had started some research on the wear characteristics of certain polymers, 
including polyethylene, for the defence industry, particularly for military aircraft. 
The industry required a weight bearing material that would operate in very strange 
environments, and particularly not be affected by the presence of water and high 
humidity. I was doing that work early in the 1960s when I first met John Charnley, 
the orthopaedic surgeon, who was developing hip replacements. After his trauma 
…with children  
there was the difficulty  
of getting the drug  
into them.
M – Monoclonal Antibodies to Migraine: Witnesses to Modern Biomedicine, an A–Z
106
of adverse reactions with PTFE (Teflon), Charnley was seeking an alternative 
polymer and he came over to Leeds to see some of the experimental work that 
we were doing. One of my lasting impressions of John Charnley is that he was a 
jolly good engineer. He wanted to understand the engineering and the physical 
principles by which these different combinations of material and different bearing 
configurations would work. Since that first contact, we had very frequent and 
stimulating exchange visits. Now there is a whole galaxy of possibilities, metal-on-
metal, ceramic-on-ceramic, metal-on-ceramic, metal-on-polymers, ceramic-on-
polymers and many of these are being very actively developed at the present time. 
Professor Duncan Dowson: Hip Replacement, pp. 28–30 
Maternal deaths
Drife:  I remember coming into the hospital where I worked as a registrar on a Monday 
morning. One of the odd things was that I came in a door about 200 yards away 
from the maternity unit and they had had a disaster, a maternal death, and I could 
sense something wrong 200 yards away, thinking something is not right. I don’t 
know what it was, a silence or a change in the atmosphere, it was quite spectacular.
Dally:  I do agree with you about remembering every detail of maternal death. When 
I was in gynaecology in Balham, I looked after a woman who took six weeks to die 
from an infected abortion, an illegal abortion. I remember every detail about her life, I 
remember every conversation I had with her, and the whole thing was very, very vivid. 
Professor James Drife, Dr Ann Dally: Maternal Care, p. 17 
Maternity services
In the early 1970s there was a revolt by many women against what they saw as 
inhuman maternity services, and the practices within them. Few of them would 
have regarded themselves as having been motivated by feminist considerations. 
Having said that, it was very important that the feminist movement was growing 
at the same time. But the reason that the National Perinatal Epidemiology Unit 
had women on its advisory committee right from the beginning was basically 
from considerations of ‘self-defence’. We felt that we would actually do the wrong 
things if we didn’t get input from people who were in touch with the women using 
the maternity services, and who knew about the concerns they were expressing. 
So it wasn’t from some sort of politically correct position that we engaged users of 
the maternity services. It simply seemed common sense to do so. 
Sir Iain Chalmers: Public Health, p. 69 
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Media
On the question of the difference in the media coverage of the foot and mouth 
outbreak in 1967/8 and at present [2001], it was certainly my impression that 
the media acted very responsibly in 1967/8. We didn’t have the problem that 
they had recently where the press tried to sensationalize everything. They did 
show photographs of burial pits and burning etc., but in general they were fairly 
responsible in their reporting. There was a big change from 1967/8, even to 
1981, in terms of the media involvement in outbreaks. I went up to Oswestry 
about two or three weeks after the 1967/8 outbreak started. I had been given the 
task of investigating the origin, because up to that point there had been no time 
to investigate the origin, as staff were fully occupied in dealing with outbreaks. 
When I arrived the Regional Veterinary Officer told me that some press people 
wanted to come in that afternoon to discuss the origin of the case, and would 
I talk to them? I said, ‘Well, I have only just arrived and haven’t started the 
investigation yet’. He said that it didn’t matter, ‘Just go and tell them what you 
are going to do’. I had to explain all the possibilities we were going to explore, 
and they were quite satisfied with that. We had no antagonism from the press 
in those days. 
Mr Howard Rees: Foot and Mouth, p. 40 
I think it’s important that scientists shouldn’t transfer blame 
directly to the public for getting things wrong. Scientists are 
largely to blame for the scares that spread among the public. 
We are all aware of publications before the data are solid, 
publications that have been made to try to produce the next 
grant application. We should know by now, and God knows 
we have had enough evidence of it, that the media exists 
to find things to entertain and amuse and worry the public. Scientists exist to 
obtain grants to continue their curious activities. Those two groups will feed off 
each other, and so much of the blame, I think, for scares about carcinogenicity 
problems does lie with part of the scientific community, not only with the media 
or the public. 
Professor Robert Maynard: Environmental Toxicology, pp. 23–4 
Scientists are largely to 
blame for the scares that 
spread among the public.
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Medical education
Many of us felt that there were several pieces missing in medical education. 
Certainly, this is true for those of us who had come from other universities, and 
for those who had come through London as well. I think we were very aware of 
the narrowness of the educational curriculum in medicine, which actually meant 
that when we talked about what the London Medical Group tackled, it was not 
what we would consider conventionally now to be necessarily ethical subjects; 
they were subjects where there was some feeling of disturbance, I think, when 
our elders and betters hadn’t really grasped it. I certainly remember raising the 
idea of an ethics discussion as a postgraduate at the Whittington Hospital, and 
one of my consultants said, ‘Higgs, when I hear the word “ethics”, I reach for my 
golf clubs’. I think he was consciously echoing a Nazi phrase to tease me, but it 
was very clear that the generation above us were not only not offering ethics as 
part of our education, but also not particularly wanting any discussion of ethical 
issues at all. Ted Shotter was told by one senior medic that: ‘these are things 
that should be discussed by consultants, with consultants, and in camera’. And 
so for us, there was a feeling of an opening up, of a revolution, which, I have to 
say, linked with other revolutionary processes in British life at the time, whether 
it was Carnaby Street, sexual liberation or whatever. But I think we were of a 
feeling of being somewhat on the crest of a wave. 
Professor Roger Higgs: Medical Ethics, p. 13 
Medical genetics – 1950s to 1960s
It’s always difficult to talk about Cyril Clarke. It’s like travelling in Ireland, when 
you ask the way, they say: ‘Well, you can’t start from here.’ I think many of 
you know Cyril’s background: he came to Liverpool in the early 1950s as a 
straightforward consultant physician, building up a private practice and with 
a major interest in asthma. There was no hint of things to come. But from his 
early childhood he had had a profound interest in butterflies and, later, genetics. 
He was breeding butterflies furiously by the early 1950s and got fascinated with 
mimicry. Purely by chance, through an advertisement for samples of butterflies, 
he met Phillip Sheppard from Oxford, who was one of E B Ford’s protégés and 
they became very close friends. Cyril told me, and I think he told several people, 
that it was while walking on the Broads that Phillip said to him: ‘Doesn’t all this 
genetics have any applications to medicine?’ 
Professor Sir David Weatherall: Clinical Genetics, pp. 37–8 
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Why did the haemoglobin field drift away from 
the mainstream of medical genetics? I think the 
only way I can put this together is to consider 
the way clinical genetics as a specialty developed 
after World War II. There really was nothing 
before that. It started in places like Baltimore 
and the west coast of the USA, and one or two 
centres here in the UK. It was natural for those 
departments to focus on local diseases, as it were, 
chromosomal abnormalities in particular, and 
standard monogenic diseases. I suspect that what 
happened was that the haemoglobin disorders 
tended to drift into haematology departments 
and there was a beginning of the separation. 
Professor Sir David Weatherall: Clinical Molecular 
Genetics, pp. 27–8 
Medical journals in Africa
We cannot take the growth of books and journals out of the context of medical 
education in East and West Africa. The East African Medical Journal had been 
there for a long time. The West African Medical Journal, which was privately 
owned, was going in 1960, and continued. The African Journal of Medicine and 
Medical Sciences developed, only to fall foul of the oil price rise and the slack in 
the economy. Other journals arose, the Ethiopian Medical Journal, the Uganda 
Medical Journal, the Medical Journal of Malawi, and this was very important 
for medical education, because it enabled local people to 
publish locally and not to get their papers turned down, 
‘because they were not well written’. This was an important 
stimulus to postgraduate expression. Finally, there were also 
the books that came and went, for example, John Lawson’s 
book, which was a very important obstetric text, and other 
specialist books like Davey’s Companion to Surgery. 
Professor Sir Eldryd Parry: Africa, p. 50 
…this was very 
important for medical 
education, because it 
enabled local people to 
publish locally…
Professor Sir David 
Weatherall: Clinical 
Genetics
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Medical Research Council (MRC)
Working for the Medical Research Council was very good for one’s career 
development, both nationally within the UK and internationally. There is no doubt 
about that. At the same time, there were no brownie points issued by the MRC or 
by their visiting subgroups for investigations targeted at more practical orientated 
issues. In general, the MRC were more interested in fundamental research, 
developments of importance to fundamental science. I think the Medical Research 
Council’s record in Africa, when viewed internationally in terms of contributions to 
international science, is pre-eminent. Perhaps in terms of applying that knowledge, 
the MRC’s record was not so good. This isn’t a new view. The same criticisms were 
being voiced in the 1960s. I remember one of them went something like, ‘We are 
now in danger of knowing more and more and doing less and less.’ 
Dr Roger Whitehead: Africa, p. 58 
Medical student projects
Herxheimer:  At the London Hospital we had projects for all students. They each 
had to do a little project, and lots of those were clinical pharmacology projects. 
And they were really very exciting and enjoyable. They were long before ethics 
committees were thought of. I remember two being published in The Lancet 
and I thought that was extraordinary for student projects. And that sensitized 
the students to clinical pharmacology thinking. Anybody else have that kind of 
experience?
Flower:  I think that is a very important point. When I was a student of 
physiology, we did all the experiments on ourselves, in the way that students just 
can’t do these days in most undergraduate centres, for various reasons.
Aronson:  A paper in 1967 in The Lancet, on medical education, by Quilliam 
and Turner, describes a large number of experiments that they expected their 
students to do on themselves. For example, mydriasis and miosis in the eye, and 
using agonists and antagonists; you are right, we can’t do that anymore.
Prescott:  Alas, times have changed. I remember the days when we gave our 
students single doses of amphetamine and barbiturates in their practical classes 
so that they could experience the drug effects and identify which agent they had 
been given. To conduct such experiments now would be unthinkable. 
Dr Andrew Herxheimer, Professor Rod Flower, 
Dr Jeffrey Aronson, Professor Laurie Prescott: Clinical Pharmacology 1, pp. 61–2 
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Medicare (US)
Stanley Shaldon has made many great 
contributions to nephrology but, I think that 
telling us how to do home haemodialysis 
overnight, three times a week, was perhaps his 
greatest. Once we adopted this in Seattle in 1965, 
most of our patients were well rehabilitated, went 
to work or school, or undertook other useful 
activities. Our state’s department of vocational 
rehabilitation was so impressed that they became 
our greatest financial supporters in about 1967, 
paying for training, equipment, and supplies for 
home haemodialysis patients. Of course, these 
were a selected group of patients. Also, one of 
the arguments we used with Congress to get them to legislate the Medicare 
End Stage Renal Disease programme was that most patients would be treated 
by home haemodialysis or a kidney transplant and would become taxpayers 
again. Little did we know what was to happen as a result of the entitlement 
and Congress completely underestimated what the costs would be. In fact, later 
that year, the New York Times ran an editorial about the unexpected costs of the 
programme and entitled it ‘Medicarelessness’. 
Professor Christopher Blagg: Dialysis, pp. 73–4 
Medicines Commission (UK)
I had something to say about the Medicines Act, which is rarely if ever talked 
about, and it is the way in which the committees meet, in which they’re held. 
In the regulatory system, in my experience, the Chair always sits with people 
from the department, and is supported by them while the other members of the 
committee always sit on the other side of the table. I think that’s the case in the 
Committee on Safety of Medicines; it was certainly the case in the Medicines 
Commission when I served on it. This meant that the most powerful member of 
the advisory body – the Chair – was on the opposite side to the members. That 
relationship, i.e. the Chair being very close to officers, civil servants, whatever, I 
think threw some of the decision-making. 
Professor Joe Collier: Clinical Pharmacology 2, p. 57 
Professor Stanley 
Shaldon: Dialysis
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…when we unwrapped 
his hand, his thumb fell 
off, because his thumb 
was gangrenous. 
Medicines Division of the Department of Health
In 1979 we moved to the Market Towers from Finsbury Square. In Finsbury 
Square we had manual typewriters. When I went to look at the building at Market 
Towers, it was all nicely equipped from a previous government department with 
word processors. The trades union insisted that all these word processors were 
going to be taken out, because it would affect our employment of secretaries. I 
created merry hell, as a result of which we got golf-ball typewriters. Now, that 
was the level of technology that we had, and I made a comment earlier on that 
the Medicines Division was under-resourced. It was grossly under-resourced. 
Professor John Griffin: Clinical Pharmacology 2, pp. 57–8 
Memorable patients
The little boy with Christmas disease. Dr Biggs got a telephone call from Dundee 
where I had come from, asking if she could take on the care of a little boy of 
four, who had had a venepuncture in the antecubital fossa and for some reason 
or other had developed a haematoma at the site of puncture. It got huge. It got 
infected and he ended up with osteomyelitis of the radius and he was in a very 
bad way. He was obviously very frightened, in great pain. 
He was referred to Oxford to be looked after by Professor 
Trueta, who was Professor of Orthopaedic Surgery then, a 
paediatrician called Dr Victoria Smallpeice and Dr Biggs. 
I remember when we unwrapped his hand, his thumb fell 
off, because his thumb was gangrenous. As soon as he was 
admitted Trueta said, ‘This forearm must come off, he’s 
very ill, he’s infected’, and this was done. I remember the 
first dose of factor IX concentrate being given. The child 
was taken to theatre and given factor IX, and he had to be sedated with rectal 
pentothal every day because he was so frightened. But the operation went very 
well, the factor IX caused no reactions whatsoever, and he healed very well. I 
know that boy well, because when I was up in Scotland last year [1997] I went 
to see him. He’s now 42 years old, he’s an architect. He has only one hand, of 
course. He did away with his prosthesis very early on, because he found the 
artificial arm more of a nuisance than a benefit, and he plays one-handed, right-
handed golf. 
Dr Charles Rizza: Haemophilia, pp. 18–19 
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MacVicar:  The Professor of Medicine had made a diagnosis of malignant ascites 
in an elderly lady, which seemed to be confirmed by radiography. Then, from 
another unit, a young upstart came with an ultrasound machine to her bedside 
and said, ‘This isn’t a malignancy, this is an ovarian cyst!’ I remember Professor Ian 
Donald kicking me under the bed-screen and saying, ‘Not at all, it is a malignancy, 
the Professor of Medicine says so.’ So I kept quiet after that. It was the first thing 
that made staff in the hospital recognize that this was a possible tool for the future.
Hall:  I think Ian Donald himself said on a number of occasions that he thought 
that that was the watershed. In his own inimitable manner, he said, ‘From that 
point on there could be no turning back’. The end of the story was that the 
patient was taken upstairs to the gynaecological department and had this great 
big cyst removed and lived, so far as we know, happily ever after.
MacVicar:  What annoyed me was that Ian Donald got a cake from that woman 
every Christmas afterwards, and I never got any!
Hall:  I think saving lives carries its own disappointments.
Professor John MacVicar, Dr Angus Hall: Ultrasound, p. 19 
Metabolic studies 
I was supposed to be becoming a nephrologist, but I was doing research on the then 
fairly new metabolic ward and discovered that all the experiments went wrong and 
produced results that I would not have expected. So I tried to find out why and 
discovered that the patients were getting the wrong drugs and the wrong electrolytes. 
And the atmosphere was unbelievable. If I could just say that in those days the 
nurses had to add up the amounts of dietary constituents to six places of decimals, 
from wartime tables that were totally irrelevant. I remember remonstrating with an 
assistant matron about this, and she said: ‘But it does them good, Dr Vere.’ 
Professor Duncan Vere: Clinical Pharmacology 1, pp. 13–14 
Midwives
My midwifery training in 1975 I found absolutely 
horrendous, it was probably the most traumatic experience 
in my whole life. Women being induced, women in agony 
all over the place, I found it just quite, quite frightful, and a general disregard for 
women. I felt as if I was mad some of the time, it was just horrible. 
Mrs Caroline Flint: Maternal Care, p. 62 
I found it just quite, 
quite frightful…
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Migraine
In the 1970s I heard a programme on Radio 4 on the trials and tribulations 
of migraine sufferers, around the time that my friends had been saying: ‘Don’t 
waste time working on migraine, it’s just something neurotic women complain 
about, it’s not a real disease.’ And it was neurologists saying that, but I realised 
it was a real disease and thought I’d better go and find out about it. I was lucky 
enough to talk to Marcia Wilkinson and spent quite a lot of time with her and 
she was a lovely lady, she knew how to treat her patients. What did I learn from 
it? She treated her patients as best she could with bed rest and keeping them in a 
dark room and so on and so on. But what she actually made me realise was that 
there were no good treatments for migraine, so it was another reason for working 
on it because it was a serious disease that needed a new medicine. I was really just 
making the point about what was available in the 1970s; not much. 
Dr Patrick Humphrey: Migraine, pp. 21–2 
Military research
When I first went to the APU, I was a lowly research student and I was amazed 
to find that there was some sort of naval unit in Cambridge. Its sole purpose, as 
far as I could work out, was to provide, I think, six naval ratings per fortnight, 
to be tested at the unit. A large amount of time was spent ‘cooking’ them to see 
how well they performed when they were hot, or locking them in a room for 
hours on end and having them perform vigilance tasks 
Professor Graham Hitch: Applied Psychology, pp. 30–1 
Mistakes
We have lived through a most exciting time in surgery, and, in fact, I think we 
have been discussing one of the greatest advances in surgery ever: hip replacement. 
We have made some mistakes along the way. I think it’s quite important, looking 
back over 30 years of a new surgical procedure, to note that it was a triumph in 
the end for the vast majority of patients, but a failure for some less fortunate, 
who were in receipt of less-than-perfect prostheses. 
Sir Rodney Sweetnam: Hip Replacement, pp. 92–3 
It’s my own personal view that medicine seems to stumble from one disaster to 
the next. All the way through it has been like that. You develop what you think 
is good therapy and you find that a significant number of patients suffer as a 
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consequence, but at the end of it there’s been a little bit of advance. It is a shame 
that people have to suffer to get there and this is my own personal feeling, others 
may not think that. All new therapies are potentially dangerous, I think, and 
have to be used with great care. 
Dr Charles Rizza: Haemophilia, p. 69 
Mixed treatment wards
What dialysis did as regards the changing attitudes to patients: I remember 
clearly the business of sharing accommodation between males and females and 
we were having to defend ourselves to the matron. She was astonished that we 
had put a female patient with a male patient for dialysis. We said: ‘Do you want 
her to die or do you want her to live? It’s as simple as that.’ 
Dr Rosemarie Baillod: Dialysis, p. 46 
Morphine
At about the same time, in March 1948, I was impelled by the stories of my 
patients that I had experienced first as a nurse, but most of all as a social 
worker. I knew I had to do something about end-of-life pain and I went, 
as a State Registered Nurse volunteer, to one of the 
early homes. There I found that the nurses seeing the 
prescriptions of morphine four-hourly ‘PRN’, pro re nata, 
as needed or as requested, by the doctors, quite quietly 
took ‘PRN’ off and gave the drug four-hourly, so as to 
prevent pain ever happening. This regular oral four-
hourly giving of morphine dates back to 1935, fairly soon 
after the Brompton cocktail was put together. Now I was very impressed by 
this, because the patients were so much better with the pain control than the 
ones I had seen in hospital before then. During that time I took Mr Norman 
Barrett, the surgeon I was working for, to see this, and to visit a patient at 
home and so on. When I said to him, ‘I am going to have to go back and nurse 
the dying somehow,’ he said, ‘Go and read medicine. So many doctors desert 
the dying, and there’s so much more to be learnt about pain, and you will only 
be frustrated if you don’t do it properly, and they won’t listen to you.’ So I did 
read medicine. 
Dame Cicely Saunders: Pain, pp. 5–6
…‘I am going to have 
to go back and nurse the 
dying somehow’ …
M – Monoclonal Antibodies to Migraine: Witnesses to Modern Biomedicine, an A–Z
116
I just wanted to say something about morphine. It’s interesting that even into 
the 1960s and early 1970s, there were still physicians who believed that a very 
small dose of morphine was an appropriate treatment for acute asthma. When 
I was a registrar at the Queen Elizabeth Hospital in Hackney in 1973 there was 
a consultant there who insisted that his patients should be given a small dose 
of morphine when admitted with acute asthma. All the senior house officers 
and registrars would carefully steer him away from these patients because they 
were absolutely petrified of ever using morphine, and would use various forms 
of subterfuge to avoid confrontation over the issue. Such comments as, ‘The 
patient was admitted just before your take started’, or ‘Casualty had already 
given him some nebulized salbutamol. The patient improved so much it was not 
necessary to administer morphine.’ 
Professor John Warner: Asthma, pp. 10–11 
Mothers and babies
Sadler:  You can’t advertise, even if you have the money, to give people jobs 
measuring newborns in hospital. It’s a very special thing to do. I was in a fortunate 
position because I’d been working with the National Childbirth Trust for a long 
time, and I knew the network, and knew this extremely valuable post-natal support 
set-up they have, where people who have been through the classes will then get 
together – sort of coffee mornings, what have you – but it’s 
a group of people whom I felt were the kind of people that 
I wanted to be talking to new mums, and handling these 
newborn babies. That’s how we got our first staff. It was 
word of mouth. When we wanted staff for the new Focus 
Clinics from four months onwards, it was the same network 
of people and also people who were known by those already 
working for us. Nepotism, absolutely. But it worked because 
we had a very special kind of group of people who were very 
good with children and babies and mothers, and knew what 
it was like and could communicate well.
Stirrat:  There was an enthusiasm, it somehow or other just caught the spirit of 
the age; it got a lot of steam behind it. Mothers recruited mothers, etc., etc., but 
in fact the midwives were key, as usual. 
Mrs Sue Sadler, Professor Gordon Stirrat: ALSPAC, pp. 24–6 
…we had a very special 
kind of group of people 
who were very good with 
children and babies and 
mothers…
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MRSA
A lot of the move by the Department of Health to reduce MRSA infection was 
driven by high-profile political people being lobbied by ordinary people in the 
country, saying that their loved ones, their dear ones, had died from hospital-
associated infection. I was the first Press Officer for the Hospital Infection 
Society, and at the time that we had our first international meeting in 1987 – I 
didn’t know anything about being a press officer and I said, ‘What do you want 
me to show?’ They said: ‘We want you to show that there is a Hospital Infection 
Society’. Of course, nobody knew anything about hospital infection at that time. 
I would say that we had quite a successful campaign, but in fact what I learnt was 
that the only news is bad news. We had some very, very interesting statements like 
those from Richard Marples, our great leader of our Staphylococcal Reference 
Lab, saying that the only way to get rid of MRSA would be to burn the hospitals 
down. Of course, MPs are lobbied, and if relatives of MPs get this infection, 
then they go to the Secretary of State for Health and say, ‘Well, what are you 
going to do about it?’ 
Dr Geoffrey Scott: MRSA, pp. 66–7 
Many people felt that we were wrong to take MRSA more 
seriously than MSSA (methicillin-sensitive Staphylococcus 
aureus) and that a great MRSA industry has arisen that 
was totally unrelated to the importance of the organism 
in their hospitals. For some hospitals this may have been 
true. When the 1998 Guidance on the control of MRSA 
came out, there was a bitter exchange of letters in the 
Journal of Hospital Infection, in which half the country’s 
microbiologists more or less said this guidance was a 
waste of time, and by implication was written by London 
elitists, who knew nothing about infection control issues. There are still some 
microbiologists who believe that the importance of MRSA is overplayed, 
although I am not among them. Microbiologists did not put their foot down 
about filthy and crowded wards. The public did, and that’s what got through 
to the politicians. MRSA became the focus for a growing understanding that 
infection control in hospitals was poor. 
Professor Gary French: MRSA, pp. 70–1 
There are still some 
microbiologists who 
believe that the 
importance of MRSA is 
overplayed…
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Multiple sclerosis
I first became aware that cannabis had a medicinal application as a young 
hospital doctor in London when I became aware of a patient with MS smoking 
the substance on the Victorian balcony. I spoke to the ward sister, a formidable 
woman who was very much of the old school, and asked: ‘Are you happy with 
this?’ She said: ‘Well, yes. It does seem to help him.’ I thought: ‘Gosh, if it 
convinces her, there really must be something in it.’ I spent a lot of time talking 
to this young guy and it was from him that I became aware of one of the most 
important things from the clinical point of view, as far as I’m concerned, about 
cannabis, which is that it has a very broad range of effects for people with 
multiple symptomatology. It isn’t just a pain reliever or a stiffness reliever or 
something that improves your sleep; it does an awful lot of things for people 
who have a whole range of symptoms; that became a difficult issue later when 
approaching scientifically robust clinical trials. 
Dr Philip Robson: Cannabis, p. 40 
Mustard gas
In 1951 leukaemia was regarded as a dreaded disease that few, if any, survived. 
The urgent need for fresh viewpoints on the nature of leukaemia and its therapy 
was acknowledged, but these were to come from a most unexpected source: 
chemical warfare. The use of mustard gas by the German forces in the First World 
War caused the allies in the Second World War to take preventive measures in 
case mustard gas should be used again. Secret research, both in the USA and here 
in Britain, on nitrogen mustards, the nitrogen analogues of the gas, found that 
they produced marked changes in the haemopoietic system. It was soon realised 
that nitrogen mustard (then known by the code name HN2) produced an action 
on blood cells and bone marrow unlike any other known chemical substance. 
This was the advent of chemotherapy. 
Dr Gordon Piller: Leukaemia, pp. 10–11
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Roger Gibbs: NATSAL
National Asthma Campaign
The Asthma Society came into being in 1980. The medical background that 
was important, and noted at that time, was that we had two effective measures 
in the therapy of asthma: good controlling drugs, the steroids, and cromoglycate 
(Intal), as well as good relief medications. That left the issues of the delivery 
devices and patient education. Patients weren’t taught how 
to use the devices properly and didn’t really understand 
the difference between steroids and bronchodilators. And 
that’s why the Asthma Society started with an educational 
programme involving patient groups, the branches that 
brought asthmatics together for support. It was very 
successful. The Asthma Society and the Asthma Research 
Council were run from the same office for a decade, but for 
organizational reasons it was obviously best that they came 
together, which they did in 1990. The National Asthma 
Campaign was the result, a charity campaigning on behalf 
of asthmatics with government and public bodies. It has 
introduced a very popular telephone helpline. The balance is 
shifting now from patient support groups to the service that is available through 
general practice asthma clinics. The National Asthma Campaign continues to 
fund research, which now, instead of being £300,000 to £400,000, is £3 to £4 
million. Quite a success story. 
Dr Donald Lane: Asthma, pp. 55–6 
Patients weren’t taught 
how to use the devices 
properly and didn’t really 
understand the difference 
between steroids and 
bronchodilators.
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National Childbirth Trust (NCT)
I am recalling experiences from when I was a junior midwife at the Simpson 
Memorial Hospital, Edinburgh in 1978 and I think it was the height of medical 
intervention. Something that really struck me as a young midwife was the women 
coming into the labour wards for their routine shavings and enemas: some 
women would come in and look at you straight in the face, and you knew that 
they were from the NCT. More than that, their case notes actually had ‘NCT’ 
in red letters on the front. As a student, I thought there must be something in 
this, because they would sometimes challenge you. 
Mrs Phyll Buchanan: Breastfeeding, p.42 
NHS central purchasing
I think the fact that so many British medical companies have disappeared is a 
tragedy. The reasons must be many and varied, but it must have something to 
do with the culture of the time. British companies appeared to be reluctant to 
engage outside the UK. Companies such as Lucas, Cambridge, and many others, 
including Watson-Marlow, all had the ability to produce and develop dialysis 
equipment to the demands of the doctors and to the special requirements of 
Dr Shaldon and others who were sending patients home to treat themselves. 
In the late 1960s and early 1970s, dialysis equipment was purchased on central 
contract and delivered to hospitals as and when required. The demand for 
machines in the UK was disproportionately high because of the demand for 
home treatment, even though the total dialysis population was much lower here 
than, say, Germany, France, and Italy. The companies therefore did not have to 
work particularly hard to make a decent business. Perhaps they got fat and lazy. 
If that seems unfair, I would like to make the point that central purchasing did 
not, in the end, do British industry many favours. 
Mr Eric Collins: Dialysis, pp. 38–9 
NHS funding
One of the big difficulties came after you had done research showing that a 
new approach or technique was beneficial and should be incorporated as part 
of routine management – namely achieving the actual takeover from research to 
NHS funding. An example from University College Hospital was the antenatal 
diagnosis of thalassaemia – where at one point the service was going to cease 
totally because I insisted that I couldn’t continue to fund this on research monies, 
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because it was no longer research, having become an accepted, necessary form 
of investigation. The decision was reversed only by involvement of the local 
population, for we were sitting in the middle of a very large Greek Cypriot 
population who relied very much on the service, and only their vociferous pressure 
brought about a last-minute change by the region to provide NHS funding. 
Professor Denys Fairweather: Neonatal Intensive Care, pp. 71–2 
National Survey of Sexual Attitudes and  
Lifestyles and AIDS policy
Johnson:  I would like to say something about what NATSAL-1 was used for, 
which was quite extensively for sex education, for the AIDS projections, so it 
was used year after year to estimate the likely spread of HIV; it was used in 
legislation.
Wellings:  It was used to underpin the whole of the national HIV and sexual 
health strategy. And also the teenage pregnancy strategy. 
Professor Dame Anne Johnson, Professor Kaye Wellings: NATSAL, pp. 49–50 
Professors Anne 
Johnson, Kaye 
Wellings: NATSAL
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Private Eye magazine front cover, 5 July 1968; 
left to right: Professor Donald Longmore, Mr 
Donald Ross, Sir Keith Ross: Heart Transplant. 
Reproduced by kind permission of PRIVATE 
EYE magazine – www.private-eye.co.uk
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Nationalism
One thing, and this may seem less medical than you would like, but the powerful 
symbolism of heart transplantation, the meaning of the human heart, the audacity 
of taking the heart out of one person and putting it in another, the tremendous 
drama that was involved in that, I think, contributed a great deal to the transplant 
boom. As a matter of fact, the image that was invoked earlier this afternoon, of 
the transplant team waving Union Jacks at a press conference is not a laughable 
phenomenon. The fact that all over the world, in various countries, teams felt 
attracted to doing at least one such transplant, had a very nationalistic dimension 
to it. Doing a heart transplant in that particular year of the transplant age was 
tremendously important for reasons that were not purely medical and surgical. 
Professor Renée Fox: Heart Transplant, p. 50 
Native remedies
We set up a study in the early 1980s in three developed countries and three 
underdeveloped countries to see what the situation was at that time, what sort 
of treatment patients were receiving and what sort of pain relief, if any, they 
received. At that time I went to two or three very poor countries, to see cancer 
patients in hospital, and it was pathetic to see the worse-than-basic conditions 
within the hospitals. I remember the women’s ward in one hospital in Sri Lanka 
in particular – there must have been 12 or 14 women there with really advanced 
cancer – and as I walked round the ward, none of them seemed to be in great 
pain. I asked the young doctor who was in charge of this ward what treatment 
they were receiving. He said, ‘They get two tablets of aspirin a day’, and I just 
couldn’t believe it. I asked, ‘Do they not receive anything except two aspirin 
tablets a day? Don’t they get any sort of native herb treatment of any kind?’ He 
said, ‘Well, yes, they do get a native medication,’ and when I asked, ‘What’s in 
the native medication?’, he said, ‘Oh, I don’t know that.’ I have often wondered 
since then why somebody hasn’t gone out there to study those herbs and what’s 
in them, because they looked to be pretty effective. 
Dr Mark Swerdlow: Pain, p. 39
I had a patient with chronic myeloid leukaemia (CML) who was doing rather 
badly, and round about 1990 she decided to go to India for therapy. She had heard 
of a practitioner called Dr Vadya Prakash, operating in Delhi and in Deradan. She 
spent about six weeks there and she came back and said it wasn’t very effective. 
But the Leukaemia Research Fund led by Gordon Piller suggested that it would 
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be worth looking at the particular compound that Prakash was using to treat 
predominantly CML. In conjunction with two other haematologists, I went to 
Delhi to look at this compound. There was no doubt that the compound that 
Prakash was making in his back garden and in his kitchen 
sink was controlling the leucocyte count. The leucocyte 
count of patients with chronic leukaemia was coming down 
in some cases to normal. To the annoyance of the All-India 
Institute of Medical Sciences and Lady Tata Memorial 
Hospital, he was building up a considerable practice in his 
own private office in Delhi. He didn’t know what was in 
the compound, or he told us it was a mixture of things he made in his back 
garden. We brought the compound back to London for analysis and, of course, 
it contained between 15 and 25 per cent arsenic. 
Professor John Goldman: Leukaemia, pp. 19–20 
Needles
I came to Oxford in 1961 and before that time transfusion equipment was rather 
unreliable. The rubber and glass drip sets sometimes came apart in the middle 
of a transfusion and created havoc. Needles and syringes in 1961 were still of a 
type that had been used for many decades. Needles were all steel, sterilized by 
autoclaving after use and resharpened in a machine similar 
to that used for sharpening gramophone needles. They were 
sometimes blunt or even had a hooked point. They were 
packed for use in glass tubes and the size was identified by 
a twist of coloured cellophane, which closed off the end of 
the tube. The syringes were glass and sometimes stuck while 
drawing blood or giving an injection, usually at the worst 
possible time, particularly if you were dealing with a child. 
Dr James Matthews: Haemophilia, p. 33 
Negative transfer situations
Gregory:  I think one of the things you didn’t mention is negative transfer 
situations. There’s the famous case about a mine trolley that had a brake pedal 
and accelerator – so the accelerator was on the right and the brake on the left for 
one direction of travel – but reversed on the way back – as one sat on a different 
seat and used the same pedals. Believe it or not, they had an awful lot of crashes.
Needles and syringes in 
1961 were still of a type 
that had been used for 
many decades.
…he told us it was a 
mixture of things he 
made in his back garden.
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Brown:  A similar situation existed in the control rooms in the electricity-
generating industry, where the engineers designed the same control panel for use 
on opposite sides of the room, so the control display relationships were reversed 
and people had to remember on which side of the room they were sitting and if 
they were on the wrong side they had to think, ‘Well, right means left’. 
Professor Richard Gregory, Dr Ivan Brown: Applied Psychology, pp. 38–9 
Neonatal research
In my opinion it was always quite difficult to get adequate funding for scientific 
neonatal research. For one thing, a whole lot of people used to say, ‘Oh, dear 
little infants, all the charities support you, no problem’, but the fact is most of 
the parent groups and the charities were interested in service or in treatment, 
and not in prevention or basic physiology. The MRC caught us paediatricians, 
I think, in a sort of catch-22 situation. They said, ‘We’d love to give more 
grants but we’re not getting good enough applications’, but the problem was 
that they didn’t really have anybody in the corridors of MRC power who was 
a paediatrician or could reasonably, I think, look in comparative terms at the 
paediatric applications. So it has, historically, been quite difficult to get funding, 
and I have alluded earlier on in this discussion to a slight problem, which is the 
legality of research unless it is of direct therapeutic benefit. 
Professor Tom Oppé: Neonatal Intensive Care, p. 72 
Niche drugs
Lewis:  I was always trying to save drugs that the marketing people were not 
in the least interested in and tried to kill off. I remember my best triumph at 
Merrell Dow in 1983 in that we had an antibiotic – Teicoplanin. But there was 
a big argument about Teicoplanin and they thought it was absolute rubbish 
and tried to kill it off. I remember a phone call in the middle of the night from 
the big boss in the US saying that they were just about to start a large feedlot 
experiment on a Texas farm, feeding this stuff to steers as a growth enhancer, and 
was I sure that the drug was actually likely to be a pharmaceutical, because if it 
was, he was going to have to kill off this experiment. They were, however, going 
to lose $2 million, because the farmer would have already prepared all the steers. 
So it was one of those moments.
Flower:  Did you go back to sleep again?
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Lewis:  Well, it took some years for me to get my equilibrium 
back, but it actually turned out to be the most successful 
drug I’ve been associated with in the industry. Not saying 
an awful lot, but anyway, it’s still going and, you know, it 
did well. But the company was risk-averse at that time; they 
had had some nasty experiences, and the last thing they 
wanted was anything that was going to go wrong. The marketing department 
only wanted blockbusters. That’s one of the terrible things; nobody wants ‘niche 
products’ and it has gotten worse and worse and worse. If you can’t show that 
this compound is likely to be a billion-dollar agent, nobody’s interested. So it’s 
very difficult for people in pharmaceutical industry research to keep working on 
things that might turn out to be interesting, because they tend to get killed off 
at a very early stage. 
Dr Peter Lewis, Professor Rod Flower: Clinical Pharmacology 2, pp. 25–6 
Nomads
In the Algerian Sahara we were comparing two anti-TB regimens: one a 
standard 12month regimen, which was based on isoniazid/streptomycin/
ethambutol; the other was a short-course, six-month rifampicin-based 
regimen. The population included quite a lot of nomads who picked up their 
drugs at convenient places, or took sufficient supplies to get them from one 
place to another or to complete their treatment. The results in the short-
course regimen were vastly better than in the standard treatment: 3 per cent 
compared with 17 per cent failures and relapses at two years. So it made an 
enormous difference that patients didn’t actually have to go on taking their 
treatment for so long. 
Professor Andrew Nunn: TB Chemotherapy, p. 13 
The Wellcome Foundation bought a company in the north of England called 
Calmic. They had a formulation of paracetamol called Calpol. This proved 
to be very much more palatable than the British Pharmacopoeia solution of 
paracetamol, which was very, very bitter. What Calmic did was to use a very 
traditional mucilage of tragacanth and acacia, which has been used for centuries 
in pharmacy to suspend the paracetamol rather than it being dissolved. Well, 
I was sitting in my office one day and a man knocked at the door. He said, 
‘Boss, can you phone the chairman and tell him we can’t make any more 
Calpol because the Bedouin have moved south.’ ‘Excuse me? The Bedouin 
have moved south?’ ‘Yes.’ Now, you see, tragacanth is a natural gum abstracted 
The marketing 
department only wanted 
blockbusters.
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from some plants in North Africa by the Bedouin as they 
tend their goats. That year the weather in the region where 
the tragacanth grows was bad so they decided to up camp 
and move south, so no tragacanth. So that’s why the man 
said to me, ‘Well, could you phone the chairman, mate, 
and tell him that we can’t make any more Calpol.’ I said, 
‘What’s this picture behind me on the wall?’ He said, ‘Oh, 
it’s a picture of the earth taken from the moon.’ I said, 
‘Well, the man who took that picture got back!’ He said, ‘What?’ and I replied: 
‘So it’s not the end of the world because the Bedouin have moved south.’ 
Professor Trevor Jones: Migraine, pp. 74–5 
Norwich Cathedral and hip prostheses
I was working as a technician in the orthopaedic theatre at the Norfolk and 
Norwich Hospital with Ken McKee and John Watson-Farrar. There are two 
things that I can recall, one may be slightly apocryphal about the design of 
the McKee hip prosthesis. He didn’t just turn to engineering, he also turned 
to tenth- and eleventh-century architecture. He copied the flying buttresses of 
Norwich Cathedral for the shape of the stem of his prosthesis. 
Mr Geoff King: Hip Replacement, p. 55
‘…we can’t make any 
more Calpol because  
the Bedouin have  
moved south.’
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Obstetric anaesthesia
Maternal deaths from anaesthesia, which were 20 in a triennium or more than 
20 in a triennium when I graduated in 1971, have been reduced to a single 
death, a single death, in the whole of the three-year period, 1994, 1995, and 
1996. For all that we grumble about anaesthetists being fussy and moaning at 
us obstetricians and holding us up when we want to get on and do things, I 
think that their achievement in making anaesthesia almost totally safe from the 
women’s point of view is one of the staggering achievements of the last 30 years. 
Professor James Drife: Maternal Care, pp. 60–1 
Obstetric ultrasound
When Ian Donald came to Glasgow in the mid-1950s I was his fellow consultant 
in the Western Infirmary and it was our custom to have a session each day 
to discuss the proceedings over a glass of sherry. He learnt that Babcock and 
Wilcox, a firm of boilermakers in the district, had an ultrasonic flaw detector so 
he immediately contacted the Director of Research in Babcock and arranged a 
meeting. I went to that meeting and the next thing was to arrange to visit the 
factory to see the flaw detector in use. We did this and there was nothing that 
would be suitable for the detection of tumours. But Ian talked this over with them 
and they decided that he could come down again, this time bringing a selection of 
tumours; my motor car boot was filled with large ovarian cysts and fibroids and so 
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on, which we took down to the factory. 
They had produced some kind of 
primitive transducer and a water-bath, 
and we took primitive pictures with 
an engrossed audience of the workers 
in the factory who thought it looked 
rather like an abattoir. We came back 
and he was still frustrated by the fact 
that there was something in this idea, 
and how could he develop it. That same 
evening a telephone call came from one 
Tom Brown, an engineer at Kelvin & 
Hughes marine technology company 
in Glasgow, purely by chance, and 
that was the start of this providential 
partnership between Tom Brown and 
Ian Donald. If it hadn’t been for them 
there might never have been ultrasound 
as we know it. 
Dr Wallace Barr: Ultrasound, pp. 58–9 
I heard, by chance, of the obstetrician Ian Donald’s use of an A-scope machine 
on people. I went home, looked up Professor Donald in the phone book and 
phoned him up, on Western 5050, that night. Had he been the least bit stuffy, 
none of this might have happened, but in fact he was delightful, and it wasn’t 
long before I was invited to go and see what he was doing. 
Mr Thomas Brown: Ultrasound, p. 16 
I consider that the success of the original work on obstetric ultrasound depended on 
three separate things: the people, the place, and the time. And I would like to start 
with the time. 1956 was a lot different from 1996 and I really don’t think a Western 
Infirmary Ethical Committee would ever have allowed us to use an industrial flaw 
detector on patients. Nor do I think that the patients would have submitted to 
examination if they had had to sign a form which said, ‘I hereby agree to this 
examination by an experimental machine and I don’t know all the consequences 
thereof.’ Although we had a lot of discussion with the patients beforehand, it 
certainly would not have been accepted nowadays. We were lucky in 1956. 
Professor John MacVicar: Ultrasound, p. 47 
Mr Thomas Brown, 
standing in front 
of the newly built 
contact scanner 
in the research 
and development 
laboratories of 
Kelvin & Hughes 
Ltd, Glasgow, 1956: 
Ultrasound
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Olympic Games
Peter Sperryn and I were both working with the British Amateur Athletic Board 
about the same time. I went with lots of teams to several Olympic Games and went 
with the hockey team on several of their world tours and so on, but was never paid 
by any of them. You were always expected to take it as holiday. At that stage I was 
working in general practice and one of my partners came out and said: ‘We don’t 
think that we ought to pay you while you are away.’ That was what you were up 
against; I can’t remember the year. But then I became a fully paid medical officer for 
track and field – I became their Chief Medical Officer in about 1986 – so at that 
stage I was paid. In 1986 there was the first Olympic medical officer being paid that 
I know of. I was also asked to be the Chief Medical Officer for the Olympics. I had 
just come out of full-time general practice, and I said: ‘Well, I think this job is at 
least four days a week for me to do it properly; how much are you going to pay me?’ 
To which they said: ‘Nothing’. And I said: ‘I cannot do the job if I am trying to earn 
a living, and you expect me to work four days a week for free; it’s impossible.’ So 
they were not paying us even at the Olympic stage in the mid-1980s. 
Dr Malcolm Read: Sports Medicine, p. 46 
Ondansetron
We used to do the ward round in Louvain every single day with 
our professor who was very, very strict. At 9 a.m. we would all 
go round, and every single child would be on their bed – you 
can’t do a ward round like that anymore – but they would all 
be there with their cardboard kidney bowls, vomiting, and 
we would do every single ward round, every morning, every 
room, and it would smell bad, and we would feel bad, and the 
children wouldn’t be able to tell us anything because they were 
just throwing up all over the place. Then once we started with 
ondansetron nobody was vomiting any more, and then in the 
cafeteria, because in Belgium the food is good, they would be 
served steak and fish, and chocolate mousse; but they couldn’t 
even have the food trays in the room before ondansetron. But 
afterwards, the kitchen staff would come running up to me 
and they would say, ‘Professor Brock, Professor Brock, what’s 
going on? All the oncology patients are ordering food, they want 
chocolate mousse, we are coming and fetching the trays and the 
food has been eaten, and it is not the parents who are eating 
Chemical structure 
of ondansetron, an 
anti-emetic drug: 
Platinum compounds 
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the food, because the parents also get their own tray.’ To me, that was a wonderful 
watershed; when we did ward rounds not only were they not vomiting, but they were 
actually ordering food and eating it. 
Dr Penelope Brock: Platinum Salts, p. 60 
Openness
If I had my time again, I would like to see much more openness. Some, but not 
all, of the problems that we are seeing now about the interpretation of science 
and the way in which science is purveyed to the public in relation to their own 
interests and in their own environment and lives derive from the fact that some 
of the discussions were held behind closed doors. I have been very impressed 
recently in various ways in the Committee on Toxicity that I have been chairing, 
about open discussion of these matters. I suspect that if there had been more open 
discussion about some of the matters that affect the environment then some of 
the concerns and worries, certainly in the public perception, would not be there. 
Professor Frank Woods: Environmental Toxicology, pp. 23–4 
Oral rehydration therapy
Although scientists and research clinicians were convinced that oral rehydration 
therapy worked, based on elegant trials, it was not until the Bangladesh war of 
independence, when Dilip Mahalanabis and his colleagues actually used oral 
rehydration therapy very effectively in refugee camps in an emergency situation, 
that oral rehydration therapy became widely used in practice. Mahalanabis 
applied it in a disaster situation for the first time, whereas others had applied 
it under more controlled research situations. It was this practical application 
which persuaded UNICEF and the World Health Organization to appreciate 
the clinical value of oral rehydration therapy. 
Professor John Walker-Smith: Intestinal Absorption, p. 44 
Out-of-hours working
The intensive care unit that I started and ran for years was very much an 
anaesthetic unit. That wasn’t because we were guarding our boundaries, but 
the physicians have changed a great deal since 1960. When we moved into the 
Royal Liverpool University Hospital, amalgamating about five small 300- to 
400-bedded teaching hospitals, in 1979 and for a few years afterwards, the most 
senior opinion for medical patients at night, or outside the consultants’ ward 
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days, was a senior house officer. Even the registrars were resistant to it; they 
certainly didn’t live in. A senior registrar visit was something of a papal visit. 
Physicians, in my experience, didn’t want to have to put in the sort of out-of-
hours work that the anaesthetists were doing. 
Dr Tony Gilbertson: Intensive Care, pp. 57–8 
Oxford academe
I found it very difficult to establish an accepted and strong identity for 
clinical pharmacology in Oxford. I remember treating a very well-known and 
distinguished professor of philosophy in Oxford after a mild stroke, who asked 
me: ‘What’s your specialty?’ in the way that they do in Oxford. I replied, ‘I am 
Professor of Clinical Pharmacology.’ ‘What’s that?’ So I said, ‘Well, studying 
how medicines work, what they do to the body, how the 
body deals with them, their effects and their side effects.’ 
‘Oh, you are the Professor of Pills.’ Straight in, ‘Professor of 
Pills.’ When I first went to Oxford, I went to an induction 
party by the Rhodes Trust. I was introduced all round by 
the secretary of the Rhodes Trust as the Professor of Criminal Psychology, which, 
of course, is very much more interesting at a cocktail party than the Professor of 
Clinical Pharmacology. And then finally, just to give the flavour of Oxford and 
how difficult it can be, going to a private dinner and sitting opposite a very nice, 
very distinguished lady of the upper classes, who said, ‘How did you get here, 
young man?’ (because I was a young man). I went through the whole rigmarole 
and she said, ‘How did they know that you would be socially acceptable?’ So, 
these are some of the things that I came across in Oxford that are relevant to the 
teething troubles of clinical pharmacology. 
Professor David Grahame-Smith: Clinical Pharmacology 1, pp. 33–4 
A distinguished Professor of Medicine in Oxford was seen moving the placecards 
at a dinner so his wife didn’t sit next to a psychiatrist. 
Professor Bill Fulford: Medical Ethics, p. 37
‘Oh, you are the  
Professor of Pills.’ 
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Professor Sir 
Salvador Moncada: 
Platelets
Pain and palliative care, 1960s
About 1961 or 1962, I asked patients to estimate their pain levels, and linked 
them to the nature of the analgesic that was prescribed for them. I did a study 
on the male oncology ward and the female oncology ward. The results were 
amazing, because there wasn’t any correlation at all between the type of analgesic 
given and the level of pain recorded, either before and after the analgesic had been 
given. So you could have had a bucket of analgesics in the middle of the ward 
and said, ‘Take one of these. It might work.’ The second observation was that 
on the ward for women all types of analgesics were available, including narcotic 
analgesics, but on the men’s ward narcotics were not available. I enquired why 
narcotics were not available to men and was told that men don’t need powerful 
drugs like that. It is hard to believe that such attitudes existed, but they did. I 
think it is worth recording that life was very bad sometimes for people with 
severe pain. 
Professor Sir Michael Bond: Pain, p. 21 
Going to St Joseph’s Hospice, which was virtually untouched by medical advance, 
I was able to introduce records and the regular giving of morphine, which they 
hadn’t started, and according to one of the sisters of the ward that I was first in, 
it was the change from painful to pain-free. Having been given four patients 
to look after, I was soon looking after every admission into those 45 beds. So 
I began keeping records in detail, pre-computer, on a punch card system, and 
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…they had this  
complex mixture of 
cocaine, morphine, 
gin, sometimes with 
phenothiazine added.
Dame Cicely 
Saunders: Pain
making tape recordings of patients talking about 
their pain from 1960, and I realised that what 
we were looking at was what I described later, 
in 1964, as total pain. And I will quote from 
one patient, when I said to her, ‘Tell me about 
your pain, Mrs H.’ She just said, ‘Well, doctor, 
it began in my back, but now it seems that all 
of me is wrong. I could have cried for the pills 
and the injections, but I knew that I mustn’t. 
Nobody seemed to understand how I felt, and 
it seemed as if the whole world was against me. 
My husband and son were marvellous, but they 
would have to stay off work and lose their money, 
but it’s so wonderful to begin to feel safe again.’ 
And so she has really talked about the physical, 
the psychological, the social, and her spiritual need for security to look at who 
she was, coming to the end of her life. And for another patient it was, ‘All pain 
and now it’s gone, and I am free.’ It is not possible to treat pain in isolation. We 
have to consider the whole person. 
Dame Cicely Saunders: Pain, pp. 6–7 
I will say that until about 1965 there was entrenched ignorance, a tremendous 
amount of severe pain. Patients who were in severe pain, or dying with pain, 
were often given the Brompton cocktail, or Mist. Obliterans, as it was politely 
known, and it was a matter of patients being rendered so that they didn’t know 
what they were doing, by doctors who certainly didn’t know what they were 
doing. They were using medicines with actions that they 
couldn’t understand, because they had this complex mixture 
of cocaine, morphine, gin, sometimes with phenothiazine 
added. Parsimony was the order of the day, which rendered 
control impossible. Pain breakthrough was frequent, and 
intermittent control is disastrous, if only for the reason of 
the self-augmentation of pain. Hospice care had, of course, 
begun but somehow it didn’t seem to have come across 
into the general medical and surgical field in hospitals and 
general practice. 
Professor Duncan Vere: Pain, pp. 15–16 
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Palliative care nurses
Nurses were put in positions usually with support from the local hospice and 
maybe an interested physician or anaesthetist. However, they were essentially 
working alone. Initially progress was slow. The nurse was referred patients who 
had been given ‘bad news’ and she would be asked to go and talk to them. This 
afforded her an opportunity to discuss pain relief and symptom control. These 
nurses, however, did not have the ‘power of the pen’, and consultants, registrars, 
and house officers would need to be persuaded to prescribe medication that 
they may have been unfamiliar with and which often seemed excessive and 
inappropriate. However, once a successful outcome was achieved, then more 
referrals would follow and this would swiftly snowball, particularly in the larger 
hospitals. These nurses soon became inundated with requests to educate fellow 
nurses, who were very keen to learn about palliative care as this was at the very 
heart of what nursing was all about and a great source of job satisfaction. 
Ms Janet Gahegan: Palliative Medicine, pp. 97–8 
Pancrease
Pancrease and Creon are the trade names for the two new pancreatic preparations 
prescribed for cystic fibrosis. The thing that was very special about Pancrease, 
and later Creon, was that they were not destroyed by stomach acid, so the actual 
enzyme was not released until the surrounding environment became alkaline in 
the duodenum or even a bit further down. Pancrease sounded like a gimmick 
initially but, by Jove, it was miraculous! I can well remember a girl of about 15 
weeping when she had been put on to Pancrease, and saying that her whole life 
was dominated by her terrible bowels, and she said, ‘Now I can live a normal 
life.’ It was absolutely awesome, the effect in some patients. I pushed it hard 
because it was a very, very important area. 
Dr James Littlewood: Cystic Fibrosis, p. 30 
Parkinson’s disease
Those who are 25 years, or more, younger than I am have no idea of the 
enormous gulf of mutual ignorance between the laboratory workers and the 
clinicians, due to the overlaps between their trainings being so slight. There was 
also the tremendous prestige and self-confidence of the top clinicians, while 
good research scientists are cautious and self-doubting. I remember an eminent 
neurologist, now dead, saying quite dogmatically that pharmacology had very 
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‘…biochemistry or 
pharmacology have 
nothing to do with 
Parkinson’s disease.’
little to teach the neurologist. Then levodopa appeared 
and I stood up at a meeting at Queen Square saying very 
diffidently: ‘There’s this new thing called levodopa and 
it helps people with Parkinson’s disease.’ A comparably 
eminent neurologist, now dead, said through clenched 
teeth: ‘If Dr Curzon had been a clinician he’d know that 
biochemistry or pharmacology have nothing to do with 
Parkinson’s disease.’ 
Professor Gerald Curzon: 5-HT, p. 107 
Patients
Patient activism
In the mid-1980s we, midwives/breastfeeding advisers, were not knowledgeable 
in the way that you doctors were, but working with women at the grass roots 
and having the pleasure of saying: ‘Yes, this does help women’, and seeing the 
satisfaction and joy that breastfeeding brought them, I think, made us all much 
more committed as time went on, and many of us have continued working with 
breastfeeding for a very long time. That was a hugely important time. I think 
it started a movement where mothers, midwives, and voluntary organizations 
started to work together and put women at the centre of what was going on. 
Mrs Jenny Warren: Breastfeeding, p. 42 
I think activism played an important part in recruitment into our clinical trial of 
cannabis. The positive activism by patients was very important to recruit people 
on to the study, but, on the other hand, there was also the negative activism, that 
patients who have had a bad experience, presumably by overdose, can influence 
other patients, who then refuse to go into clinical trials, particularly if they have 
not taken cannabis before. 
Dr Anita Holdcroft: Cannabis, p. 63 
Patient influence
There was one British Society of Gastroenterology (BSG) meeting where we 
were presenting some work on Helicobacter pylori and its effect on physiology 
and gastrin. I was asked by the BSG to speak at a press conference and presented 
the work and then other members of the press came up to me afterwards. I 
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was then met by one of the secretaries of the BSG, and told I was not to speak 
to the press because one of the pharmaceutical companies had complained. 
There was a sense that pharmaceutical industries were even working through 
British medical societies to discourage the release of scientific knowledge that 
was relevant to clinical treatment. The way in which this new treatment became 
adopted was not from the profession down, it was from the patients up. And it 
was through the press getting hold of this story and through their programmes 
and newspapers, that the patients demanded this new treatment. I think there 
is a problem when introducing a new treatment that cures a chronic condition 
from which the pharmaceutical companies were receiving a large income due to 
their drugs that controlled, rather than cured, the disease. 
Professor Kenneth McColl: Peptic Ulcer, p. 95 
Patient records
I want to pay tribute to the large all-encompassing patient chart. It may sound 
like a trivial thing compared to all the equipment etc., but I think it made a huge 
difference to really understanding what was going on with the patient where you 
had your total patient physiology out there in front of you and you could really 
see what was happening and why. 
Ms Sheila Adam: Intensive Care, p. 63 
While you’ve got the patient there, the large paper chart is useful; everyone can 
have a look at it. But, of course, it is irretrievable data, because once the patient 
leaves, what are you going to do with it? We had filing cabinets marching down 
the corridor filled with charts. It is a fire hazard, that’s all, so you might as 
well throw the charts away. But when you say you’re going to dispose of them: 
‘Oh, you can’t throw them away!’ What are you going to do with them? I think 
the computerized records are obviously the way forward. The difficulty is that 
there is not a standard system anywhere, as far as I know. We’re back to the 
early days of word processing where everybody did something differently. I used 
to go round to hospitals to visit intensive care units for the Royal College of 
Anaesthetists, and I would go to a unit where it is all wonderful and ask: ‘How 
long would it take a new person, a nurse or a doctor, to learn how to use this 
system?’ Sometimes it was weeks, and that raises the question of whether this is 
the best way forward. 
Professor Leo Strunin: Intensive Care, pp. 64–5 
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…he had enough 
penicillin available to 
create what he called 
‘miracles’…
Peak flow meter
Just after the 1955 MRC report on lung function in coalworkers’ pneumoconiosis, 
Dr Martin Wright was appointed to the Pneumoconiosis Unit. He decided that 
even the measurement of FEV (forced expiratory volume) could be improved if one 
could measure the actual peak gas flow during exhalation instead of a volume related 
to time. With this idea in mind he designed the peak flow meter. That test too has 
become of almost universal clinical use and was later developed into the breathalyser. 
Dr Philip Hugh-Jones: Population-based Research, p. 35 
Penicillin
The first break in CF treatment came after the Second World War when penicillin 
became available. The paediatrician Paul di Sant’Agnese had access to penicillin 
from the US Army, which was the organization in the USA with top priority in 
obtaining penicillin. I don’t know how Paul got the penicillin, but he had enough 
penicillin available to create what he called ‘miracles’ in response to antibiotic 
chemotherapy using aerosolized penicillin. Paul told me that 
it seemed to make no difference how the penicillin was given, 
whether it was given by aerosol, or by parenteral therapy. In 
his judgement, the Staphylococcus aureus was so exquisitely 
sensitive to penicillin that any treatment with penicillin in 
these children with progressive staphylococcal pneumonia 
could be effective. I remember vividly Paul telling me when 
I was his clinical research fellow at NIH in the 1970s what 
a wonderful feeling it was, and how exciting it was, to be able essentially to cause 
miracles through treatment with penicillin in these children, who otherwise were 
going to die within weeks or months; patients slowly dying from the chronic 
pulmonary disease revived in a few days. For the first time there was an effective 
tool to help control the lung infection as the predominant organism in the 
bronchi of patients with CF. 
Dr Philip Farrell: Cystic Fibrosis, pp. 8–9 
Pesticides
The 1940s and 1950s were, of course, times of innocence. We all believed that 
science was benign and that eventually the sensible use of chemicals would set 
humankind free from pests and disease. But it was also, of course, a time when many 
new herbicides and pesticides were invented, including the organophosphates. 
Professor James Lovelock: Environmental Toxicology, p. 4 
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…5-HT
3
 antagonists 
are some of the most 
cost-effective drugs, 
or probably the most 
cost-effective drugs in 
oncology.
Pharmacoeconomics
When the 5-HT antagonist anti-emetic drugs first came out, they were 
very expensive, and many of the companies were very concerned that the 
people were not getting the compounds because of the cost. I think it was 
Glaxo who actually calculated the cost of a vomit for a patient, how much 
the bowl cost, how much cleaning up cost, and factored that into these 
pharmacoeconomic models, and the 5-HT
3
 receptor antagonists were the first 
examples of drugs where pharmacoeconomics played a major role in the whole 
marketing package. 
Professor Paul Andrews: Platinum Salts, p. 61 
We oncologists need to reach the point where we can 
face every patient and say, ‘Emesis is not likely to be a big 
problem for you.’ The 5-HT
3
 antagonists are some of the 
most cost-effective drugs, or probably the most cost-effective 
drugs in oncology. They prevent hospitalization. You don’t 
have to prevent very many hospitalizations to make them 
economically sound. They are a dominant strategy for 
many patients, again because they allow us to de-hospitalize 
patients. I must say, in the UK people have been slow to de-
hospitalize patients. 
Professor Richard Gralla: Platinum Salts, pp. 67–8 
Placentas
It was common practice, but not widely known, that maternity hospitals used 
to sell placentas for cosmetics. It was traditionally viewed by the midwives 
as a bit of a perk, and the money that was gained, I think in most hospitals, 
went into what was effectively a slush fund for midwives to use. It was only 
a small amount of money per placenta and I suspect the cosmetic companies 
made huge profits out of it. The important thing was that most women who 
delivered didn’t know that that was going to happen, and the hospitals were, 
in my view, unethical in not telling them. So when ALSPAC came along and 
wanted to take the placentas away, this was a potential barrier to the midwives’ 
participation. I’m not sure how we managed it, but we managed to pay 50p 
per placenta. 
Professor Alan Emond: ALSPAC, pp. 45–6
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One of the things I was really excited about was the collection of placentas. There’s 
still a huge amount of information in a warehouse somewhere incarcerated 
within the placentas, which I think could add to the study even now. 
Professor Gordon Stirrat: ALSPAC, pp. 9–10 
Plastics
I think very few people below a certain age can remember our working conditions 
in the early 1950s. For example, nowadays people use butterfly cannulas for 
intravenous transfusions and they can do all kinds of things with them. In our 
day we had dreadful glass syringes; they had a central nozzle and there was no 
way you could get into a small vein – we always had to use the cubital fossa 
veins. If we wanted to put up a drip, for example, we had to rummage about in 
a great cardboard box where there were lots of rubber tubings of different sizes, 
and we had to fit these up and stick them into a glass rod that fitted into a hole 
in a cork in a bottle – we didn’t have any plastic transfusion equipment. All this 
took a great deal of time. 
Professor David Galton: Leukaemia, p. 27
In 1962, Victoria Smallpeice in Oxford started feeding 
babies who weighed 1,000 to 2,000g at birth early, with 
expressed breast milk. The relatively newly available 
polyvinyl feeding tube passed into the stomach was a great 
advance over the teaspoon and ‘fountain pen’ dropper. An 
enthusiastic young nursing staff showed that even ill babies 
could be fed small amounts frequently from soon after birth 
with indwelling tubes strapped in place. 
Dr Pamela Davies: Neonatal Intensive Care, p. 69 
Polyposis Register
Neale:  Dick Bussey was a grammar school boy who came from a family that did 
not have the resources to put him through university. He started working with 
Cuthbert Dukes, the pathologist at St Mark’s Hospital, when he was 17 years 
old, and Dukes soon recognized that he had someone who was both intelligent 
and meticulous. He encouraged Bussey to go to university to do a degree in 
chemistry and then later to do his PhD in familial adenomatous polyposis (FAP). 
He was an amazingly gentle person, I only ever heard him cross once. As much 
as I questioned him or didn’t understand what he was saying, he would patiently 
…enthusiastic young 
nursing staff showed that 
even ill babies could be 
fed small amounts…
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go over it again and say that if someone didn’t understand something it was the 
fault of the person not explaining it properly, not the person who was being a bit 
dim. I worked with him for many years. I became very friendly with him.
Harper:  How did the register originate? Was this St Mark’s patients or was it 
from a wider range from the beginning?
Neale:  Well, the Polyposis Register started with St Mark’s Hospital patients 
but Dr Dukes would lecture and publish in the journals of the day. He soon 
acquired an international reputation and so people would send pathological 
slides or descriptions of cases of polyposis from all over the world, and Dr 
Bussey would record them all and catalogue them. So sometimes we had full 
families; sometimes we would just have the slides titled something like ‘Girl 
from Thailand’. But, of course, in those early days we did not know if polyposis 
was an international condition. Dr Bussey had cards that he called his ‘cohort 
cards’, because of course this is before computers, and the cohort cards would list 
the years of birth of patients who had polyposis and the part of the country that 
they lived in. We weren’t even sure if there were cases of polyposis throughout 
the UK, although now we know they are all over the world. 
Ms Kay Neale, Professor Peter Harper: Clinical Cancer Genetics, pp. 21–3 
Dr Bussey’s original 
Polyposis Register 
patient record cards, 
St Mark’s Hospital, 
London, 2013: Clinical 
Cancer Genetics
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Population research
It was very non-medical work in a way. I was busy learning how to read 
pneumoconiosis in chest X-rays, interviewing miners, Welsh miners, and my job 
largely was, apart from the X-ray reading, going round the houses, interviewing 
those who had abnormal X-rays, or who ought to be recommended to go for 
compensation. I was doing that sort of thing for a year or two and then we were 
increasingly realizing that the facility of having a general population all censused 
on what were then Hollerith cards, or punch cards. It was an opportunity to 
look at other diseases apart from miners’ chest diseases. 
Dr Bill Miall: Population-based Research, p. 36 
Postnatal trauma
One of the things they were not measuring in the 1970s was what labour was 
like for the mother being induced, as against not, and what the mental health of 
the mother was. On the basis of the letters I got, which gave the first descriptions 
I had seen of post-traumatic stress disorder, which at that time wasn’t described 
I think in the literature, and I could only correlate it with First World War 
shell shock, women describing nightmares, the kind of 
nightmares where you woke up screaming and flashbacks 
and so on. I telephoned the Mother and Baby Psychiatric 
Units around the country, in areas where I knew there was 
a high induction rate on the basis of published studies, 
and said, ‘Have your mother and baby admissions gone 
up?’ They said, ‘It’s funny you should mention that.’ I was 
getting, ‘We had one midwife who gave birth, who hid in the lavatory in the 
hospital till she was too far gone to be interfered with, and a woman GP who 
lied about her dates, so that she wouldn’t be induced. The women who came out 
with least psychological damage were the ones who had had intensive support 
from midwives, who said, ‘I had a midwife who had formerly worked on the 
district, and she supported me, and I couldn’t have got through it otherwise.’ 
And then I realised that you could ameliorate the effects of the technology, when 
you had these one-to-one midwives, but I knew that things were changing, soon 
you would have high-tech midwives, and high technology, and the result was 
going to be disaster. That was how the consumer movement in childbirth started. 
Professor Jean Robinson: Maternal Care, p. 48 
…I could only correlate 
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Pre-implantation genetic diagnosis (PGD)
The first couples were treated with pre-implantation genetic diagnosis in 
September 1989. We had no idea whether they would get pregnant at that 
stage. They were fertile couples, so we were optimistic from that point of view. 
However, we had no idea whether the embryo would be lost. We knew from 
animal experiments that this could destroy the embryo. We then had a very 
nervous period of waiting to have the diagnosis confirmed. We counselled 
all of the couples that this was very early and experimental. So they went on 
to have the diagnosis confirmed by CVS (chorionic villus sampling) in the 
majority of cases. When we had the results from several couples confirming 
the sex as female, I approached Nature to see if they would be interested in this 
publication, and they said that they would be very interested but wanted to 
make sure it was published ahead of the debate in the House of Commons. So 
we were literally working day and night to write the paper against these tight 
deadlines. The peer reviewers had already been set up, and it was probably one 
of the first papers to be peer reviewed by fax. It was submitted and accepted, 
after peer review and corrections, in only two days, because 
the editor was absolutely clear that the public should be 
aware of the potential benefits of embryo research. In the 
week of publication he organized a press conference and the 
two women who carried the first pregnancies came along 
because they wanted to support the work and enable other 
couples to benefit following PGD. I think they were very 
brave and both of them were heavily pregnant with twins, but it had a significant 
impact on the press conference and their story was featured on the front page 
of the Daily Telegraph the following day. The following week at the end of the 
debate, even Margaret Thatcher went through the ‘aye’ lobby and voted to allow 
human embryo research, which was carried by a substantial margin. 
Professor Alan Handyside: Genetic Testing, pp. 58–9 
Prenatal diagnosis
At this time, I had patients coming to me, young women with one child with 
thalassaemia, saying they wanted to be sterilized, and I said, ‘No, under no 
circumstances because it looks as if we might be able to do prenatal diagnosis. 
Get your contraception organized.’ So all my patients’ mothers knew that this 
was in the wind: one of them was a Pakistani paediatric haematologist with a 
child who had thalassaemia major. She came in one day and asked, ‘How are 
…even Margaret 
Thatcher went through 
the ‘aye’ lobby…
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you getting on?’ And I said, ‘It’s getting very exciting. Would you like to come 
into the lab and see?’ So I showed her results for five cases: we’d got one normal, 
three that looked like heterozygotes, one that looked like a homozygote, so it 
looked as if we could do it. She said, ‘Oh, that’s very interesting’, and she went 
away. We carried on. Three months later she rang up and said, ‘I’m pregnant. 
I want you to try and do a prenatal diagnosis because the worst you can do is 
cause a miscarriage, and if you won’t do it I’m going to have to terminate this 
pregnancy.’ The point I’m making here is that the patients really pushed the 
pace. We tried and the end result was that we were hustle-bustled into actually 
having to provide a prenatal diagnosis service for thalassaemia. When the news 
got about, people started getting on planes in Cyprus, Italy, and Greece to come 
for the service. 
Professor Bernadette Modell, Clinical Molecular Genetics, pp. 24–5 
Prescribing
There is one thing that you can do on day one as a doctor, and that is kill 
someone with a pen if you are not a safe prescriber or you haven’t got a British 
National Formulary. You probably won’t be able to kill them with your lack of 
knowledge of anatomy, although that’s possible if you are a surgeon. It’s much 
easier to kill people with drugs, and I think the whole prescribing arena has 
become so complex now that it is impossible to be safe without a very strong 
foundation in clinical pharmacology. 
Professor Mark Caulfield: Clinical Pharmacology 1, pp. 70–1
I want to pay a tribute to Jim Crooks. He, I and Dr William Wallace, a youngster 
in my department, looked at errors in prescribing in the hospitals where we 
were working in the early 1960s. It was really after that that Jim produced the 
‘Aberdeen’ prescribing form, which is now so widely used in hospitals. In the 
old days, doctors used to write a prescription in the patient’s notes, and the 
ward sister would make a list for nurses to administer the medicines – it was all 
very casual, and accuracy was becoming much more important with the arrival 
of antibiotics and corticosteroids, etc., in the postwar period. More precision 
was needed, and I think Jim Crooks played a very big part in this important 
development. 
Professor Owen Wade: Clinical Pharmacology 1, p. 31 
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Prescriptions
If you look at the 2010 prescription sales, out of the top ten there are, I think, 
four or five compounds that are related to 5-HT research; we’re talking about 
billions of prescriptions, which highlights the impact that 5-HT research and 
development has had on industry and academia. 
Dr Tom Blackburn: 5-HT, p. 53 
Prisoner of war experiences
I first met the epidemiologist Archie Cochrane in 1946 – I think I had just got 
out of the army. I don’t know when he got back from the war, as it was very 
difficult, people got held up for a long time. On the whole, prisoners of war got 
back quicker, but I imagine he got back in 1945. I went as a student to a meeting 
of the Socialist Health Association, which was the Socialist Medical Association 
in those days, somewhere in west London, and Archie was the speaker. He was 
telling us all about his experiences as a prisoner of war, and what was striking 
Aberdeen 
Prescription Sheet: 
Clinical Pharmacology 1. 
Copyright © 1967 
Royal College of 
Physicians. Reproduced 
with permission
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about this, it made a tremendous impression on me, I really remember it very 
well and I have forgotten most things from that time, but he described it in 
a quite different way than he ever did in anything that he has written. The 
biggest messages out of it were first of all the degradation that the prisoners were 
subjected to as soon as they were taken from Crete to Salonica, where they were 
systematically terrorized by the Germans; everyone had diarrhoea and so they 
were going all the time to the latrines to shit and the Germans would toss in 
hand grenades, just randomly, from time to time. They had a hospital of some 
sort, with a staircase with windows along the staircase, and as health personnel 
and patients were taken up and down these Salonica stairs, again randomly from 
time to time they were sniped at and shot as they went up 
and down these stairs. This was happening in this reception 
area in Salonica before the prisoners were dispersed to their 
destinations. The big point that Archie made was how 
every nationality and racial group was given a place in a 
hierarchy, a pecking order with the Americans at the top 
and the British immediately after the Americans, and then 
all the way down to Poles and then finally Russians. This also is a perception of 
order and Archie was interested in the ordering of things. I think he eventually 
was glad to forget about all this or at least never to bring it up again. At that 
time he really did want to talk about it. I think it is difficult for people to grasp 
really how different our view of the world is now than it was in the 1950s and 
the 1960s. 
Dr Julian Tudor Hart: Population-based Research, pp. 24–5 
Prisoners
I was in Iowa City on sabbatical in 1964/5. They actually used prisoners in the 
University Hospital. They could come out of the prison and stay on the wards 
and they would swallow the tubes and be perfused, and they got off some of 
their sentence. It was the absorption of substances like methionine that they 
were doing at that particular time, but I remember seeing them. They were in 
pyjamas so that they couldn’t escape. 
Dr Roy Levin: Intestinal Absorption, p. 41
It is interesting to look back at the way the experimental studies in RhD-negative 
male volunteers were conducted respectively in Liverpool and Baltimore. In 
Liverpool, it was in an atmosphere of simple altruism that the work was carried 
out in the Blood Transfusion Centre or at places like Vauxhall’s factories or the 
I think he eventually  
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petrochemical factories in Ellesmere Port and so on. Such volunteers were not 
available in the US where it was common practice to use prisoners for medical 
research. In Baltimore the ‘volunteers’ for the experiments were inmates of the 
Maryland State Penitentiary. The prisoners used to receive, as I remember, a 
pack of cigarettes and US$3 for each injection or sample of blood. This use of 
prison inmates was forbidden under subsequent legislation. 
Professor John Woodrow: Rhesus Factor, p. 32 
Project Whitecoat
It came as a shock to all of us to realise how the tobacco industry had been 
tracking us, looking at us, criticizing WHO internally, much earlier than we 
ever dreamt of. The documents gave us a sense of betrayal, because they showed 
that many of our colleagues, in public health in particular, 
had been paid off by the industry to deny the evidence, 
particularly on issues of passive smoking, and to try to 
obstruct tobacco control legislation. In most countries in 
Asia there were two or three people who had been recruited, 
including people I myself knew. I was shocked, really shocked, to realise that the 
tobacco industry had recruited colleagues. It was called Project Whitecoat in 
Asia. They recruited the whitecoats, that is, the doctors and scientists, and paid 
them to try to obstruct tobacco-control measures. 
Dr Judith Mackay: Tobacco Control, pp. 28–9 
Psychology
Absolutely all areas of modern technological society have had psychological 
input somewhere along the line, and yet if you ask the public what their image 
of the psychologist is, they still think of Freud or something like that. 
Professor Graham Richards: Applied Psychology, p. 69
The documents gave us a 
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Professor Monty 
Losowsky, Sir Roger 
Bannister: Sports 
Medicine
Questionnaires
With hindsight, I would have loved to have sent questionnaires to the 
grandparents, because that’s the generation that is very important regarding the 
parents of our study children, and it would have been good to capture them 
before they dropped off more than they had already. With work that Marcus 
Pembrey and I are doing, the intergenerational effects of traumas and such 
things that happen during one’s upbringing can be passed down the generations, 
and that would have been good to capture. 
Professor Jean Golding: ALSPAC, p. 38 
A rare tumour
In 1946, I was a senior registrar in medicine at St Mary’s Hospital, London, 
with a vague idea about becoming a cardiologist. One day there was a patient 
who came in; she was 17 years of age, and she was the most breathless person 
I have ever seen in my life. She had crawled into the hospital. The casualty 
admission card read, ‘hysterical hyperventilation, good teaching case’. I looked 
at her and, as a budding cardiologist, I found she had a biggish right heart 
and the chest X-ray was clear. She denied having been pregnant, but she had 
pulmonary hypertension. She died three days later, and the autopsy was done 
on a Saturday morning by the Professor of Pathology and he said, ‘Oh, look, 
she’s been a naughty girl, she’s had pelvic sepsis and it’s spread to her lungs.’ 
QRS
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But my predecessor was at the autopsy, Dr Adrian Joekes, who had been a 
senior registrar for about 20 years, and he said, ‘That’s not pelvic sepsis, that’s 
choriocarcinoma. There was a case like this at the Hammersmith ten years 
ago.’ And it proved to be choriocarcinoma, occluding her pulmonary blood 
vessels. Six months later, I was called to the gynaecology ward to see a woman 
who had had a hysterectomy for bleeding, but the uterus didn’t contain any 
tumour and she went home on anticoagulants and a diagnosis of pulmonary 
embolism – a very common event after hysterectomy. She came back to the 
hospital a few weeks later, short of breath, and by chance it was our admission 
day, and we put her back on anticoagulants, but she continued to deteriorate. I 
thought it couldn’t be another case of choriocarcinoma, but still went to see the 
pathologists, and they said, ‘Ken, you have got it on your brain, you’re crazy, 
it couldn’t be another case of choriocarcinoma, they are very rare anyway, 
and that Hammersmith case is unique, it is the only one in the literature.’ 
So she continued to deteriorate and after about four or five weeks she was 
in an oxygen tent, because you weren’t allowed to die in the 1950s without 
being put in an oxygen tent, it hastened one’s departure, but that wasn’t 
known until a few years later. There was one way of making sure it could be 
a choriocarcinoma, and that was to measure human chorionic gonadotropin 
(hCG), which is secreted by the tumour. The pregnancy tests available at that 
time, very crude biological tests, one called the Friedman test, measured hCG 
in urine by injecting it into a rabbit and looking for changes in the rabbit’s 
ovary. So I took her urine to the lab. The man who ran the lab had lost an 
eye, and when he was confronted by a junior doctor asking for something 
that he thought was stupid, he removed his glass eye, polished it on a red 
and white spotted handkerchief that he kept in his top pocket. If you were 
still there when he put his eye back in its socket, which wasn’t usual, because 
you usually disappeared on these occasions, anticipating his conclusion. He 
said he wasn’t going to sacrifice a rabbit for a woman who 
couldn’t be pregnant and the pathologists said there was 
no tumour in the uterus. Anyway she was obviously dying, 
and that was on a Wednesday. As I came back from the lab 
I met the medical superintendent and he said, ‘Well, old 
so and so who runs the lab is always very interested in 
hospital scandal, so why didn’t you send the urine under 
a pseudonym?’. We went through all the bits of hospital scandal we knew at 
the time, and one of the chief surgeons was alleged to be having an affair with 
one of the nurses. I found this lass, and asked if she would mind sending in 
this urine under her name. She thought that was a great joke. So off it went 
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on the Wednesday. On the Friday afternoon, the consultant came round and 
said, ‘You had better phone the husband, she is not going to last the weekend.’ 
That evening after the ward round, the nurse appeared with this form saying, 
‘I must be very pregnant, it says Friedman test strongly positive.’ So this was 
another choriocarcinoma. I got 6-mercaptopurine from the pharmacy, and 
we gave her big doses over the weekend, and on the Monday morning when I 
went in she was out of the oxygen tent, sitting up eating breakfast. She is still 
alive 49 years later. 
Professor Kenneth Bagshawe: Platinum Salts, pp. 38–9 
Research subjects
I remember early on that there was a time when we tested both naval ratings and 
Cambridge housewives at the MRC Applied Psychology Unit. I knew someone 
who lived across the road from the building we were in and he would leave in the 
morning as naval ratings came to get tested and, when he came home for lunch, 
they were apparently walking out as Cambridge housewives, and he wondered 
what on earth our research was doing to them. 
Dr Ivan Brown: Applied Psychology, pp. 30–1 
I remember when we were doing very early research on Human Computer 
Interaction, we set up a decoding task to look at command languages where we 
presented sentences with scrambled words, and the problem for the participant 
(as we now have to call them) was to unscramble the message and turn it back 
into an English sentence. At the end we debriefed the subjects to tell them what 
the experiment was really about, and why we had done it that way. One lady 
came into the lab, and did the task very effectively, and when we debriefed 
her she said, ‘Well, I think you have done jolly well. You know I did work at 
Bletchley Park during the war!’ 
Dr Philip Barnard: Applied Psychology, p. 69 
Rolls Royce
As far as academic medicine is concerned in London, one has to recall that until 
the end of the war there were only five professors of medicine in the twelve 
undergraduate schools in London. So academic medicine as we now know it 
was very much a young and tender flower then. The other professors who had 
been there right up until, say, 1960 had a battle establishing themselves among 
the part-time consultants who arrived in their Rolls Royces. It is very difficult to 
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recruit people to academic medicine when they could see Lord Horder arriving 
in his Rolls Royce. There was a financial disincentive in academic medicine; you 
earned much less. You didn’t do private practice, not in those days, so you were 
poorer as far as your lifestyle was concerned. There were problems. That was the 
first problem in recruitment. 
Sir Christopher Booth: Dialysis, pp. 35–6 
Rugby
In 1966 I was invited to assist the Scottish Rugby Union in establishing a 
medical service for international rugby. I was the pre-registration house officer, 
and they had invited my chief, Professor Sir John Bruce, 
who was the Queen’s surgeon, the President of the Royal 
College of Surgeons and Chairman of Hibernian Football 
Club. He said he didn’t know anything about rugby, but 
commented that I played the game and asked me to set 
something up for him. That was probably one of the very 
earliest sporting bodies to establish any form of consistent 
medical support. It was through that experience that it became apparent that 
more players were injured during training than playing, and that’s where my 
interests developed. 
Professor Donald Macleod: Sports Medicine, p. 30 
Rustenburg Platinum Mines
Alexander Haddow, who was the Director of the Chester Beatty Research 
Institute at the time, had consulted on nickel carcinogenesis in the south 
Wales metallurgical industry and he knew enough inorganic chemistry to 
know that platinum and nickel were in the same group in the periodic table. 
There was a paradox called ‘Haddow’s paradox’, which said that all things that 
cause cancer will also cure cancer, which presumably was a statement about 
attacking DNA, whether you mutate it, or whether you kill it. So Haddow 
thought maybe the fact that platinum would appear to cure cancer, and nickel 
would cause it, was another example of ‘Haddow’s paradox’. Once Haddow 
had picked this up it, of course, meant that the whole power of the Chester 
Beatty Research Institute then became very interested in this problem. It led 
to the setting up of a group of people in the early 1970s in the UK, which 
was funded by a man called Ken Maxwell, from Rustenburg Platinum Mines 
in South Africa, and also by Johnson Matthey. It was a very interesting group. 
…more players were 
injured during training 
than playing…
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That group worked together in the UK for a number of years with funding from 
Rustenburg Platinum Mines. The work of that group meant that the clinical 
work went much more rapidly. In the USA it didn’t go quite as fast. There, 
progress was dependent on the National Cancer Institute, but the influence of 
the Chester Beatty here, working in that group, pushed the clinical work forward 
extremely rapidly. 
Professor Andrew Thomson: Platinum Salts, pp. 14–15 
Salbutamol
I have regularly been asked how we managed to market salbutamol for asthma 
treatment only three years after its first synthesis. The simple answer is that in 
the early stages we experimented on one another, a procedure that I commend 
to all responsible for recommending new medicines to other people. I was 
first to take salbutamol by inhalation and by mouth under the supervision 
of Wilfred Simpson, a bold and intelligent clinical 
pharmacologist, who was then our medical director. He 
had the drug next under my supervision. Salbutamol was 
obviously innocuous in us but neither of us is asthmatic. 
The first asthmatic to take salbutamol was Desmond 
Poynter, our friend and colleague, who was head of 
pathology. Desmond had unwisely told me that he was 
very sensitive to sulphur dioxide. Since he knew more than anybody else about 
his condition and the toxicology of salbutamol, I had no hesitation in inviting 
him to inhale a small amount of sulphur dioxide to see if inhaled salbutamol 
relieved bronchoconstriction. Desmond readily agreed and we soon established 
that salbutamol is an effective bronchodilator with minimal cardiovascular side 
effects. In the next stage, salbutamol was tested on two asthmatic volunteers, 
Anne Ruffel and Graham Williams, who were researchers in Allen & Hanburys 
pharmaceutical company. Within a month we knew the effective doses of 
salbutamol, by inhalation and by mouth, the duration of the action and the 
probable use-limiting side effects. Thus it took only six months from the date 
of first synthesis to establish the probable efficiency and safety of the drug. 
Today that would take at least two years which, in my view, is an unnecessary 
self-inflicted wound. 
Sir David Jack: Asthma, p. 38 
…in the early stages we 
experimented on one 
another…
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Sativex
[Sativex is a licensed cannabis-based drug developed by GW Pharmaceuticals. The key 
active principle is tetrahydrocannabinol (THC).]
What we at GW Pharmaceuticals did was to set about growing very, very specific 
varieties of the cannabis plant, defined by their chemical components. We had 
one of the world’s top geneticists to help us do that, to select what cannabinoid 
component we want. Once we had the cannabinoid composition in the plant, 
everything else in the manufacturing and pharmaceutical process to arrive at 
consistency stems from that. The plants are grown indoors, away from bird 
droppings, away from heavy metals; no chemicals are put on them whatsoever; 
we used biological methods for pest control. We are able to get quite remarkable 
consistency. The consistency of THC, for example, from a THC breeding variety 
when we make a primary extract, is of a higher purity than the standard 
the FDA would accept for synthetic THC. So we are able to produce 
extremely consistent extracts with known quantities of the primary 
cannabinoids and known quantities of at least nine other cannabinoids. 
We’ve characterized about 90 per cent of the plant entirely: so this plant 
is now the most highly characterized medicinal plant anywhere in the 
world. The plants are all identical because they are grown from clones. 
Dr Geoffrey Guy: Cannabis, pp. 33–4
I was diagnosed with MS in 1997, when I was 19, so I’ve had it for 
about 12 years. The pain really started to come in about 2001 and 
then got worse and worse. I was prescribed tablet after tablet: baclofen, 
gabapentin, tizanidine. I found that I couldn’t tolerate the side effects 
for the amount of tablets I’d have to take. Then, a couple of years 
ago, I got referred to the pain clinic with Dr Notcutt, and he tried 
me on Nabilone, which was great. I wanted to increase the dose, but I 
found that I couldn’t think straight, I was slurring and I couldn’t have 
a proper conversation. It wasn’t working for me, so we tried Sativex; 
oh, it’s just changed my life. It’s changed my life, it really has. I can 
eat and sleep and the pain is less. It’s just changed my life. I went on a 
withdrawal study: you could have been given the placebo or Sativex, 
and I knew within about 12 hours that I had the placebo. The first 
day wasn’t too bad, but the second day it was like having boiling water 
poured down my legs, so I came off the study. 
Ms Victoria Hutchins: Cannabis, p. 62 
Sativex oromucosal 
spray, 2009: Cannabis
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School milk
The Ministry of Health asked us, when school milk was 
stopped in 1972, if we would evaluate the benefit of school 
milk, welfare milk. We set up two studies actually. Welfare 
milk in those days was supplied to all pregnant women 
and all children under five and to all schoolchildren, but 
it was very severely curtailed; it wasn’t actually stopped, 
but it was very severely curtailed. We set up randomized 
controlled trials in both those groups. We selected 1,000 
pregnant women and arranged for the tokens to be issued 
to them and to all their children under five – at Ministry of Health expense. 
The ‘index child’ from that pregnancy was followed to the age of five; half were 
supplied with milk tokens and half were not, and we monitored growth in those 
children and we collected a lot of further information. At the same time, we 
ran a trial in schoolchildren where we selected schools by a number of well-
defined criteria to get the most nutritionally vulnerable children and we set up a 
randomized controlled trial in something like 600 children, 7 to 9 years of age. 
Half of them were supplied with school milk and half were not. To make a point 
in passing about the Department of Health’s response to our answers, we had 
shown that iron added to bread was of virtually no benefit, but it is still added 
to white flour in this country. We later showed that school milk was of benefit to 
the most vulnerable children, but it was never reintroduced, so the effectiveness 
of that research can be called into question. 
Dr Peter Elwood: Population-based Research, pp. 85–6 
Screwdrivers
During the 1960s I was appointed Sister in the labour suite at Dundee Royal 
Infirmary. This was when intrapartum continuous monitoring was in its infancy 
using Hewlett-Packard machines. Obstetricians and midwives were fascinated 
with the new technology and some of the midwives even began to have 
screwdrivers in the top pockets of their uniforms, to adjust the temperamental 
apparatus when required. 
Ms Ellena Salariya: Breastfeeding, p. 58 
…school milk was 
of benefit to the most 
vulnerable children, 
but it was never 
reintroduced…
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Self-experimentation
Roger Altounyan, chest physician and asthmatic, wanted to know what happened 
when cromoglycate was given intravenously and he asked me if I would inject 
him with it. I refused. But he was very persistent and said he had tried it on 
pretty well every animal species without adverse effect, but admitted that they 
hadn’t tried it on primates. A few months later he said they had now given it 
intravenously to a marmoset without ill effect and would I please give him the 
injection. I felt I could resist no longer and with considerable reluctance agreed. 
He came to our clinical room at the Royal Infirmary where first he did skin tests 
on himself, blew into the spirometer to measure his forced expiratory volume 
in one second (FEV1). He lay on the couch, I then attached ECG leads and a 
blood pressure cuff and started a slow injection. Roger said I gave him 12mg; 
my recollection was 7mg. For about half a minute nothing appeared to happen 
but then he said in quick succession, ‘I’m feeling something on my skin, my face 
is burning, I’m burning all over.’ His pulse rate and blood pressure went up; so 
did mine. But the burning sensation quickly subsided and Roger jumped off the 
couch, repeated his skin tests and measured his FEV1 as if nothing happened. 
Later I told Roger jokingly that my main concern was what I was going to say 
to his wife Hella and he embellished this to ‘Hella, I’m afraid I have killed Roger 
– with some of his own medicine.’ There is no doubt that I was foolish to agree 
to do it, but Roger was a very persuasive, very courageous, absolutely single-
minded man and I wonder how many of you in this room would have been able 
to refuse to give that injection to him. 
Professor Jack Howell: Asthma, p. 36 
Self-poisoning
We had many foreign pharmacology students over the years in Oxford, from 
Russia, China, Australia, Brazil etc. We had one student from Sri Lanka who 
went back after getting his DPhil and when I next saw him he said, ‘You have 
made my life a misery.’ I said, ‘Why’s that?’ He said, ‘You taught me to say 
no.’ And, of course, over there you don’t say ‘no’. Somebody asks you to do 
something and you say ‘yes’ and then you don’t do it. But, I expected him to say 
‘no’ if ‘no’ was what he meant, and that was very difficult for him to adapt back 
at home. The serious side of that story is when I went to visit him and discovered 
that there was an epidemic of self-poisoning with oleander seeds, mostly by 
young farmers, young men not doing well. I said, ‘The pharmacology of what 
these seeds contain suggests to me that repeated doses of activated charcoal 
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may be beneficial.’ So they did what may be, if not the 
largest, certainly one of the largest prospective randomized 
controlled trials of self-poisoning in any form. Within 
8 months they randomized 400 patients and reduced 
mortality from 8 per cent to 2.5 per cent and that has 
changed practice in Sri Lanka. We are now doing another 
study in snakebite. I think this collaboration abroad has 
been very fruitful and very influential. 
Dr Jeffrey Aronson: Clinical Pharmacology 1, p. 60 
Sexual disorders
When we started to look for sexual side effects in patients who were receiving 
the antidepressant chlorimipramine, they were common. I knew a physician in 
Manchester who’s a specialist in sexual medicine and, I said, ‘look, this compound 
does something to ejaculation, and I know that premature ejaculation is one of 
the commonest problems that you see. Why don’t we turn this to our advantage?’ 
So we did a clinical trial in premature ejaculators, using chlorimipramine, and 
what we indeed found was that you could control ejaculation and that moreover 
you didn’t have to take it all the time. We thought this was a wonderful discovery 
and I organized a symposium in Jersey, where the results of this study were 
reported. I didn’t think the press were present, in fact I am sure the press weren’t 
present, but somebody must have leaked the story to them, because when I 
got back to the office on Monday morning, the managing director of Geigy 
pharmaceuticals stormed into my office and slapped down a copy of one of 
the tabloids on my desk and said, ‘George, what the hell is all this about?’ and 
I said, ‘What’s all what about?’ and he said, ‘Splashed all over the front of the 
newspaper is this story about a wonder drug for your sex life.’ Geigy being a very 
Calvinistic company, he said, ‘We’re not having anything to do with this, stop it.’ 
So there and then the whole clinical trial programme on sexual disorders ground 
to a halt. Now it’s interesting really that that was happening in 1970, because 
now I hear people say sexual disorders are the greatest area of opportunity for the 
pharmaceutical industry. 
Professor George Beaumont, Psychiatric Drugs, pp. 177–9 
…the largest, certainly 
one of the largest 
prospective randomized 
controlled trials of self-
poisoning in any form.
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Sexual terminology
We in SIGMA finished up having a sheet with terminology for sexual behaviour, 
including both medical name and ‘street’ name, and going through the list with 
each respondent before we started, asking them whether they understood what 
each term meant. They were also asked to give their preferred term for each. 
Then a set of their preferred substitutions was used throughout the interview. 
Yet usage was by no means predictable. There were some people who would, 
in their ordinary language talking among themselves, use street terminology, 
but wanted to be interviewed using medical terminology – that was not an 
uncommon response. So, what we did was to establish the preferred terminology 
and description first, and, yes, indeed, it was a very important issue. 
Professor Tony Coxon: NATSAL, p. 37 
Socio-economic diseases
We did study the genetics of gastric and duodenal ulcer, and we found they 
inherited differently in families. If you had gastric ulcer, you had a greater 
proportion of gastric ulcers in your families, and the same applied to duodenal 
ulcers, and they were dissociated genetically. But, of course, there are factors in 
common, I don’t deny that for a moment, with the two types of ulcer, but there 
are also important differences between them. The striking one in the 1950s 
was the socio-economic difference. The gastric ulcer was a 
disease essentially of the poorer section of the community 
and the duodenal ulcer being a disease of the professionals. 
Professor Sir Richard Doll: Peptic Ulcer, p. 22
We should not forget that cystic fibrosis isn’t only about 
genes and their modification. There was a paper this year 
[2008] in American Journal of Respiratory Disease and Critical 
Care Medicine, which said that the single biggest factor 
in determining the severity of cystic fibrosis for anyone 
with a given genetic make-up was their socio-economic 
circumstances. I think that’s one of the factors that has 
contributed to the increasing lifespan since the 1940s, before 
we even had the NHS, that improving socio-economic 
conditions have, I am sure, made quite a big contribution to 
the survival of patients. 
Professor John Dodge: Cystic Fibrosis, p. 64 
Professor Sir Richard 
Doll: Population-based 
Research
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Special clinics
We had a special cystic fibrosis clinic in Edinburgh for quite some time and the 
family doctor was often squeezed out. We had the multifactorial team policy, 
with physiotherapists, nurses, doctors, dieticians, everybody in the hospital 
environment, but when the patient deteriorated and perhaps was dying and 
wishing to remain at home during those last few weeks, we had a GP who 
had scarcely met this 20-year-old individual. I think that was something 
that was eventually starting to be put right, perhaps as a secondary effect of 
intravenous therapy at home, and certainly in the 1990s, the psychosocial effect 
was recognized. 
Professor Sandy Raeburn: Cystic Fibrosis, pp. 21–2 
Speed reading
At the Applied Psychology Unit, John Morton, among other things, used to do 
some research on speed-reading, at least he used to do practicals on speed reading. 
This would involve all the students being encouraged to bring a paperback book 
and to read it for x minutes, followed by a period when John would urge them 
to go faster and faster and faster, and demonstrate then that they could actually 
read a lot faster, and that there was nothing very magical about it. It was just that 
we tend to read slowly – it’s a habit. 
Professor Alan Baddeley: Applied Psychology, p. 56 
Spinhaler
On the development of Intal for asthma, one for me was a very salutary lesson 
in the importance of the basic scientist sitting in on clinics. I remember one of 
the early trials on Intal and I was talking to the clinician 
and he called the child and his mother in and I said, ‘Well, 
how did you find the result?’ ‘Oh a wonderful drug, very 
good.’ I then said, ‘Well, what about the Spinhaler? Did 
you have any difficulty with that?’ The child looked at his 
mother and neither knew what to say, as they hadn’t been given the Spinhaler, 
they had just taken the capsule as it was. There was no way that they could have 
got a result. 
Dr Jim Cox: Asthma, p. 31 
…they had just taken the 
capsule as it was.
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Sports medicine
You had coaches sending their boys to elite clinics in Munich or other 
fashionable places to semi-qualified people who gave eccentric treatments, and 
that was together with the belittling propaganda by journalists and coaches – 
even national coaches – against the deficiencies of British sports medicine. It slid 
gradually into this new attitude: ‘Oh, well, sport is rich now so it can pay for its 
own special needs. There’s no real justification for spending public funds on free 
medicine for top athletes.’ It was the athletes and a few doctors who pretty well 
forced sports medicine upon reluctant governing bodies, whose attitude was: ‘If 
someone doesn’t sponsor it, you can’t have the service.’ 
Professor Peter Sperryn: Sports Medicine, pp. 45–6 
Statisticians
I must say that the most significant point about the early leukaemia trials in the 
1950s was the way in which the statisticians were involved. The first meetings 
were attended by Sir Austin Bradford Hill and Sir Richard Doll. The trouble they 
take is immense, their efficiency is terrific, and I was tremendously impressed 
from the start by the trouble the young disciples of Richard Doll and later 
Richard Peto were prepared to take, to understand something about the disease. 
Professor David Galton: Leukaemia, pp. 55–6 
Stillbirth
There was, of course, one important aspect of the ALSPAC study that we must 
not forget and that is that quite a few women were recruited early in pregnancy 
and not all those pregnancies proceeded. Of course, even when they went to 
term, there were, unfortunately, some tragedies and some stillbirths. A huge 
amount of effort was put in to make absolutely certain that that was dealt with 
extremely sensitively, trying to balance the importance of information that 
might be obtained from such sad events. These unfortunate women were facing 
this grief and tragedy, and we had to avoid forcing ourselves on them and adding 
to their grief. We had to be very careful to make sure that we didn’t include 
someone in the continuing study who had unfortunately lost their child. I think 
it is important to mention that. 
Professor Gordon Stirrat: ALSPAC, pp. 31–2 
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Streptomycin
My function in the first streptomycin trial was a very junior one. I had been three 
months as a registrar at the Brompton Hospital and was then asked to coordinate 
the Brompton side of that trial. The control trial was ethically acceptable, because 
there was a limited amount of streptomycin, so it was ethically reasonable to 
randomize these advanced pneumonic tuberculosis cases to 
a streptomycin and non-streptomycin group. The original 
idea was that they should be treated for six months, but 
in fact resistance developed quite quickly with subsequent 
deterioration in many patients. Before the trial was finished 
the Medical Research Council decided that this was only an 
adjunct to treatment of tuberculosis and they reduced the 
treatment period to three months. It’s interesting looking 
back at that. It’s interesting also to look at when resistance 
developed. The World Health Organization now accepts people into trials and 
regards them as new patients if they have had less than a month of treatment, 
assuming that no resistance could have developed. But if you look back at the 
original streptomycin trial several of the patients developed resistance really 
quite early towards the end of the first month. That is something, which we 
ought to remember. 
Sir John Crofton: Post Penicillin, pp. 10–11 
Streptomycin patents
Eveleigh:  The implications of the Merck-Rutgers agreement are important. In 
brief, the pharmaceutical company, Merck, supported the university, Rutgers’, 
research and, for that support, Merck had the rights to university results: as it 
turned out, for actinomycin and streptomycin.
Booth:  Can I just get something clear here, because the patenting side of 
streptomycin was rather important. Who held patents, were there any patents? 
Where were Rutgers involved in that?
Eveleigh:  The initial aspect was the agreement that Merck held the patents for all 
rights. However, when streptomycin came along Selman Waksman went back to 
Merck and simply noted that conceptually ‘this discovery is major and could you 
change the patent agreement?’ It was changed in two senses. One, the university 
became the beneficiary and, secondly, the university set up a non-exclusive 
licence. As such, seven companies actually took out the licence at that time.
…resistance developed 
quite quickly with 
subsequent deterioration 
in many patients. 
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Booth:  So, it was free for anybody to get in on any act if they wanted to?
Eveleigh:  Absolutely. Waksman said that he felt streptomycin was so important 
that he wanted to ensure that it could be widely developed on a humanitarian 
basis. As there could be a problem with production, he wanted development via a 
non-exclusive rights agreement. This was practical at that time. Subsequently, in 
hindsight, the non-exclusive rights decision has been criticized as not necessarily 
a well-founded, wise decision. Thus when neomycin was discovered, there 
were several other competing antibiotics ready for commercial development, 
and naturally an industrial company wanted exclusive rights. In spite of that 
competitive commercial status, the Rutgers patent policy did not change from a 
non-exclusive basis until 1976. 
Professor Douglas Eveleigh, Sir Christopher Booth: Post Penicillin, pp. 8–9 
Sudden infant death syndrome
I do think that disease-specific charities have a particular role. I saw it in relation 
to sudden infant death syndrome. A wealthy businessman lost his child and, 
as a practical man, in addition to grieving, he and his family decided to start a 
foundation. In starting the foundation, they said they would spend half their 
money dealing with the bereft parents and the other half would go into research, 
because they believed it was a real problem. At that time, many parents were dealt 
with as criminals and there was a lot of argument as to whether there really was 
a syndrome, or whether it was child neglect. They needed to put a small research 
group together themselves, because they couldn’t find any of the research bodies, 
the big research bodies, who were prepared to take any interest. They started 
a small group and I was privileged to be part of it and its work. For example, 
some epidemiology was done, documenting cases that were 
occurring in places like Sheffield and in other parts of the 
country. The point that impinged on our present topic was 
that they thought it would be a good idea to go to the MRC 
and say they had these data, that there are real problems and 
that they might be due to infection, to respiratory disturbances, or immaturity 
at a physiological level; would the MRC be interested to work on this? We had 
an informal meeting with members of the board who said that the MRC did not 
work on non-existent diseases. They had decided that this wasn’t a real problem. 
It was therefore very good that the charity went back to their office to find more 
funds to support more research. 
Dr David Tyrrell: Clinical Research, p. 46 
…the MRC did not work 
on non-existent diseases.
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Suicide/attempted suicide of patients
I first encountered CF in Windhoek in South West Africa, Namibia, as it was 
called at the time, in 1967. I inherited a patient who had been looked after by 
the paediatrician who had left there two years before, and his care had been 
neglected and I admitted him to hospital almost at death’s door. On active 
antibiotics, pancreatic enzymes, and physiotherapy, he gained 4 kg in ten days in 
hospital. This particular boy was then for many years one of the less ill patients 
in our CF clinic, because, although I was on the edge of the medical world, I 
read a lot and I realised the importance of setting up a clinic. But unfortunately 
at the age of 16 he attempted to take his own life. Why? Because he and his 
parents had been told that he would not survive beyond the age of 12. He finally 
did die at the age of 24. 
Dr Maurice Super: Cystic Fibrosis, p. 23 
Can I draw attention to something that only recently, and after great consumer 
pressure, is getting adequate consideration, and is not adequately recorded for 
historical statistics, and that is suicide. It is of substantial importance, but still 
under-recorded because the figures only go up to a year after delivery. Dealing 
with suicidal women is the bread and butter of our consumer group work, 
particularly those who have had postpartum, post-traumatic stress disorder, and 
we now know from our work day to day that these women are very high suicide 
risks. So we really don’t know how much that was the cause of death in earlier 
days and how much it is the cause of death now. 
Professor Jean Robinson: Maternal Care, p. 18 
I am amazed that home dialysis was as successful as it was. The patients took 
an awfully long time to train; they were very highly selected in the early days of 
dialysis. In the early days we never took anybody over 50. We took one at 55 who 
was a GP, but most of them were white, intelligent, and relatively young, and even 
then it was an enormous stress on them. The social consequences were enormous, 
the marital breakdowns were quite considerable. I used to show a slide of a ‘typical’ 
successful home dialysis couple. The wife was absolutely gorgeous, the husband 
was wonderful. She eventually died and he came up to me and said: ‘Frank, thank 
you for everything you have done, but home dialysis really is a nightmare.’ And 
for many patients it was. Not only were there worries about blood spills, but it 
also provided an opportunity for some patients to commit suicide. I remember 
being called by the police to one patient in the Southend area and they said that 
she had died, having disabled the alarms on her monitor. I went down post haste 
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to her dialysis room and I literally waded through an inch of 
blood on the floor in galoshes. It was horrible. So we did put 
our patients through an awful lot. They were chronic dialysis 
patients and there was relatively little hope of transplantation in 
those days. Later on there was greater hope of transplantation 
and home dialysis fell out of favour for a number of reasons, 
including that. Now, of course, transplantation is a major problem because there 
aren’t enough transplants to go round. But I think that the nursing staff, the 
hospital administrative staff, the home dialysis administrators, the technicians, and 
the patients really deserve a gold star. 
Dr Frank Marsh: Dialysis, p. 65 
Support groups
Rodeck:  I think it is relevant to point out that the activity of prenatal screening 
and diagnosis is controversial in some areas and there are opponents on ethical 
grounds, and indeed the people who are involved in that activity have been 
accused of eugenics and of ‘search and destroy’ and that kind of thing. That is in 
very sharp contrast to the attitude of most of the patient support groups who, 
in my experience, have nearly always welcomed advances in prenatal diagnosis 
for the families with their particular conditions, because they see it as simply 
another medical facility that is made available to their members.
Povey:  I was just going to reiterate about the support groups. For example, in 
tuberous sclerosis, the support group there really started out as a smallish group of 
articulate parents and that group has been responsible for genetic testing being ten 
years ahead of where it would be by their pressure and their support for the work. 
Professor Charles Rodeck, Professor Sue Povey: Genetic Testing, p. 70 
Surgical training
The orthopaedic surgeon John Charnley had an arrangement with Thackray’s, the 
manufacturers of his hip prostheses, whereby they would not supply a Charnley 
replacement unless the surgeon had actually spent three days at Wrightington 
Hospital and learned how to do the operation. 
Mr Alan Lettin: Hip Replacement, p. 33 
…I literally waded 
through an inch of blood 
on the floor in galoshes.
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Survey fatigue
Survey fatigue particularly affected the Rhondda Valley, in Wales. There was a 
Mr Jones who came up for the fifth time in a survey and he saw Archie Cochrane 
because he was one of the refusals, and he said, ‘How is it that my name has 
been drawn so many times?’ and Archie said, ‘Well we put all the names in a hat, 
and we shake them up very, very well, and then draw out a certain percentage at 
random.’ ‘Oh I see’, said Mr Jones, ‘A bloody funny hat!’ 
Dr Jean Weddell: Population-based Research, p. 95 
Survey interviewers
Sometimes it was a bit of a problem when it was a man who was to be interviewed 
and one of the interviewers was a young lady, and the wife was not particularly 
keen on her husband discussing sex with this lady who has just knocked on the 
door, but when you actually got in and were doing the interview it wasn’t too 
bad. Normally you would establish rapport with the subject quickly so that they 
would give us any information, but, in this survey, there had to be a distance 
between you and the interviewee. Not so much with the women, but if it was a 
male subject and a female interviewer. 
Mrs Wendy Williams: NATSAL, pp. 36–7 
Syringe driver
I don’t think we have said much about other ways of prolonging drug action and 
have focused a great deal on the short-acting drugs. I thought it might be right to 
mention Dr Martin Wright’s contribution at the MRC, who not only designed the 
peak flow meter, which made it possible for us to measure respiratory depression 
in some ways, but also designed the syringe driver pump, which has made such 
a difference to continuous pain control. One can certainly remember what a 
splendid thing it was to see patients at Northwick Park Hospital, for example, 
who had been out shopping that day, who had had a metastasized tumour for 
two years with severe pain, and had continuous diamorphine treatment for two 
years, with a syringe driver pump, going about their daily business. 
Professor Duncan Vere: Pain, pp. 63–4 
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Syringe exchange
The real opportunity to put the new public health on the map came with the 
arrival of heroin and HIV/AIDS. We brought the San Francisco Director of 
Public Health, Dr Glen Margo, over to Liverpool to run workshops to set an 
agenda for action. This he did with incredible drive over a two-week period, 
exposing several hundred people to the facts, the realities, the urgency, and 
the practical way forward. This led to the establishment of the first large-scale 
syringe exchange programme in the country some months before the Minister 
of Health authorized pilots of this approach. 
Professor John Ashton: Public Health, p. 34
166
…toddlers cried because 
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T
Sir John Crofton:  
TB Chemotherapy
Taking blood from children
Golding:  We had this 10 per cent sample of Children in Focus from the ALSPAC 
cohort that we took heel prick samples from. Now heel prick samples are actually 
very painful. When we started using venepuncture, we used an anaesthetic cream 
and that worked much better, and was much less of a hassle and less painful for 
the child, and the parent. So blood samples were possible, the Ethics Committee 
approved of them, and we’ve collected other biological samples from the children 
as well. Some of the offspring give blood every time they come nowadays.
Pembrey:  I absolutely want to reiterate my admiration for the system the ALSPAC 
team had for taking venepunctures from children. This was probably the first time 
EMLA cream was used in epidemiological scale studies. Of course, in hospital EMLA 
cream, the anaesthetic cream, got a slightly bad reputation. 
The child usually had it put on for too short a time, and it 
was clearly linked psychologically with having the needle, 
whereas the way they sorted it out in the clinic for ALSPAC 
was absolutely admirable. The magic cream would be put on 
and then they would be doing all sorts of other things and 
exactly three quarters of an hour later, or whatever it was, 
they then came back. I understand that more often than not 
the toddlers cried because the video of Postman Pat had been 
turned off than during the venepuncture, so it was brilliant.
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Sadler:  As Marcus said, the venepunctures worked brilliantly. We took a lot of 
trouble getting it right, though. We had a play leader from the hospital to talk 
about playing with the children, distracting them during the procedure. We also 
took a lot of trouble over the technique. We ended up using Sarstedt Monovettes, 
which I don’t think were much used in the hospitals, but with butterflies. We had 
the company rep down and one of his assistants thoroughly trained the staff in 
using them because I don’t think many of them had actually used them before. 
We very, very rarely used a syringe. It was exceptional if one of the people used 
a syringe. The other thing is, we chose our blood takers with enormous care. 
For many, many years these were very experienced paediatric phlebotomists; we 
only used them for most of the time I was there. Towards the end of my time, 
which was in 2008, we had spent a couple of years using them to train up one or 
two of the staff and several of them became also extremely good phlebotomists. 
Phlebotomy in children is a real art: you really need people who are expert at 
it, and we had a team who could get blood out of anything, I swear. They were 
absolutely brilliant and it was so rare for a child to be in the least bit bothered. 
Professor Jean Golding, Professor Marcus Pembrey, Mrs Sue Sadler: ALSPAC, pp. 51–3 
The other thing that we did, when the children were aged four or five, was to 
start allowing them to make the decision themselves whether they were going to 
give blood. This was no longer purely a parental decision. At that age, children 
are clearly not old enough to give consent in the legal sense, but we allowed 
them to say ‘yes’ or ‘no’, in a meaningful way, that we took seriously from quite 
an early age. 
Mrs Elizabeth Mumford: ALSPAC, pp. 55–7 
Technicians
The technician in an intensive care unit has to be a polymath. We found a 
wonderful polymath in a man who’d been injured in a mining accident; some 
of his fingers were missing, and he wanted to do something. He came into the 
intensive care unit and was taught on the job, to clean, service, and to sterilize 
equipment and he became an expert at mixing the right solution for dialysis, 
for example. I don’t know whether there is a training course for intensive care 
technicians now, or whether each of the specialties must have its own, but this 
man did absolutely everything. Even better than that, he was a wonderful dancer 
and taught the nurses how to dance. 
Dr Joe Stoddart: Intensive Care, pp. 70–1 
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Medics also talk up  
what is possible, especially 
the ‘-ologists’.
Our theatre technicians sterilized our ventilators and always had one ready when 
we wanted it and did a myriad of things that they weren’t paid for at all. They 
were actually theatre technicians and because I was in charge of the anaesthetic 
department as well, we were able to persuade a couple of them to take an interest in 
intensive care, and they were absolutely invaluable. They had no career prospects, 
no career structure, but they did it out of the goodness of their hearts. 
Dr Tony Gilbertson: Intensive Care, p. 71 
Television
From my experience, we are now far less paternalistic than in the 1980s; decisions 
used to be made on behalf of the patient but now there is far more involvement of 
the patient and his/her family. I think this is absolutely right, but now, if anything, 
it is perhaps swinging too much the other way. I spend a large amount of time 
trying to manage the patients’ and relatives’ expectations. 
They see the majority surviving on television programmes 
such as House and Holby City. Medics also talk up what is 
possible, especially the ‘-ologists’. The change has not been 
particularly subtle, but more of a quantum shift in the way 
we manage patients and the way we manage death. 
Professor Mervyn Singer: Intensive Care, p. 80 
Tetanus
I was a medical student in Newcastle from 1956 onwards, and there they used to 
ventilate patients with tetanus by hand. As medical students, we got paid to do 
it, there was great demand, and you could tell when there was a tetanus patient, 
because they were ventilated in a side room off one of the wards on the ground 
floor, and carpets would appear in the corridor to cut down the noise to prevent 
any seizures. When the carpets appeared, everybody would queue up because 
one could get paid. 
Professor Leo Strunin: Intensive Care, p. 18
It all started one night in December 1958 as a result of a chance meeting with the 
Clinical Reader in Pharmacology at UCH, who told me that he had just come 
back from South Africa where he and the Professor of Medicine in the University 
of Natal were running controlled trials on the treatment of tetanus in Durban. 
Jokingly I said to him: ‘Well, why don’t you get an anaesthetist to go out and treat 
the patients with curare?’ I thought no more about it and about two months later 
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…a reduction in 
mortality in neonatal 
tetanus treated with 
curare and mechanical 
ventilation…
I got a letter from the Wellcome Trust saying they were going 
to pay my fare out to Durban and were offering me £1000 
for equipment. I sold my car to pay for the travelling expenses 
of my wife and young family and spent six months in 1959 
setting up a small respiratory unit to investigate the use of 
curare and mechanical ventilation in the treatment of adult 
and neonatal tetanus. Two years later we were able to report a 
reduction in mortality in neonatal tetanus treated with curare 
and mechanical ventilation from 85 per cent to 40 per cent. 
Over the next six years mortality was reduced to 34 per cent. 
Professor Sir Keith Sykes: Intensive Care, pp. 11–12 
Thalidomide
The thalidomide disaster brought home to the public and hence politicians 
the thorough inadequacy of the control of medicines in the UK. Inevitably, 
the reaction was the setting up of a committee and, either by wisdom or good 
fortune, the Minister of Health appointed the late Lord Cohen of Birkenhead to 
chair the Committee. Even looking back from this distance, one can’t fail to be 
impressed by the perceptiveness and the practicability of the recommendations 
of the final report, which was submitted in March 1963. The main features were 
that there should be comprehensive legislation on the control of drugs, but in 
the meantime the Committee on Safety of Drugs should be established to review 
the safety of new drugs, to monitor adverse reactions to existing drugs and to 
keep medical practitioners informed. Submissions by manufacturers should 
be voluntary and the committee would have the responsibility of advising the 
Minister if a drug did not receive the approval of the committee. 
Mr Wilfred Turner: Safety of Drugs, p. 108 
Time to market
The orthopaedic surgeons Ken McKee and John Watson-Farrar, although they 
started doing ‘large volume’ hip replacements in 1961, did not publish until 
they had five years’ data. In their words ‘to see how they went’. Nowadays it is 
possible to put things in to the market more quickly. 
Mr Keith Tucker: Hip Replacement p. 38
Doyle:  The antibiotic methicillin was an interesting case. We actually made a 
in the lab, I think it was the May of 1959, and it was on the market in the 
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…we are all rather 
reluctant to identify some 
of the real baddies…
September of the following year and being prescribed. It took about 18 months, 
a bit less than 18 months. Now that was before the Dunlop Committee, it was 
before the Committee on the Safety of Medicines, before thalidomide, I think 
we did two weeks of toxicity studies. It was very minimal.
Booth:  Could you do that now?
Doyle:  No, of course you can’t. Today, it would take between eight to ten years.
Dr Peter Doyle, Sir Christopher Booth: Post Penicillin, pp. 31–2 
The Times
My colleague Christopher Poulton was doing work on speed-reading and 
recognition of lower case versus capitals and, as a result of his research, they 
completely changed the front page of The Times newspaper, which you recall was 
incredibly boring and almost illegible in the early days. 
Dr Ivan Brown: Applied Psychology, p. 56
Tobacco control
I would say that we are all rather reluctant to identify some of the real baddies 
here. I have often said that I thought the Framework Convention on Tobacco 
Control (FCTC) got through because of them. Some of the big countries 
were very overbearing, very bullying, and offered inducements. There was a 
groundswell of feeling among the low- and middle-income 
countries that they didn’t want to be bullied in this way. 
In fact, we’ll have to look back at the record, but I think it 
was the Indian Minister of Health, who said at one point 
on the floor that ‘public health could not be bought’. In a 
sense, the real big baddies helped us, because many nations 
felt that they were not going to be browbeaten: they were going to get this treaty 
through. So, in a funny sense, I think they were quite helpful to the process. 
Dr Judith Mackay: Tobacco Control, p. 55 
From the Kenyan angle, I will say that we suffered some of the very early 
pressures from the industry when it came to the negotiation of the FCTC. The 
first days when we were developing the initial positions, our technical boss, then 
the permanent secretary in the Kenyan Ministry of Health, received visitors 
one Friday evening. A tobacco industry member came to his office with a raft 
of proposals on how Kenya would handle the negotiations, which were tilted 
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Equipment that Ron 
Bradley and Margaret 
Branthwaite used 
to wheel round St 
Thomas’ before the 
designated ICU, the 
Mead ward, was 
opened in 1966: 
Intensive Care
Professor Ronald 
Bradley: Intensive Care
towards the general codes of self-regulation. He was very insistent that global 
frameworks like the FCTC would not work. Our boss informed us at about 
7pm that Friday evening and said that he was not very sure that he was going 
to be in post on Monday. We were very curious why he thought so. And he 
said: ‘You see, the industry representative came and tried to influence us.’ The 
Kenyan voice was pretty significant in the African group. If the tobacco industry 
could influence the group’s position in certain areas, they could tilt them towards 
this self-regulating position. They were very clear with him: ‘You know, if you 
don’t take the money and influence your team, then you’ll not be in a job come 
Monday.’ For sure, come Monday, on the 1 o’clock news – usually the time 
when people were sacked from or appointed to government in Kenya – he was 
no longer the permanent secretary, but was sent to a country as ambassador, 
which is a step down in the civil service. Before countries engaged at the regional 
and global level, there were a lot of challenges at country level. 
Dr Ahmed Ezra Ogwell: Tobacco Control, pp. 39–40 
Travelling first class
This was my first job with the MRC and in my briefing they said, ‘Oh, by the 
way, you’ll be travelling by train, I’m sure, in Wales. Travel first class’. So I said, 
‘That’s very nice, why?’ So they said, ‘Well, we don’t want you to have too many 
conversations with the miners’. We didn’t carry out that rule, we saved a bit of 
money and we had some quite interesting conversations. 
Dr Philip D’Arcy Hart: Population-based Research, p. 12 
Trolley for intensive care
A large trolley was wheeled around 
the wards, which had the monitoring 
apparatus, the ECG, the blood 
gas analysis, and so on, and much 
recording apparatus. Ron Bradley 
and I were deemed the ‘death watch 
beetles’, because unfortunately we 
weren’t always successful. 
Dr Margaret Branthwaite: 
Intensive Care, p. 30 
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Tropical medicine
For those who don’t know the Will of Henry Wellcome, the answer to why 
the Wellcome Trust has been involved in tropical medicine from the very early 
days is that Wellcome’s Will enjoins the Trust to support research relating to the 
health of mankind in the tropics and elsewhere, and ‘in the tropics’ comes first 
rather than the ‘elsewhere’. 
Dr David Gordon: Clinical Research, p. 36 
Tuberculosis (TB)
There was a general feeling, especially among the old chest physicians, who had 
seen tuberculosis patients lying about in sanatoria for years, to regard tuberculosis 
as something that needed very prolonged treatment. They had seen a number 
of apparently wonderful breakthroughs like gold therapy and they had seen all 
that fail, so there was a great deal of scepticism about short-term chemotherapy 
in the later 1960s. 
Dr Kenneth Citron: TB Chemotherapy, p. 68 
Tuberculosis in communist Poland
I went to Poland in about 1956, but their system there was that they had one 
major postgraduate training centre for tuberculosis. The head of that unit, 
Professor Marion Zierski of Lodz, spent quite a long time with us in Edinburgh 
and went back convinced about the ordinary good chemotherapy. Under the 
Communist regime, all chest physicians had to attend a revision course in 
Zierski’s unit every five years. So it was very easy to spread a good chemotherapy 
regimen quite quickly. Then they went on to do their own trials. 
Sir John Crofton: TB Chemotherapy, p. 29
173
Mrs Wendy Williams: 
NATSAL
Uganda
I want to tell you about one difference between the six years I spent in Uganda 
(1950–1955) and the subsequent six or seven years in Kenya. When I arrived, 
Bob Hennessey, the Director of Medical Services in Uganda, said to me, ‘Nelson, 
you have only one job to do in this country, and that is to train an African to 
do the job better than yourself.’ This was a philosophy that Murray Baker and I 
both followed and our assistant, and the man who was the 
joint author of the first paper that I ever published, was Dr 
Semambo, who succeeded us as District Medical Officer 
and went on to become the Medical Superintendent of the 
Mulago Hospital in Kampala, then Director of Medical 
Services and later Minister of Health. It was quite different 
in Kenya, which was a colony and not a protectorate like 
Uganda. Uganda had one of the best medical schools in Africa, whereas Kenya 
didn’t even have a medical school. When I arrived in Nairobi in 1955, I was 
shown around the Division of Vector-borne Diseases by the Director, who said, 
‘If an African puts his head above the ground, stamp on it.’ Most of my research 
was actually done in Kenya and I was forbidden to include Africans or European 
technicians as joint authors of my scientific papers from Kenya at the early stages 
of my period there. 
Professor George Nelson: Africa, pp. 9–10 
UVW
‘...train an African  
to do the job better  
than yourself.’
174
Ultrasound scanner: first designs
I was a final-year art student at the Glasgow School of Art and, like a number of 
my colleagues, we all fell in love with Tom Brown’s sister-in-law, Elsa, who was 
a first-year art student at the Glasgow School of Art. She had told me that her 
brother-in-law was developing this new machine at Kelvin & Hughes and that he 
didn’t think much of industrial designers. That gave me the spark, because I was a 
very cheeky so-and-so then and I was determined that I would meet this chap and 
we would talk about it. I have actually kept the records of it all, including my first 
order for drawing, probably the first artist’s drawing of an ultrasonic machine. 
That’s how I got involved in it and got fascinated by it. I knew nothing whatever 
about the whole business, but had a desire to make the thing ergonomically better 
so that the approach to the patient was better and the doctors would find it easier 
to use. Indeed, Tom’s view was to make it ‘doctor-proof ’ and we tried to do this.
These, in fact, were the first sketches done on Tom’s dining room floor. This is the 
automatic contact scanner that we were talking about. And that was the proposal 
that Tom had – to make the Lund machine. I remember saying that I thought it 
looked like a gun turret and that it was thoroughly inappropriate for pregnant 
ladies. This was the design drawing: Tom and I were arguing over how to make 
it so that it could be used by a seated or a standing doctor, but we determined, 
in fact, that you couldn’t. That was my attempt to give a three-dimensional view 
of what that machine was going to look like. That was the first drawing which I 
Professor Dugald 
Cameron’s sketch 
ideas on an original 
proposal for the 
Lund machine c.1960: 
Ultrasound
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had been commissioned to do, and for which I received an order for £21. You will 
notice one thing: in the history of engineering drawings there are very few that 
have been drawn to a scale of one-sixth. This one was because it was the biggest bit 
of tracing paper that I had and I couldn’t afford any others. 
Professor Dugald Cameron, Ultrasound, pp. 21–22
Under-medication
Under-medication is the main problem for two billion people who can’t get the 
essential drugs they need. Improved access to medicines could save 10 million 
lives a year. 
Dr Andrew Herxheimer: Clinical Pharmacology 2, pp. 40–1 
Unripe time
I cannot help but recall very well the time, in the 1970s, that President Nixon 
had decided he was going to throw a lot of money at cancer in the United 
States to cure it within five years. I remember your comment, Douglas (Sir 
Douglas Black) in your Rock Carling lecture when you said that ‘lavish finance 
is impotent in the face of unripe time’; and that is a quote that I have used on a 
number of occasions since..
Lord Walton: Clinical Research, p. 53 
General arrangement: 
the redesigned Lund 
machine as it was 
actually built and 
delivered. Drawing 
by Dugald Cameron 
c.1960: Ultrasound
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Vaginal examination
Maclean:  When I started as a medical student in the 1960s, midwives were not 
allowed to perform vaginal examination; the patient was rolled into a left lateral 
position and examined by a rectal examination. I remember at that time among 
New Zealand obstetricians and midwives, there was a long debate as to the safety 
of rectal versus vaginal examination in assessing progress for labours that went 
on for several days. I suspect there are people present in the room who would be 
able to enlighten us as to why these practices developed and why they changed 
in the 1960s.
Savage:  I was taught as a medical student to examine rectally, because it was 
thought that this would reduce the risk of infection. It was just at that point 
when we were changing from rectal to vaginal examination.
Tait:  I trained at Bart’s and we did our obstetrics on the district. I remember 
doing what I was told and doing a rectal examination and the patient turned to 
the midwife and said, ‘Tell the young doctor he’s in the wrong hole.’ 
Professor Allan Maclean, Mrs Wendy Savage, Dr Ian Tait: Maternal Care, p. 12 
Ventilation
I very soon discovered that there were some babies who, after they had been 
resuscitated, stopped breathing again when you stopped ventilating. Most of them 
were all right and breathed on their own but there were always some, especially 
the very premature, who could not breathe on their own. The problem was how 
to go on ventilating them for hours if not days. Fortunately, we had an endless 
supply of immensely fit medical students at St Thomas’ and 
we put them to work, which they did willingly. I am not 
quite sure what they got out of it, but they sat there for hours 
finger-ventilating apnoeic babies, and before mechanical 
ventilators this worked well. However, after 24 hours and up 
to 36 hours, we began to run into problems. We didn’t run 
out of medical students but into problems of humidification, 
which I didn’t realise for a time. It was also obvious to me that this was not the 
best use of medical students. However, I am still in regular contact with someone 
who is now 35 and who, as a premature infant in 1964, was ventilated for some 
four or five days. The 1960s can best be summed up as the decade when effective 
resuscitation led to intensive care in special centres to which babies would have to 
be transported with all the new problems that this entailed. 
Dr Herbert Barrie: Neonatal Intensive Care, pp. 19–20 
…they sat there for  
hours finger-ventilating 
apnoeic babies…
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Venturi mask
In the late 1950s and early 1960s during heavy fogs and smogs, it was not 
unusual for there to be 20 or more patients with respiratory failure on trolleys 
in corridors of the Central Middlesex Hospital in north-west London. The 
majority were chronic bronchitics, many of whom had chronic CO
2
 retention. 
Quite a few of these patients would have been killed by the administration of 
unrestricted oxygen. That they survived was largely due to the work of a single 
man: Dr Moran Campbell. He studied the effects of chronic CO
2
 retention, 
which led to the development of the Venturi mask, which delivers precisely 
graduated percentages of oxygen in to the patient’s inspired air. 
Dr Peter Hunter: Environmental Toxicology, p. 63 
Vicks
I joined the Committee of Safety of Medicines, the main committee, in 1980. 
At my very first meeting we had before us a transfer of a licence from one 
manufacturer to another. It was for Vicks, the stuff you rub on your chest. It 
was just about to go through on the nod and I said, very pompously, ‘Chairman, 
what’s the evidence for efficacy there?’ And he gave me a sort of withering look 
and said, ‘Rawlins, we have a long tradition at this committee of granting licences 
to products the public have enjoyed for many years. So while you’re looking out 
of the window and not paying any attention, we’re going to give it a licence.’ 
Professor Sir Michael Rawlins: Clinical Pharmacology 2, p. 61 
Visitors from the Soviet Union
On the question of industry and academic funding, when I used to have visitors 
from the old Soviet Union in my lab, I’d say to them: ‘The best thing that I can do 
for you is let you look along the shelves and if there are any compounds of interest 
to you there, take a little of them.’ The fine chemicals industry was much, much 
more advanced in the West than in the East – an advantage of capitalism with the 
competition between drug companies leading to all these nice, new compounds. 
Professor Gerald Curzon: 5-HT, p. 89 
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Volunteers in hospice care
I’d like to say a word about the volunteers because they actually became a very 
important part of the early hospice. This was part of Cicely Saunder’s vision too, and 
she needed somehow to connect with the local community. I remember someone 
reporting passing the hospice in a bus and the bus conductor had turned and said: 
‘You don’t want to go in there. You’ll never get out of there alive.’ This was in the 
first year or so, and all sorts of myths were being developed about this strange place 
where people went to die. We felt that the volunteers were not 
only a very important resource and point of contact with the 
community but that they could become an important part 
of the hospice, not arranging the flowers in the wards as they 
did in most hospitals, but be actively involved in supporting patients and families, 
working closely with the staff on a wide range of things: ferrying patients to and 
from the hospice; looking after the garden; and also some very challenging things. 
I was aware that we desperately needed a bereavement service but there was no way 
we could afford to pay a team of psychologists to work in the hospice, but I’d already 
worked with volunteers in other settings and I had the feeling that, if we could pick 
and choose our volunteers, we might get some very good bereavement counselling 
out of them and in 1970 we started the first hospice-based bereavement service. 
Dr Colin Murray Parkes: Palliative Medicine, pp. 21–2 
Volunteer drug testers
It so happened that I took ten drugs myself for the first time in the course of drugs 
coming into the medical department. Another thing, which would cause a gasp 
now but didn’t cause a gasp in those days, was that I didn’t pay any of the volunteers. 
We had 1,500 people on site and everybody was keen to take part. It never occurred 
to us to offer to pay anybody, everybody was very pleased to take part.
Dr Arthur Fowle: Clinical Pharmacology 2, p. 18 
War
I joined the MRC on the auspicious day of 1 September 1939. As it was a 
Sunday and the day war was declared, I didn’t turn up until the following day. 
But this fact did, of course, have an influence on all the subsequent activities that 
we indulged in. At the start of the war, there was considerable concern about the 
possibility of epidemics following the disruption and air raids, and this was the 
sort of thing that set us off onto cross-infection problems. 
Dr Owen Lidwell: Common Cold Unit, p. 228 
‘…You’ll never get out of 
there alive.’
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When I return to the time when the interest in ethics started in Denmark and in 
the other Nordic countries, I would say that we had brought something from the 
Second World War. My father’s younger brother, a vicar, was severely tortured, 
but survived three German concentration camps. My father was involved with 
the underground, another uncle received the weapons that the Royal Air Force 
dropped to the Danish resistance movement, and I was in a military group, 
partly underground. We took these experiences with us, and I heard from the 
concentration camps about the experiments on prisoners, learnt that it took place 
in the gulags and Japanese prisoner of war camps, and this knowledge was there 
when I was a young doctor in 1952, and still it was a motivation for changes. 
Do not just say ‘never again’ after the 1930s and the 1940s and the Third Reich, 
but also say: ‘Is it now time for creating a new society without being a fascist 
or a communist?’ This motivation created a need for a new language, a new 
structure, a terminology, and by thinking about: ‘What is research?’ ‘What are 
the rights of the citizens, the patients?’, it started from the bottom at that time. 
Professor Povl Riis: Medical Ethics, p. 24 
Water management
Is it absolutely too late, in investment terms, to reverse this idea of putting all our 
solid wastes into water? It has always struck me as being a most extraordinary idea 
that we do it, but is it possible to imagine going back to a pre-Edwin Chadwick 
system? Are we condemned to have a situation where sewage management and 
drinking water supply management are always combined? 
Mr Stanley Johnson: Environmental Toxicology, p. 58 
Websites
I think that the MAFF/DEFRA website that was in action during this recent foot 
and mouth disease epidemic has been an exceptional example of a website giving 
authoritative information, quite exceptional. But I remember manning the hotline 
one day and a farmer’s wife was asking for information on disinfectants and I said, 
‘Well, if you go to the MAFF website, you will find an enormous amount of helpful 
information there.’ She said, ‘So, what is a website?’ I think that’s quite typical. It 
is wrong to assume that everybody has access to modern information technology. 
Dr Tony Garland: Foot and Mouth, pp. 40–1 
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‘Whippet disease’
Callender:  In the 1930s during the Depression, I know from my own experience 
of ‘district deliveries’ in Dundee, many women had multiple pregnancies, 
increasing iron requirement, and also they were existing mainly on diets of bread 
and tea. Tea exerts an inhibitory effect on iron absorption.
Booth:  When I was in Dundee we used to call it ‘whippet disease’. Certainly 
when the miners in Fife kept whippets in food-rationing time, the meat was given 
to the whippet and nobody else got it, so we used to call it ‘whippet disease’.
Callender:  In my time before the war they were existing on the dole of 30 
shillings a week, and if ever there was a scrap of meat, it was given to the men in 
the family, because they had to keep their strength up!
Dr Sheila Callender, Sir Christopher Booth: Intestinal Absorption, p. 64
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Professor Maureen 
Young: Corticosteroids
X-ray
Two chest X-rays could be taken of the same patient and one would look hazy, 
showing evidence of early pneumoconiosis, and the other would be much clearer 
and normal. The reason for this was that the definition of a radiograph is related 
to the number of peaks of alternating voltage that occur during the very short 
exposure time. Our radiographer modified the X-ray machines so that the 
current always switched in at exactly the same phase of the alternating current, 
so that in identical exposure times there would be the same number of peaks of 
current voltage. This was important because so much of the work of the unit 
depended on an accurate assessment of the degree of radiological change caused 
by pneumoconiosis. 
Professor Owen Wade: Population-based Research, pp. 29–30 
We worked from a schoolroom, which was lent to us and 
did clinical examination of the miners, X-rays, some sort 
of respiratory disability tests, rather crude ones I have to 
say in retrospect, was all we could do, and history taking. 
There was no X-ray set-up there and we used a mobile van, 
Portable X-rays Limited, which trundled round the valleys, 
and it is amazing what beautiful X-rays they took for the 
period. We confirmed by X-rays and by post mortems 
that coalface workers who had not worked in hard rock 
did have serious, disabling lesions. And they did not look 
XYZ
…we used a mobile van, 
Portable X-rays Limited, 
which trundled round  
the valleys…
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like classical silicosis. So this confirmed the suspicions that had been around. 
Secondly, we were also able to trace the progression of these lesions according to 
the length of exposure to their work in the coal-seams. We were able to do that, 
not by following people along, of course, but by taking people who had been 
for different periods at Ammanford colliery, and matching them against the 
lesions they showed in their X-rays. And we were able to describe the character 
of the lesions, as it appeared on X-ray, starting with a reticular appearance, then 
a nodular appearance, and then big masses, with increasing disability. In contrast 
to silicosis we didn’t find tuberculosis to be a leading feature of pneumoconiosis 
of colliers. 
Dr Philip D’Arcy Hart: Population-based Research, pp. 5–7 
One of the interesting differences between the survey work I did in south Wales, 
and my later work in Belfast was the names. I don’t think we realised how difficult 
it was going to be when surveying miners in south Wales where so many men 
had names like Jenkins, Jones, Thomas, or Williams. Archie Cochrane solved 
this by ensuring that every man X-rayed was also photographed holding a board 
with his X-ray number and his name. When the unit returned four or five years 
later to re-X-ray that pit, it was possible to identify and radiograph the right Mr 
Jones. Of course, the miners all know each other by Jones ‘longtuff ’ or Jones ‘big 
nose’ or some phrase of that sort, but that wasn’t very useful to the survey team.
Professor Owen Wade: Population-based Research, pp. 49–50 
Yellow cards
Now the story of the yellow card, I think, is typical of the many administrative 
complexities that we faced. The Adverse Reactions Subcommittee needed a 
method by which doctors could report adverse reactions. A list of questions 
was prepared by the Medical Assessor from which I produced a draft card. We 
agreed that the card must be post-free for doctors, if we were going to get them 
to submit it to us and I tried to negotiate what, in those days, was an ‘On 
Her Majesty’s Service’ frank, which appeared on all official 
correspondence. The Stationery Office wouldn’t have it, so 
I then tried the idea of the post-paid business reply rate 
which businesses used. Now you must remember in those 
days the Committee had no budget of its own and the 
Ministry of Health Finance Department didn’t like the idea 
of using money to pay the necessary fee for a business reply 
envelope. We had to work very hard indeed in persuading 
…this very simple form, 
which is still used today, 
experienced a difficult 
gestation.
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the Ministry to go to the Treasury and get the Treasury actually to allow that 
bit of money that we needed to pay the fee for the business reply envelope. So 
we got over that. Then there was the problem of distribution, which in theory 
sounded easy, but we had to negotiate with several parts of the Ministry, those 
responsible for general practitioners, for hospitals, and the health committees, 
to get this yellow card out to the people who ought to be using it. There were 
difficulties and obstructions all the way. Thus, this very simple form, which is 
still used today, experienced a difficult gestation. And the reason for the card 
being yellow is also amusing, because it arises from my own colour blindness. 
Each Subcommittee wanted a colour-coding for their papers and as I kept the 
Secretaryship of the Adverse Reactions Subcommittee to myself I chose yellow 
as the house colour, because this was a colour that I could most easily identify. 
Greens and pinks, which were the others, were quite beyond me. Hence, with 
the house colour of yellow, inevitably the card that we used was a yellow card 
and that’s why it’s known as the yellow card. 
Mr Wilfred Turner: Safety of Drugs, p. 110–11 
Zantac and Tagamet
[Tagamet was the name under which Smith Kline and French (later SmithKlineBeecham, 
later part of GSK) marketed cimetidine, an H
2
 receptor antagonist that inhibits acid 
production in the stomach. Tagamet was the first ever ‘blockbuster drug’ to achieve sales 
of more than $1 billion a year. Ranitidine, a rival H
2
 receptor antagonist, was marketed as 
Zantac by Glaxo (later Glaxo Wellcome, later GSK).]
Tagamet made an enormous contribution to patients’ lives. I have spent about 
15 years of my life working on trials and other studies with ranitidine, and 
the newspapers used to portray us as adversaries and I guess indeed we were 
adversaries. Ironically we are now (2000) about to merge, Glaxo Wellcome and 
SmithKlineBeecham, but in those days we were competitors and we conducted a 
large number of studies to compare the relative benefits of Tagamet and Zantac. 
Zantac eventually took over from Tagamet as the leading drug on a global 
basis being prescribed for the treatment of peptic 
ulcer and stayed up there as the world’s top-selling 
ethical pharmaceutical for 11 years, which is quite 
an achievement. At the peak of its sales, the drug was 
selling to £2.3 billion per annum on a global basis. 
Dr John Wood: Peptic Ulcer, p. 75
…the drug was selling to 
£2.3 billion per annum 
on a global basis.
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clinical genetics, 109
cystic fibrosis treatment, 36
exchange transfusion, 50
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medical ethics, 179
NHS see National Health Service 
whippet disease, 180
1950s 
animal immunology, 83 
artherosclerosis, 15
asthma treatment, 8
Beechams, 11
breastfeeding, 14
Brompton Cocktail, 15–16
Common Cold Unit, 74
ethics and intensive care, 49–50
exchange transfusion, 51
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haemophilia research, 72–3
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home birth, 77
leukaemia treatment, 97
leukaemia trials, 159
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cannabis research, 18–19
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children with asthma, 45
cholesterol monitoring, 24
clinical trials, 27
Committee on Safety of Drugs 
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GP maternity unit, 69
haemophilia treatment, 73
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leukaemia treatment, 97
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pain and palliative care, 133–4
pain clinics, network, 90 
steroids for asthma, 45
thalidomide, 169
total hip replacement surgery, 169
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children with asthma, 45
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doctor–patient relationship, 41
high dependency units, 75–6
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induction of labour in childbirth, 
142 
migraine, 114
oncology units, UK, 24–6
steroids for asthma, 45
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academic attitudes towards 
pharmaceutical industry funding, 
64
asthma see asthma care nurses
breastfeeding movement, 136 
condom adoption by gay men, 31 
cystic fibrosis dietary management, 
35
drug compounds availability, 63
Helicobacter pylori, 75
HIV epidemic and hospice 
movement’s discrimination, 79
HIV patients’ care, 76–7
HIV awareness television 
advertisements, 32
HIV tests, Blood Transfusion 
Service, 31–2
infant food contamination, 56
leukaemia trials, 98
Liverpool International Garden 
Festival, 99
medical school funding from 
external sources, 66
metal standards for hip prostheses, 
76
native remedies for cancer 
treatment, 123
paternalism towards patients, 168
peptic ulcer and Helicobacter pylori, 
75
sports medicine payment, 130
tobacco resolutions (World Health 
Authority), 104
1990s, 37 
ALSPAC, 9–10
clinical research, 27
cystic fibrosis, psychosocial effect, 
158
drug compounds availability, 63
ethnic minority health interest 
(ALSPAC), 50 
tobacco resolutions (World Health 
Authority), 104
Aberdeen Prescription Sheet, 144–5
abortion, illegal, 106
academic medicine, in London,  
150–1
Action Research, 41–2
activism, patient, 2–3, 136
adverse drug reactions
official warnings, 28–9
reporting, 29, 183–4
Africa, xiii, 41, 49
foot and mouth disease vaccine trial, 
63
Kenya, 63, 170–1
kwashiorkor, 95
Malawi, 104–5
medical journals in, 109
Medical Research Council’s role, 
110
Nigeria, 95
nomadic populations, 126–7
South, 168–9
TB chemotherapy study, 84
tobacco growers, 104–5
training local Kenyans/Ugandans, 
173
Uganda, 173
Zambia, 84
African Journal of Medicine and 
Medical Science, 109
age discrimination, 1, 162
AIDS see HIV infection/AIDS
air pollution, xiv, 1
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alcohol, driving performance and, 2 
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All-India Institute of Medical Sciences, 
124
Allen & Hanburys (later part of 
Glaxo), 43–4, 152
allergies
cats, 8
Alliance for Cannabis Therapeutics, 
2–3
alosetron (Lotronex), 92–3
ALSPAC see Avon Longitudinal Study 
of Parents and Children
American Journal of Clinical Nutrition, 
92
American Journal of Respiratory Disease 
and Critical Care Medicine, 157
aminopterin, 3, 97
Ammanford colliery, Wales, 183
amphetamines, 110
amputation, haemophilia patient,  
112
anaesthesia, obstetric, 103, 128
Animal Virus Research Institute, 
Pirbright, 62
animals, 72–3
drug testing, 155
ferrets, 57–8
mice, 83
see also foot and mouth disease 
anonymity, research participants, 3–4
antenatal corticosteroids, xv, 4
antibiotics, 4
cystic fibrosis, 36, 138
methicillin, 169–70
staphylococcal infections, 81
time to market, 169–70
anti-emetics, 5-HT antagonist, 11–12, 
130–1
ferret studies, 57–8
grateful patients, 69–70
pharmacoeconomics, 139
antihaemophilic globin, 72–3
antihistamines, 9
Applied Psychology Unit, MRC, 53–4, 
114, 150, 158
architecture, 87–8, 93–4, 127
see also design 
Arran Island, 47
arsenic, 124
Asian languages, 50, 51
aspirin, 123
aspirin studies, 5 
colorectal cancer prevention, 5
Association of Radical Midwives, 6
asthma, 6–9
care nurses, 6
education of children with, 45
masks for drug delivery, 105
morphine therapy, 116
National Asthma Campaign, xiii, 
119
new drug development, 85–6, 152, 
155, 158
treatment, 1950s–1960s, 8–9
see also lies
Asthma Research Council, 119
Asthma Society, 119
Atherosclerosis Discussion Group, 15
Atomic Energy Research 
Establishment, Harwell, 91–2
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Avon Longitudinal Study of Parents 
and Children (ALSPAC), 9–10
anonymity of participants, 3–4
child protection, 23–4, 89
collection of placentas, 139–40
ethics (and law) committee, 9–10, 
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ethnic minorities, 50
funding problems, 9
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involvement of grandparents, 148
questionnaire, 148
staff recruitment, 116
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Aylesbury spatula, 22
Ayre spatula, 22
Babcock and Wilcox, 128–9
babies
brain imaging, 82–3
breastfeeding, 14, 136
exchange transfusions, 50–2
Farley food epidemic, 56
feeding very small, 140
mothers and, 116
stillborn, 159
ventilation by hand, 176
see also fetal monitoring; mothers  
Balint Society, xiv, 41
Baltimore, United States, 146–7
Bangladesh war of independence, 131
barbiturates, 110
Beaufort, south Wales, 47
Bedouin, 126–7
Beecham 
Pharmaceuticals, 11–12, 57–8, 64
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Been to America (BTA), 12
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bereavement services, 178
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blood groups see Rhesus babies and 
Rhesus factor studies
blood transfusion
equipment, 124, 140
exchange, Rhesus babies, 50–2
haemophilia, 72, 73
HIV contamination, xii, 31–2
leukaemia, 97
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see also platelet transfusion
Blood Transfusion Service, 31, 73, 146
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bottle-feeding, 14
bovine spongiform encephalopathy 
(BSE), 83
Bradford Telegraph and Argus, 70
bread, 90–1, 154, 180
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breathalyser, 138
Bristol, 81
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British Orthopaedic Association, 80
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136–7
British Standards Institute, 76
Broadgreen Hospital, Liverpool, 87
Brockham Park, Surrey, 4, 11
Brompton cocktail, 15–16, 115, 134
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15–16, 21, 75, 160
bronchodilators, 119, 152
buildings, 78, 80–1, 87–8, 93–4, 112
Burkholderia cepacia, 35–6
Burkitt’s lymphoma, 49
butterflies, 16, 108
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Calmic, 126
Calpol, 126–7
Cambridge, 2, 96, 114, 150
Cambridge Evening News, 53–4
Cambridge Instruments artificial 
kidney, 120
Canada
see Newfoundland
cancer
breast, male, 18 
care, 17, 24–6
cervical, screening, 22–3
chemotherapy see chemotherapeutic 
agents, cancer
colorectal, 5, 54–5 
endometrial, 54–5
environmental causation, 18
familial, 54–5
genetics, 17–18
HIV/AIDS patients, 79
native remedies, 123
ovarian, 20, 25, 54–5
pain management, 99–101, 133–4, 
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platinum-based chemotherapeutic 
drugs 
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information from patients, 19–20
patient activism, 2–3, 136
research funding in US, 18–19
Sativex production, 153
use in multiple sclerosis, 2–3, 118
cannulae
butterfly, 140
glass in exchange transfusion, 50, 52
Guest, 97
intravenous, 57
Cardiff, 59
career influences, xi, 20–1
cat allergy, 8
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CE mark, hip prostheses, 76
Central Middlesex Hospital, London, 
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central venous line, re-insertion, 61
Centre for Rheumatic Diseases, MRC, 
Taplow, 94
cerebral haemorrhage, newborn babies, 
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cervical screening, 22–3
chapattis, radioactive, 91–2
Charing Cross Hospital Medical 
School, London, 66
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Charnley hip prosthesis, 105–6, 163
charts, patient, 55, 99–101, 137
chemotherapeutic agents, cancer, 20, 
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clinical studies, 24–6
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see also cisplatin; nitrogen mustard
chest infections, cystic fibrosis, 35–6, 
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chest X-rays, 142, 181–3
Chester Beatty Research Institute, 
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Chief Medical Officer, 83
child abuse, 10, 24, 89, 101
child protection, 23–4
children
asthma 7–9, 45, 85–6, 105
chronic conditions, education of, 45
cystic fibrosis, 36
dialysis, 40, 45, 111 
haemophilia, 31–2, 73
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masks for drug delivery, 105
ondansetron usage, 130–1
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cholesterol, 24, 33–4
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Christmas disease, 112
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cigarettes, 147, see also smoking
cimetidine (Tagamet), 75, 184
cisplatin, 17, 24–6, 57–8
clinical pharmacology, 20, 26, 132
medical student projects, 110
clinical research, 27
methods, 27
Clinical Research Centre (CRC), 
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clinical trials, 28
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Colonial Medical Service, Africa, 49
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aspirin for prevention, 5
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Committee on Safety of Drugs (CSD), 
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Committee on Safety of Medicines 
(CSM), 29, 170, 177
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seating arrangements at meetings, 
111
Committee on Toxicity, 131
common cold, 16, 74
Common Cold Unit, MRC, 16, 30, 
178
computers, 137, 141, 150
condoms, 30–1, 32
conferences, 31, 32–3
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informed, 84, 101
by research subjects, 25
contamination problems, 31–2, 56
contraceptive pill, xv
contracts, doctor–patient, 42
controlled trials, 32–3
coronary artery bypass surgery, age 
discrimination, 1
coronary heart disease (CHD), 33–4
nutritional influences, 33–4
occupational differences, 33
corticosteroids
antenatal, xv, 4
asthma, 45, 105, 119
cost-effectiveness, 5-HT
3
 antagonists, 
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drug development, 28
endoscopes, 46
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heart transplant programme, 61–2
home haemodialysis, 111
ward closure, 37
Coventry, 91–2
Creon, 135
cromoglycate (Intal), 85–6, 119, 155, 
158
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curare, 168–9
cycling, 20, 44
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attempted suicide, 162
career influences, 21
dietary management, 35, 36
infections, 35–6, 138
life expectancy, 35
nihilistic attitudes, 21, 35
pancreatic enzyme preparations, 135
patients falling in love, 102
penicillin therapy, 138
socio-economic factors, 157
special clinics, 158
treatment, in 1945, 36
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Daily Telegraph, 143
DDT (dichloro-diphenyl-
trichloroethane), 46
deaths, 168
 animal, 62
 babies, 56
 cancer, 20, 26, 54–5, 148
 cardiac, 24, 33
 dialysis patient, 162–3
 cystic fibrosis, 35–6
 hospital associated infection, 117
 hospitalisation of, 21
 leukaemia, 3, 97
 maternal, 106, 128
 neonatal, 4
 sudden infant, 161
 see also stillbirths; suicide
death-watch beetles, 24–6, 171
decoding task, 150
Delhi, India, 123–4
Department of Health, 37
control of hospital infections, 80, 
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heart transplant programme, 61–2
implementing research results, 154
Medicines Division, 112
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design
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British equipment suppliers, 120
doctor–patient relationship, 42
education of children on, 45
equipment, 38-40, 111, 120
home, 37–41, 111, 162–3
mixed wards, 115
patient selection, 41
role of biochemists, 12
diamorphine (heroin), 164, 165
dieldrin, 46
diet
cystic fibrosis, 35, 36
coronary heart disease, 33
metabolic ward, 113
whippet disease, 180
difficult doctors, 41
diphtheria, 7–8
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ethics education, 101
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paternalism, 49, 73, 168
reimbursement system in Japan, 94
severe pain relief, pre-1965, 134
see also GPs 
domiciliary care, 43
domiciliary midwives, 69
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halted by drug companies, 28, 85, 
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marketing, 125–6, 139 
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adverse reactions, 28–9
administration by nurses, 87
distribution of free samples, 63
lack of access to, 175
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safety, 169
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duodenal ulcers, 157
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(ESRC), 30–1
Edinburgh, 18, 120, 158, 172
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lead, 47–8
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embryo research, human, 143
emesis, chemotherapy-induced, 17
children’s cancer ward, 130–1
ferret model, 57–8
letters from patients, 69–70
research at Beechams, 12
EMLA cream, 166
endometrial cancer, 54–5
endoscope, smuggled into UK, 46
environmental awareness, 46
environmental toxins, 131
ephedrine, 9
epidemiology, 13, 49, 93, 161
Epidemiology Unit, MRC, xii–xiii, 32, 
47–8, 90–2, 181–2
see also National Perinatal 
Epidemiology Unit 
Epstein–Barr virus, 49
equipment, 27, 167, 169
dialysis, 38-40, 111, 120
intensive care, 167, 171
obstetric ultrasound, 64-5, 69
transfusion, 50-2, 124, 140
ethical pharmaceuticals, 11
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ethics, 49–50, 54, 108, 110, 179
ethics committee, ALSPAC, 9–10, 56, 
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ethnic minorities, 50
exchange transfusion, rhesus babies, 
50–2
expert committees, 52
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factor IX concentrate, 112
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140–1
familial cancers, 54–5
families, 38, 40–1, 56, 161, 179
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famine oedema, 32–3
Farley infant food epidemic, 56
fathers, 9, 56
feeding tubes, polyvinyl, 140
feminist movement, 106
ferrets, 57–8
fetal monitoring, 58, 154
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one second), 138, 155
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fieldwork, 59
fieldworkers, 59–60
first class, travelling, 171
flaw detectors, industrial, 128–9
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food
bacterial contamination, 56
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Food and Drug Administration (FDA), 
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food industry, 33–4
foot and mouth disease (FMD), 62–3
1967 outbreak, 62, 107
media coverage of outbreaks, 107
role of websites, 179
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Foundation for Sudden Infant Death, 
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Framework Convention on Tobacco 
Control, 170–1
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Friedman test, 149–50
funding
conferences, 31
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new NHS services, 120–1
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Oxford GP maternity unit, 69
research see research funding
gas-and-air analgesia, 103
gastric ulcers, 157
gastroenterology, 75, 136–7, 156
see also Helicobacter pylori
gastroscope, smuggled into UK, 46
gay men
palliative care for HIV-infected, 77
socio-sexual research, 30–1
Geigy Pharmaceuticals, 156
gender, and disease, 18, 33, 70
gender, and propriety, 69, 115
gender, and analgesics, 133
general practice (GP) maternity unit, 
69
waiting rooms 50
general practitioners (GPs)
cystic fibrosis care, 158
hospice-at-home service, 80
sports medicine, 130
as obstetric patient, 142
as dialysis patient, 162
in asthma care, 6
maternity unit, 69
genetic code, 67
Genetic Nurses and Social Workers 
Association, 68
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role of biochemists, 13
genetics
butterfly, 16, 108
cancer, 17–18
medical, 108–9
genetics network, UK, 67–8
Geneva, Switzerland, 68
Glasgow
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cancer patient survival, 26
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Regional Physics Department, 74
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see also Kelvin & Hughes Ltd
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